flecainide has been researched along with Auricular Fibrillation in 378 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The mechanism of the action of flecainide in the termination of human atrial fibrillation (AF) is not fully understood." | 9.14 | Increase in organization index predicts atrial fibrillation termination with flecainide post-ablation: spectral analysis of intracardiac electrograms. ( Jeilan, M; Kundu, S; Mantravadi, R; Ng, GA; Osman, F; Stafford, PJ; Tuan, J, 2010) |
| "The beta(1)AR Arg389Arg genotype is associated with increased flecainide potency and higher heart rate during atrial fibrillation." | 9.14 | Beta1-adrenoceptor polymorphism predicts flecainide action in patients with atrial fibrillation. ( Aslan, O; Caglayan, E; Duru, F; Er, F; Erdmann, E; Gassanov, N; Hellmich, M; Nia, AM; Rosenkranz, S; Zimmermann, T, 2010) |
| "It has been reported that bepridil is as good as amiodarone in converting persistent atrial fibrillation (AF) to sinus rhythm (SR)." | 9.13 | Use of bepridil in combination with Ic antiarrhythmic agent in converting persistent atrial fibrillation to sinus rhythm. ( Aoyama, H; Enomoto, M; Hirayama, A; Imai, S; Kushiro, T; Saito, F; Takase, H; Yagi, H; Yamaji, S; Yokoyama, K, 2008) |
| "To compare flecainide and dronedarone for sinus rhythm (SR) maintenance following electrocardioversion of persistent atrial fibrillation (AF), in patients with minimal or no structural heart disease." | 9.12 | Comparison of dronedarone vs. flecainide in the maintenance of sinus rhythm, following electrocardioversion in adults with persistent atrial fibrillation: a systematic review and meta-analysis. ( Moore, Z; Nugent, L; O'Connor, T; Patton, D; Wilson, H, 2021) |
| "Flecainide acetate instant release (LI) has been prescribed for years in the prevention of atrial fibrillation (AF) relapse after sinus rate conversion." | 9.12 | [Flecainide controlled-release for prevention of atrial fibrillation relapse]. ( Chatelin, A; Jaillon, P; Mary-Krause, M; Simon, T; Thuault, M, 2006) |
| "The study aimed to report our experience of intravenous flecainide administration in the treatment of paroxysmal atrial fibrillation (PAF) in the Emergency Room (ER)." | 9.12 | [Intravenous flecainide administration for conversion of paroxysmal atrial fibrillation in the emergency room]. ( Antonelli, D; Darawsha, A; Feldman, A; Freedberg, NA; Rosenfeld, T, 2006) |
| "A double-blind, randomized, parallel-group, placebo-controlled trial was conducted in patients with paroxysmal atrial fibrillation or flutter (PAF/PAFL) experiencing 2 or more episodes of symptomatic PAF/PAFL during a 28-day observation period to determine the dose-response effect and safety of flecainide." | 9.12 | Dose-response effect of flecainide in patients with symptomatic paroxysmal atrial fibrillation and/or flutter monitored with trans-telephonic electrocardiography: a multicenter, placebo-controlled, double-blind trial. ( Atarashi, H; Hamada, C; Inoue, H; Ogawa, S, 2007) |
| "This study compared the efficacy and safety of intravenous flecainide and ibutilide for immediate cardioversion of atrial fibrillation (AF)." | 9.11 | Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset. ( Aicher, F; Bachleitner, T; Eisserer, G; Gatterer, E; Grander, W; Heinze, G; Kühn, P; Lang, W; Niemeth, C; Reisinger, J; Siostrzonek, P; Vanicek, T, 2004) |
| "We sought to assess the efficacy and safety of ibutilide cardioversion for those with atrial fibrillation (AF) or atrial flutter (AFL) receiving long-term treatmentwith class IC agents." | 9.11 | Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents. ( Bonso, A; Glatter, KA; Hongo, RH; Raviele, A; Rossillo, A; Scheinman, MM; Themistoclakis, S; Yang, Y, 2004) |
| "The objectives were to study the absorption kinetics and pharmacodynamics of two oral formulations of flecainide in patients with atrial fibrillation (AF) and to assess the relationship between pharmacokinetic parameters and the efficacy in restoring sinus rhythm." | 9.11 | Absorption kinetics and pharmacodynamics of two oral dosage forms of flecainide in patients with an episode of paroxysmal atrial fibrillation. ( Brouwers, JR; Deneer, VH; Dunselman, PH; Gossen, SA; Kingma, JH; Lie-A-Huen, L; Proost, JH; Stuurman, A; Uytdehaag, GM, 2004) |
| "Flecainide and sotalol prolong the atrial action potential during atrial fibrillation in humans." | 9.11 | Electrophysiological effects of flecainide and sotalol in the human atrium during persistent atrial fibrillation. ( Breithardt, G; Eckardt, L; Engelen, M; Franz, MR; Haverkamp, W; Kirchhof, P; Ribbing, M; Wasmer, K, 2005) |
| "[corrected] Bepridil, a multiple ion-channel blocker, has been reported to prevent paroxysmal atrial fibrillation (PAF)." | 9.10 | Bepridil prevents paroxysmal atrial fibrillation by a class III antiarrhythmic drug effect. ( Hara, H; Ikeda-Murakami, K; Inuo, K; Izumi, T; Kojima, J; Niwano, S; Saito, J; Yoshida, T, 2003) |
| "To evaluate the impact, on atrial fibrillation (AF) recurrences, of verapamil addition to a class IC or III antiarrhythmic drug in patients, with persistent AF, who underwent an electrical cardioversion (EC)." | 9.10 | VErapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF Study). ( Alfano, F; Campana, A; Canciello, M; De Fabrizio, G; De Matteis, C; De Pasquale, M; De Simone, A; Di Mauro, M; Manzo, M; Sabino, L; Stabile, G; Turco, P; Vitale, DF, 2003) |
| " low-dose flecainide followed by oral pilsicainide might be a promising strategy for the outpatient treatment of paroxysmal atrial fibrillation." | 9.10 | Low-dose flecainide infusion followed by oral pilsicainide is highly effective and safe for paroxysmal atrial fibrillation. ( Kubota, I; Nagai, S; Takeishi, Y, 2003) |
| "To investigate whether an oral loading dose of flecainide is as safe and effective as intravenous flecainide for the cardioversion of acute atrial fibrillation." | 9.09 | Randomised double blind trial of oral versus intravenous flecainide for the cardioversion of acute atrial fibrillation. ( Alp, NJ; Bell, JA; Shahi, M, 2000) |
| "In a prospective, single-blind trial, we randomized 150 consecutive symptomatic patients with acute (< or = 48 hours' duration) atrial fibrillation to receive intravenous flecainide, propafenone, or amiodarone." | 9.09 | Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. ( Camacho, C; Fernández-Gómez, JM; García-Garmendia, JL; Martínez-Marcos, FJ; Ortega-Carpio, A; Santos, JM, 2000) |
| "The authors report their experience in recent-onset atrial fibrillation treated with intravenous flecainide and propafenone, in comparison with the placebo group." | 9.09 | [Effectiveness and side effects of the treatment with propafenone and flecainide for recent-onset atrial fibrillation]. ( Caccavale, F; Catanzaro, M; Coppo, A; Corsini, F; Corsini, G; Di Maggio, O; Fattore, L; Iodice, E; Martone, A; Romano, A; Romano, S; Toscano, G, 2001) |
| "We tested the hypothesis that the response to flecainide infusion can identify patients with atrial fibrillation (AF) in whom the hybrid pharmacologic and ablation therapy reduces the recurrences of AF." | 9.09 | Response to flecainide infusion predicts long-term success of hybrid pharmacologic and ablation therapy in patients with atrial fibrillation. ( Astarita, C; De Matteis, C; De Simone, A; Di Napoli, T; La Rocca, V; Maresca, F; Nocerino, P; Stabile, E; Stabile, G; Turco, P; Vitale, DF, 2001) |
| "Aim of the present study was to assess the efficacy and safety of flecainide (F) and sotalol (S) for the prevention of recurrences of paroxysmal atrial fibrillation (PAF)." | 9.08 | [A comparison between flecainide and sotalol in the prevention of recurrences of paroxysmal atrial fibrillation]. ( Burattini, M; Carunchio, A; Ceci, V; Fera, MS; Galati, A; Greco, G; Mazza, A, 1995) |
| "In a randomized, double-blind, controlled study of 98 patients with atrial fibrillation (AF) (present for > or = 30 minutes, < or = 72 hours, and a ventricular response of > or = 100 beats/min), intravenous flecainide (2 mg/kg, maximum 150 mg) was compared with intravenous amiodarone (7 mg/kg) and placebo." | 9.08 | Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. ( Dobb, GJ; Donovan, KD; Hockings, BE; Lee, KY; Power, BM, 1995) |
| "In order to compare the efficacy and long-term tolerability of flecainide acetate versus quinidine, 239 patients with paroxysmal atrial fibrillation were prospectively treated with flecainide (n = 122) or quinidine (n = 117) in an open-label, randomized trial." | 9.08 | Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group. ( Coumel, P; Dorian, P; Hohnloser, SH; Naccarelli, GV, 1996) |
| "To compare the relative safety of flecainide acetate to propafenone HCl during long-term treatment (12 months), we conducted a randomized, open-label, comparative, parallel, multicenter trial in 200 patients with paroxysmal atrial fibrillation (AF) and no history of heart disease." | 9.08 | Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators. ( Casadei, G; Chimienti, M; Cullen, MT, 1996) |
| "To assess the cardiac and extracardiac safety and efficacy of flecainide versus propafenone in patients suffering from episodes of paroxysmal atrial fibrillation (AF) or atrial flutter, 97 patients were enrolled in a randomized, open-label, long-term, parallel, comparative multicenter study." | 9.08 | Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group. ( Aliot, E; Denjoy, I, 1996) |
| "Patients with supraventricular arrhythmias have been safely and effectively treated with flecainide." | 9.08 | Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group. ( Buxton, AE; Heilman, JM; Hopson, JR; Kienzle, MG; Nademanee, K; Rinkenberger, RL, 1996) |
| "In order to compare the long-term safety of flecainide and propafenone, an open label, randomized, parallel group study was performed in 335 patients with paroxysmal atrial fibrillation (n = 200) or paroxysmal supraventricular tachycardia (n = 135), and no history of heart disease." | 9.08 | Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. ( Casadei, G; Chimienti, M; Cullen, MT, 1995) |
| "This study sought to compare the efficacy and safety of intravenous flecainide and sotalol for immediate cardioversion of atrial fibrillation." | 9.08 | Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation. ( Ebner, A; Gatterer, E; Gattermeier, M; Heinze, G; Hohenwallner, W; Kratzer, H; Kuhn, P; Lenz, K; Poelzl, G; Reisinger, J; Slany, J; Wiesinger, K; Zeindlhofer, E, 1998) |
| "The purpose of our study (conducted between August 1995 and September 1996) was to evaluate prospectively the efficacy of intravenous administration (in 10 min) of sotalol, flecainide or the combination of these drugs to restore sinus rhythm in patients (without cardiac/pulmonary failure) who came to the First Heart Aid of our hospital with atrial fibrillation lasting less than 24 h." | 9.08 | Treatment of recent onset atrial fibrillation with intravenous sotalol and/or flecainide. ( Braat, SH; Heymeriks, J; Peters, FP; Wellens, HJ, 1998) |
| "In this prospective, controlled and randomized cross-over study we tried to establish the efficiency and safety of flecainide vs procainamide for the treatment of acute atrial fibrillation." | 9.07 | Comparison of flecainide and procainamide in cardioversion of atrial fibrillation. ( Costa, A; Madrid, AH; Marín-Huerta, E; Mestre, JL; Moro, C; Novo, L, 1993) |
| "The effects of intravenous flecainide and propafenone (2 mg/kg) administered in random order were compared in 16 patients with Wolff-Parkinson-White syndrome." | 9.07 | Effects of flecainide on atrial electrophysiology in the Wolff-Parkinson-White syndrome. ( Camm, AJ; Katritsis, D; Nunain, SO, 1992) |
| "In order to assess efficacy, safety, and long-term tolerance of flecainide for the prevention of paroxysmal atrial fibrillation (PAF), 944 patients (555 male) were enrolled in an open multicenter study." | 9.07 | Flecainide acetate in the prevention of paroxysmal atrial fibrillation: a nine-month follow-up of more than 500 patients. ( Clementy, J; Denjoy, I; Dos Santos, P; Dulhoste, MN; Laiter, C, 1992) |
| "The efficacy and safety of intravenous flecainide to convert recent-onset atrial fibrillation (AF) (present for greater than or equal to 30 minutes and less than or equal to 72 hours and a ventricular response greater than or equal to 120 beats/min) was investigated." | 9.07 | Efficacy of flecainide for the reversion of acute onset atrial fibrillation. ( Clarke, GM; Coombs, LJ; Dobb, GJ; Donovan, KD; Lee, KY; Murdock, CJ; Weekes, JN, 1992) |
| "Efficacy and safety of intravenous flecainide (2 mg/kg body weight in 10 minutes), verapamil (10 mg in 1 minute), and propafenone (2 mg/kg body weight in 10 minutes) were investigated in 90 consecutive patients with atrial fibrillation (AF) or flutter (AFL)." | 9.07 | Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil. ( Kingma, JH; Suttorp, MJ, 1992) |
| "In 34 patients with a symptomatic accessory atrioventricular connection the reversible protective effect of orally administered flecainide (300 mg/day) and of propafenone (900 mg/day) in control of ventricular response during atrial fibrillation by exercise was assessed." | 9.07 | Reversible protective effect of propafenone or flecainide during atrial fibrillation in patients with an accessory atrioventricular connection. ( Auricchio, A, 1992) |
| "Sixty-two patients with recent-onset (less than or equal to 1 week) atrial fibrillation (New York Heart Association functional class 1 and 2) were randomized in a single-blind study to 1 of the following treatment groups: (1) flecainide (300 mg) as a single oral loading dose; or (2) amiodarone (5 mg/kg) as an intravenous bolus, followed by 1." | 9.07 | Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. ( Binetti, N; Boriani, G; Capucci, A; Cavazza, M; Fontana, G; Lenzi, T; Magnani, B; Trisolino, G, 1992) |
| "We compared the electrophysiological effects of intravenous propafenone and flecainide on accessory pathway conduction by a randomized crossover study in 16 patients with Wolff-Parkinson-White syndrome." | 9.07 | A comparison of intravenous propafenone and flecainide in the treatment of tachycardias associated with the Wolff-Parkinson-White syndrome. ( Camm, AJ; Garratt, CJ; Gill, J; Linker, NJ; O'Nunain, S; Ward, DE, 1991) |
| "The dose-response relations for efficacy and tolerance of the antiarrhythmic drug flecainide acetate were studied in 28 patients with paroxysmal supraventricular tachycardia (Group 1) and 45 patients with paroxysmal atrial fibrillation or flutter (Group 2)." | 9.07 | Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: dose-response studies. The Flecainide Supraventricular Tachycardia Study Group. ( DaTorre, SD; Hougham, AJ; McCarville, SE; Platt, ML; Pritchett, EL, 1991) |
| "To evaluate the efficacy of flecainide acetate in the prevention of paroxysmal atrial fibrillation and flutter, 43 patients (23 men) (mean age 53 years) were randomized blindly to receive either placebo or 150 mg of flecainide twice per day for consecutive periods of 3 months." | 9.07 | Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Danish-Norwegian Flecainide Multicenter Study Group. ( Hellemann, H; Pietersen, AH, 1991) |
| "The efficacy of oral cibenzoline (260 mg/day and 320 mg/day) and flecainide (200 mg/day and 300 mg/day) in the conversion of chronic atrial fibrillation to sinus rhythm were compared in 31 patients in a randomized order." | 9.07 | Randomized comparison of flecainide and cibenzoline in the conversion of atrial fibrillation. ( Kühlkamp, V; Risler, T; Schmid, F; Seipel, L, 1991) |
| "In 69 consecutive patients with recent-onset atrial fibrillation, we compared the usefulness of verapamil, flecainide and propafenone for the acute conversion to sinus rhythm within 1 hour of the start of intravenous infusion." | 9.06 | Comparative evaluation of verapamil, flecainide and propafenone for the acute conversion of atrial fibrillation to sinus rhythm. ( Kastrati, A; Kondili, A; Popa, Y, 1990) |
| "Seventy-seven patients with symptomatic atrial fibrillation (AF) received oral flecainide acetate (247 +/- 8 mg/day)." | 9.06 | Clinical efficacy of flecainide acetate in atrial fibrillation. ( Kulbertus, HE; Mary-Rabine, L, 1990) |
| "We compared the efficacy of flecainide versus quinidine in preventing paroxysms of atrial fibrillation in a randomized open crossover study." | 9.06 | Flecainide versus quinidine in the prevention of paroxysms of atrial fibrillation. ( Crijns, HJ; den Heijer, P; Lie, KI; van Gilst, WH; van Wijk, LM, 1989) |
| "In a single-blind randomized study, the efficacy of intravenous flecainide (2 mg/kg/10 minutes) versus verapamil (10 mg/1 minute) was assessed in 40 patients with paroxysmal atrial fibrillation (AF) or atrial flutter (AFI)." | 9.06 | Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. ( Kingma, JH; Lie-A-Huen, L; Mast, EG; Suttorp, MJ, 1989) |
| "The efficacy and safety of flecainide were studied in the maintenance of sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter." | 9.06 | Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. ( Crijns, HJ; Hamer, HP; Lie, KI; Van Gelder, IC; Van Gilst, WH; Van Wijk, LM, 1989) |
| "This study was designed to assess the clinical efficacy of oral flecainide for the prevention of paroxysmal attacks of atrial fibrillation (AF)." | 9.06 | Oral flecainide for prophylaxis of paroxysmal atrial fibrillation. ( Chouty, F; Coumel, P, 1988) |
| "The efficacy and safety of oral (up to 400 mg in 3 h) and intravenous regimens (up to 150 mg in 10 min) of flecainide acetate were compared in the acute conversion of atrial fibrillation to sinus rhythm." | 9.06 | Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate. Comparison of two regimens. ( Crijns, HJ; Kingma, JH; Lie, KI; van Gelder, IC; van Gilst, WH; van Wijk, LM, 1988) |
| "The efficacy and safety of flecainide for long-term prevention of paroxysmal atrial fibrillation (AF) were studied in an open trial." | 9.06 | Long-term efficacy of flecainide in paroxysmal atrial fibrillation. ( Kallryd, A; Nylander, E; Rydén, L; Sonnhag, C, 1988) |
| "The effectiveness and safety of flecainide and quinidine for conversion of atrial fibrillation (AF) to sinus rhythm were compared." | 9.06 | Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. ( Borgeat, A; Goy, JJ; Grbic, M; Kaufmann, U; Maendly, R; Sigwart, U, 1986) |
| "The aim of this review is to evaluate the available data on efficacy and safety of flecainide in all the spectrum of its indications including cardioversion of recent-onset AF, sinus rhythm maintenance in paroxysmal AF and management of ventricular tachyarrhythmias." | 8.89 | Flecainide acetate for the treatment of atrial and ventricular arrhythmias. ( Apostolakis, S; Breithardt, G; Fabritz, L; Kirchhof, P; Oeff, M; Tebbe, U, 2013) |
| "The efficacy and safety of the single oral loading dose of flecainide for cardioversion of recent-onset atrial fibrillation was examined by reviewing the trials on the subject identified through a comprehensive literature search." | 8.82 | Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation. ( Khan, IA, 2003) |
| "A short cut review was carried out to establish whether amiodarone is better than flecainide at restoring sinus rhythm in patients with atrial fibrillation." | 8.82 | Best evidence topic report. Amiodarone or flecainide for cardioversion in acute onset atrial fibrillation. ( Argall, J; Crawford, I, 2004) |
| "This report summarizes efficacy and safety data on the use of flecainide acetate for supraventricular arrhythmias." | 8.78 | Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias. ( Hohnloser, SH; Zabel, M, 1992) |
| "The effects of flecainide on electrophysiologic parameters and arrhythmias in the Wolff-Parkinson-White syndrome were reviewed." | 8.78 | Flecainide in the Wolff-Parkinson-White syndrome. ( Crozier, I, 1992) |
| "Flecainide is a benzenacetamide synthesised about a decade ago and only recently introduced into the treatment of arrhythmias." | 8.77 | [Flecainide and anti-arrhythmia therapy]. ( Croce, L; Lomuscio, A; Pozzoni, L; Romano, S, 1988) |
| "Flecainide and propafenone are Class Ic antiarrhythmic drugs that block the cardiac fast inwards Na+ current and are used for rhythm control in patients with atrial fibrillation (AF)." | 8.31 | Medical therapy with flecainide and propafenone in atrial fibrillation: Long-term clinical experience in the tertiary care setting. ( Duru, F; Eriksson, U; Kovacs, B; Krasniqi, N; Yakupoglu, HY, 2023) |
| "Amiodarone, the most effective antiarrhythmic drug in atrial fibrillation, inhibits apixaban and rivaroxaban elimination, thus possibly increasing anticoagulant-related risk for bleeding." | 8.31 | Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial Fibrillation : A Retrospective Cohort Study. ( Chung, CP; Daugherty, JR; Dickson, AL; Dupont, WD; Hung, AM; Murray, KT; Ray, WA; Smalley, W; Stein, CM; Zimmerman, E, 2023) |
| "A 62 year old Caucasian man with a history of paroxysmal atrial fibrillation treated with flecainide, presented with atrial flutter with 1:1 conduction to the ventricles and was cardioverted." | 8.31 | Failure of diltiazem to prevent 1:1 conduction of atrial flutter: a case report. ( Ganesan, AN; Lahiri, A; Martin, DK; Quah, J; Tiver, KD, 2023) |
| "Oral and intravenous flecainide is recommended for cardioversion of atrial fibrillation." | 8.12 | Open-Label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution for Acute Conversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm. ( Aksoy, I; Al-Windy, N; Badings, E; Belardinelli, L; Camm, AJ; Crijns, HJGM; Elvan, A; Kowey, PR; Madhavapeddi, P; Ruskin, JN; Tuininga, YS; Van Gelder, IC, 2022) |
| "Flecainide, a widely prescribed class IC agent used to treat atrial arrhythmias, can in rare cases cause 1:1 atrial flutter with rapid conduction." | 8.02 | Flecainide-Induced Atrial Flutter With 1:1 Conduction Complicated by Ventricular Fibrillation After Electrical Cardioversion. ( Colangelo, T; Ho, R; Johnson, D, 2021) |
| "Inhaled flecainide significantly alters atrial electrical properties with the potential to terminate atrial fibrillation (AF) efficiently by optimizing dose and drug formulation." | 7.96 | Multimodal mechanisms and enhanced efficiency of atrial fibrillation cardioversion by pulmonary delivery of a novel flecainide formulation. ( Araujo Silva, B; Belardinelli, L; Bortolotto, AL; Hurrey, M; Madhavapeddi, P; Medeiros, SA; Pedreira, GC; Schuler, C; Tessarolo Silva, F; Verrier, RL, 2020) |
| "Flecainide pill-in-the-pocket therapy is a pharmacologic treatment option for patients with infrequent episodes of symptomatic atrial fibrillation." | 7.96 | Paroxysmal Atrial Fibrillation on Flecainide Therapy. ( Gavin, JL; Kim, SS; Peigh, GS, 2020) |
| "Vernakalant was safe, more effective and faster than flecainide in the cardioversion of recent-onset atrial fibrillation." | 7.91 | Intravenous vernakalant in comparison with intravenous flecainide in the cardioversion of recent-onset atrial fibrillation. ( Hartikainen, J; Heikkola, A; Hyppölä, H; Lekkala, M; Pohjantähti-Maaroos, H; Sinisalo, E, 2019) |
| "We investigated whether rapid administration of a low dose of flecainide, either intratracheally or intravenously (IV), could accelerate conversion of atrial fibrillation (AF) while reducing adverse ventricular effects." | 7.91 | Optimizing flecainide plasma concentration profile for atrial fibrillation conversion while minimizing adverse ventricular effects by rapid, low-dose intratracheal or intravenous administration. ( Belardinelli, L; Bortolotto, AL; de Antonio, VZ; Marum, AA; Silva, AC; Silva, BA; Verrier, RL, 2019) |
| "OBJECTIVE To compare the efficacy of quinidine and flecainide in treating naturally occurring, recent-onset atrial fibrillation (AF) in Thoroughbred racehorses." | 7.88 | Treatment of recent-onset atrial fibrillation with quinidine and flecainide in Thoroughbred racehorses: 107 cases (1987-2014). ( Ishikawa, Y; Ohmura, H; Takahashi, Y, 2018) |
| "Class Ic antiarrhythmic agents flecainide and propafenone are amongst the drugs most frequently prescribed to control atrial arrhythmias, in particular atrial fibrillation (AF)." | 7.88 | 1:1 atrial flutter induced by flecainide, whilst the patient was at rest. ( Cervellin, G; Comelli, I; Pigna, F, 2018) |
| "The antihistaminic antazoline (ANT) was reported to be highly effective and safe for rapid conversion of atrial fibrillation (AF)." | 7.85 | Effective suppression of atrial fibrillation by the antihistaminic agent antazoline: First experimental insights into a novel antiarrhythmic agent. ( Bögeholz, N; Bogossian, H; Dechering, DG; Eckardt, L; Fehr, M; Frommeyer, G; Kaese, S; Milberg, P; Pott, C; Sterneberg, M, 2017) |
| "Vernakalant is a new, safe and effective drug used intravenously, which has proved to be more rapid in converting recent onset atrial fibrillation (AF) to sinus rhythm compared to placebo, amiodarone, propafenone, and flecainide in clinical studies." | 7.80 | Vernakalant: Perception of state of health in patients with a recent-onset atrial fibrillation. ( Aragon, M; Conde, D; Costabel, JP; Lambardi, F; Trivi, M, 2014) |
| "Acute atrial fibrillation (AF) is often treated with the administration of intravenous flecainide; however, this treatment may not always be successful and is potentially hazardous." | 7.80 | Tissue velocity imaging of the left atrium predicts response to flecainide in patients with acute atrial fibrillation. ( Blaauw, Y; Crijns, HJ; De Vos, CB; Delhaas, T; Limantoro, I; Marcos, E; Pisters, R; Schotten, U; Tieleman, RG; Van Gelder, IC; Weijs, B, 2014) |
| "An oral single dose of flecainide is used worldwide for conversion of recent onset atrial fibrillation (AF) in hemodynamically stable patients without structural heart disease." | 7.79 | Flecainide versus vernakalant for conversion of recent-onset atrial fibrillation. ( Caro, M; Conde, D; Corrales Barboza, A; Costabel, JP; Ferro, A; Lambardi, F; Lavalle Cobo, A; Trivi, M, 2013) |
| "In several clinical and pre-clinical studies, application of ranolazine (RAN) led to suppression of atrial fibrillation (AF)." | 7.79 | Sodium channel block by ranolazine in an experimental model of stretch-related atrial fibrillation: prolongation of interatrial conduction time and increase in post-repolarization refractoriness. ( Belardinelli, L; Breithardt, G; Eckardt, L; Frommeyer, G; Ghezelbash, S; Milberg, P; Osada, N; Rajamani, S; Razvan, R, 2013) |
| "Blockade of inward-rectifier K+ channels by chloroquine terminates reentry in cholinergic atrial fibrillation (AF)." | 7.78 | Chloroquine terminates stretch-induced atrial fibrillation more effectively than flecainide in the sheep heart. ( Bandaru, K; Berenfeld, O; Calvo, CJ; Ennis, SR; Filgueiras-Rama, D; Jalife, J; Kalifa, J; Martins, RP; Mironov, S; Noujaim, SF; Yamazaki, M, 2012) |
| "To assess the safety of long-term treatment with flecainide in patients with atrial fibrillation (AF), particularly with regard to sudden cardiac death (SCD) and proarrhythmic events." | 7.77 | The safety of flecainide treatment of atrial fibrillation: long-term incidence of sudden cardiac death and proarrhythmic events. ( Almroth, H; Andersson, T; Englund, A; Fengsrud, E; Friberg, L; Linde, P; Rosenqvist, M, 2011) |
| "Flecainide is used as a pill-in-the-pocket treatment for pharmacological cardioversion in patients without structural heart disease and atrial fibrillation (AF)." | 7.76 | Flecainide for cardioversion in patients at elevated cardiovascular risk and persistent atrial fibrillation: a prospective observational study. ( Aslan, O; Caglayan, E; Er, F; Erdmann, E; Gassanov, N; Nia, AM; Rosenkranz, S, 2010) |
| "Flecainide can "organise" atrial fibrillation into atrial flutter with 1:1 conduction, leading to cardiovascular compromise." | 7.76 | Tachycardia due to atrial flutter with rapid 1:1 conduction following treatment of atrial fibrillation with flecainide. ( Gandhi, MM; Lloyd, G; Taylor, R, 2010) |
| " The aim of this study was to determine the effects of IPC versus intravenous (IV) d,l-sotalol and flecainide infusion on transmural atrial electrophysiology and sustained atrial fibrillation (AF) in the goat." | 7.75 | Effects of intrapericardial sotalol and flecainide on transmural atrial electrophysiology and atrial fibrillation. ( Accord, RE; Allessie, MA; Hermans, JJ; Maessen, JG; Schotten, U; Smits, JF; van Brakel, TJ, 2009) |
| "We present a case of flecainide-induced hyponatremia in a 67-year-old woman who was treated for paroxysmal atrial tachycardia." | 7.75 | A case of flecainide-induced hyponatremia. ( Ahmed, M; Akhtar, M; Mortada, ME; Sra, J, 2009) |
| "A 72-year-old male patient with dilated cardiomyopathy was treated with oral flecainide (100 mg/day) for persistent atrial fibrillation (AF) that could not be converted to sinus rhythm by electrical cardioversion." | 7.74 | Impact of serum flecainide level on control of atrial fibrillation in a case treated with cardiac resynchronization therapy. ( Aonuma, K; Doki, K; Homma, M; Kawano, S; Kohda, Y; Kuga, K; Yamaguchi, I, 2007) |
| "The relation between flecainide's plasma level and its influence on human atrial electrophysiology during acute and maintenance therapy of atrial fibrillation (AF) is unknown." | 7.73 | Pilot study: Noninvasive monitoring of oral flecainide's effects on atrial electrophysiology during persistent human atrial fibrillation using the surface electrocardiogram. ( Binias, KH; Bollmann, A; Geller, C; Husser, D; Klein, HU; Molling, J; Olsson, SB; Sornmo, L; Stridh, M, 2005) |
| "The purpose of this study was to evaluate the hypothesis that presumed reversion of electrical remodeling after cardioversion of atrial fibrillation (AF) restores the efficacy of flecainide." | 7.73 | Does flecainide regain its antiarrhythmic activity after electrical cardioversion of persistent atrial fibrillation? ( Allessie, MA; Bennekers, JH; Bosker, HA; Bracke, FA; Crijns, HJ; Haaksma, J; Kingma, T; Kirchhof, CJ; Tieleman, RG; Van Gelder, IC; Veeger, NJ; Wilde, AA, 2005) |
| "A 37-year-old man with symptomatic acute atrial fibrillation and a low-voltage electrocardiogram was treated with flecainide intravenously." | 7.73 | [Life-threatening ventricular tachycardia during flecainide treatment for symptomatic atrial fibrillation in a patient with a structural cardiac disorder]. ( Rienstra, M; van Gelder, IC; van Veldhuisen, DJ; Wiesfeld, AC, 2006) |
| "Bepridil, a multi-ion channel blocker, is effective for some types of cardiac arrhythmias, and so its effect on the paroxysmal atrial fibrillation (PAF) was evaluated in the present study, comparing it with class Ic antiarrhythmic drugs." | 7.72 | Evaluation of the effect of bepridil on paroxysmal atrial fibrillation: relationship between efficacy and the f-f interval in surface ECG recordings. ( Hara, H; Ikeda-Murakami, K; Inuo, K; Izumi, T; Kojima, J; Niwano, S; Saito, J; Yoshida, T, 2003) |
| "The cardiac safety of a once-a-day 200 mg controlled-release formulation of flecainide acetate in the prevention of paroxysmal atrial fibrillation (PAF) was assessed in outpatients." | 7.72 | Safety of a controlled-release flecainide acetate formulation in the prevention of paroxysmal atrial fibrillation in outpatients. ( Aliot, E; Capucci, A; Coumel, P; De Roy, L; Denjoy, I; Hernández, J; Lupoglazoff, JM, 2003) |
| " We describe the case of a 62-year-old male with latent Brugada syndrome in whom the intravenous infusion of flecainide for paroxysmal atrial fibrillation caused ECG abnormalities similar to those of an acute septal myocardial infarction." | 7.72 | [Infusion of flecainide in a patient with atrial fibrillation and latent Brugada's syndrome has determined modifications of the electrocardiogram similar to those of a septal myocardial infarct]. ( Carotenuto, F; Cirillo, R; D'Errico, L; di Palma, F; Fontana, D; Granato, L; Pagano, V; Sestri, C; Vitiello, N, 2003) |
| " flecainide has a high efficacy for the treatment of experimentally-induced acute atrial fibrillation (AF) in horses and that its use is associated with minimal toxic side effects." | 7.72 | Use of intravenous flecainide in horses with naturally-occurring atrial fibrillation. ( Blissitt, KJ; Keen, JA; van Loon, G; Young, LE, 2004) |
| "We present a case report describing an interaction between topical timolol maleate, verapamil, and flecainide resulting in symptomatic bradycardia." | 7.71 | Symptomatic bradycardia secondary to interaction between topical timolol maleate, verapamil, and flecainide: a case report. ( Herd, A; Minish, T, 2002) |
| "Chronic persistent atrial fibrillation was converted in 13/19 (68%) patients at baseline and in 16/19 (84%) patients after flecainide." | 7.70 | Favorable effects of flecainide in transvenous internal cardioversion of atrial fibrillation. ( Ayers, GM; Biffi, M; Boriani, G; Branzi, A; Bronzetti, G; Capucci, A; Magnani, B; Zannoli, R, 1999) |
| "(1) To investigate the electrophysiological effects of flecainide and propafenone during atrial fibrillation, and their relation to arrhythmia termination; (2) to investigate the effects of isoprenaline on atrial fibrillation in basal conditions and during treatment with class 1C drugs to evaluate the role of adrenergic stimulation on proarrhythmic events occurring during this treatment." | 7.70 | Electrophysiological effects of flecainide and propafenone on atrial fibrillation cycle and relation with arrhythmia termination. ( Biffi, M; Boriani, G; Branzi, A; Bronzetti, G; Capucci, A; Magnani, B, 1999) |
| "To determine a safe and efficacious dose of flecainide acetate for treating equine atrial fibrillation (Af), the safe dosage level was determined by injecting 1, 2, or 3 mg/kg i." | 7.70 | Safe and efficacious dosage of flecainide acetate for treating equine atrial fibrillation. ( Amada, A; Mizuno, Y; Nakayama, T; Nukada, T; Ohmura, H; Yamaya, Y, 2000) |
| "This study sought to determine the mechanisms of idiopathic atrial fibrillation and the atrial antifibrillatory action of flecainide in dogs." | 7.69 | Idiopathic atrial fibrillation in dogs: electrophysiologic determinants and mechanisms of antiarrhythmic action of flecainide. ( Feng, J; Nattel, S; Wang, Z, 1995) |
| "The effects of pilsicainide, a new class Ic antiarrhythmic agent, on the atrial fibrillation threshold (AFT), the atrial effective refractory period (ERP), and the interatrial conduction time (ACT) in Langendorff-perfused guinea pig hearts were investigated." | 7.68 | Effects of pilsicainide on the atrial fibrillation threshold in guinea pig atria. A comparative study with disopyramide, lidocaine and flecainide. ( Asayama, J; Inoue, D; Inoue, M; Ishibashi, K; Nakagawa, M; Omori, I; Sakai, R; Yamahara, Y, 1993) |
| "Flecainide (100 mg twice daily) was used for prevention of paroxysmal atrial fibrillation (PAF) in 52 patients with frequent symptomatic attacks that were resistant or intolerant to quinidine (600-900 mg/day)." | 7.68 | Flecainide in quinidine-resistant atrial fibrillation. ( Chouty, F; Coumel, P; Denjoy, I; Leclercq, JF; Slama, R, 1992) |
| "Twenty-eight patients with atrial fibrillation of less than 1 month's duration were given a single intravenous bolus of flecainide (2 mg/kg)." | 7.68 | Cardioversion of atrial fibrillation of recent onset with flecainide. ( Carr, B; Channer, KS; Hawley, K, 1991) |
| "The arrhythmogenic effects of flecainide in atrial fibrillation and flutter were assessed in a consecutive material of 100 patients without severe heart failure (NYHA class I or II)." | 7.68 | Flecainide acetate in atrial flutter and fibrillation. The arrhythmogenic effects. ( Hansen, FA; Pedersen, AK; Rasmussen, J; Sihm, I; Thygesen, K, 1990) |
| "Intravenous flecainide (2 mg/Kg for 15 min) was used in 30 patients (18 men and 12 women aged 23 to 85 years: mean 62) with recent or paroxysmal atrial fibrillation: 5 patients returned to sinus rhythm during flecainide administration while other 23 patients did it not later than 2 hours." | 7.67 | [Effects of intravenous flecainide in the treatment of paroxysmal or recent-onset atrial fibrillations]. ( Bolognesi, R; Manca, C; Tsialtas, D; Visioli, O, 1989) |
| "Flecainide acetate has a recognized proarrhythmic effect in patients treated for ventricular tachycardia." | 7.67 | Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. ( Falk, RH, 1989) |
| "The action of intravenous flecainide was studied in patients presenting a tachyarrhythmia secondary to a permanent atrial fibrillation of recent onset." | 7.67 | [Flecainide by the intravenous route: a new method for decreasing auricular fibrillation]. ( Assyag, P; Brechenmacher, C; Chauvin, M; Fass, H; Klein, JM, 1987) |
| "Thirty-nine patients with symptomatic ectopic atrial tachycardia (9 paroxysmal, of which 5 were incessant) and atrial fibrillation (AF) (25 paroxysmal, 5 chronic) were treated with oral flecainide acetate (100 to 400 mg/day)." | 7.67 | Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillation. ( Berns, E; Dougherty, AH; Jeang, MK; Jenkins, M; Naccarelli, GV; Rinkenberger, RL, 1987) |
| "Fifty-one consecutive patients with atrial tachycardia [atrial fibrillation (FA) 37, atrial flutter (Fl) 10, tachycardia (TSA) 4] received a single 2 mg/kg dose of flecainide injected intravenously over 5 to 10 minutes." | 7.67 | [Reduction of auricular fibrillation and tachycardia using intravenous flecainide]. ( Aumont, MC; Boujon, B; Charlier, P; Cohen-Solal, A; Dahan, M; Farinotti, P; Jaeger, P; Juliard, JM, 1987) |
| "The efficacy of flecainide acetate for conversion of atrial fibrillation into sinus rhythm was assessed in 69 patients (mean age of 63 +/- 14 years)." | 7.67 | Restoration of sinus rhythm with flecainide in patients with atrial fibrillation. ( Goy, JJ; Kappenberger, L; Kaufmann, U; Sigwart, U, 1988) |
| "A 42-year old man with non-obstructive myocardiopathy complicated by paroxysmal atrial fibrillation treated with amiodarone (200 mg per day) received flecainide in daily doses of 400 mg for undocumented palpitations." | 7.67 | [Bundle branch reentry tachycardia: a possible mechanism of flecainide proarrhythmia effect]. ( Berland, J; Cribier, A; Letac, B; Saoudi, N, 1988) |
| "Flecainide is reported to be effective in patients with paroxysmal tachycardias, but its effect on rapid ventricular response over accessory atrioventricular pathway during atrial fibrillation is not known." | 7.67 | Evaluation of flecainide acetate in rapid atrial fibrillation complicating Wolff-Parkinson-White syndrome. ( Fromer, MA; Gloor, HO; Kappenberger, LJ; Shenasa, M, 1985) |
| "Flecainide has been tested with variable efficacy." | 6.87 | Time-dependent antiarrhythmic effects of flecainide on induced atrial fibrillation in horses. ( Buhl, R; Carstensen, H; Fenner, M; Flethøj, M; Hesselkilde, EZ; Jespersen, T; Kanters, JK; Loft-Andersen, AV; Pehrson, S; Sattler, SM; Tfelt-Hansen, J, 2018) |
| "In order to prevent AF recurrences, many anti-arrhythmic drugs are currently available, but most of them are burdened by serious side effects and suboptimal efficacy." | 6.82 | Flecainide-metoprolol combination reduces atrial fibrillation clinical recurrences and improves tolerability at 1-year follow-up in persistent symptomatic atrial fibrillation. ( Capucci, A; Gabrielli, D; Guerra, F; Piangerelli, L; Ricciotti, J, 2016) |
| "The pharmacodynamic equivalence of flecainide acetate immediate-release (IR) and controlled-release (CR) formulations was assessed from QRS duration in patients currently treated with the IR formulation." | 6.71 | Pharmacodynamic equivalence of two flecainide acetate formulations in patients with paroxysmal atrial fibrillation by QRS analysis of ambulatory electrocardiogram. ( Coumel, P; Leenhardt, A; Maison-Blanche, P; Milliez, P; Périer, A; Tarral, E, 2003) |
| "Patients with paroxysmal atrial fibrillation (PAF) are prone to recurrence." | 6.67 | A randomized double-blind crossover study comparing the efficacy and tolerability of flecainide and quinidine in the control of patients with symptomatic paroxysmal atrial fibrillation. ( Lau, CP; Leung, WH; Wong, CK, 1992) |
| "In the acute treatment of paroxysmal atrial fibrillation several drugs can be used." | 6.67 | [The efficacy of oral treatment with flecainide for paroxysmal atrial fibrillation: correlation with plasma concentration]. ( Arruzzoli, S; Dieci, G; Gandolfini, A; Gazzola, U; Groppi, F; Groppi, M; Piepoli, M; Rosi, A; Villani, GQ, 1990) |
| "Amiodarone was associated with the highest rate of patients experiencing at least one serious adverse event (OR 2." | 6.47 | Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. ( Eckert, L; Freemantle, N; Lafuente-Lafuente, C; Mitchell, S; Reynolds, M, 2011) |
| "This study suggests that flecainide and beta-blockers association is complementary to implantable cardioverter-defibrillator and catheter ablation and is safe for treating persistent symptomatic VA in patients with ARVC." | 5.72 | Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy. ( Badenco, N; Duthoit, G; Frank, R; Gandjbakhch, E; Hidden-Lucet, F; Himbert, C; Laredo, M; Maupain, C; Rolland, T; Waintraub, X, 2022) |
| "Flecainide is a class 1C antiarrhythmic, which is known to cause several cardiac and non-cardiac adverse reactions." | 5.62 | Flecainide-induced myalgias and weakness: a rare adverse reaction. ( Kumar, D; Mersfelder, T; Patel, P; Rehman, ME, 2021) |
| "Treatment with flecainide CR significantly improves QoL in both paroxysmal as well as persistent AF patients, with an excellent safety profile and associated patient compliance." | 5.56 | Beneficial Effect of Flecainide Controlled Release on the Quality of Life of Patients with Atrial Fibrillation-the REFLEC-CR Study. ( Asvestas, D; Gavriilidou, M; Giannakoulas, G; Kapetanios, K; Karlis, D; Koufaki, P; Kourouklis, S; Kouskos, G; Papadimitriou, G; Patsourakos, F; Taxiarchou, E; Tsiachris, D; Tzeis, S; Vatkalis, N, 2020) |
| " We analysed the differences between amiodarone and class IC group in terms of efficacy and safety that is conversion to sinus rhythm rates within 12 and 48 h after starting treatment, time to conversion, and adverse drug effects." | 5.46 | Efficacy and safety in pharmacological cardioversion of recent-onset atrial fibrillation: a propensity score matching to compare amiodarone vs class IC antiarrhythmic drugs. ( Bonora, A; Dilda, A; Franchi, E; Maccagnani, A; Olivieri, O; Pistorelli, C; Taioli, G; Turcato, G; Zerman, G, 2017) |
| "Pill-in-the-pocket treatment should be prescribed only if the administration of a loading oral dose of flecainide or propafenone has been proved safe in hospital, since major adverse effects have been reported in 5% of patients during in-hospital treatment." | 5.36 | Intravenous administration of flecainide or propafenone in patients with recent-onset atrial fibrillation does not predict adverse effects during 'pill-in-the-pocket' treatment. ( Alboni, P; Boriani, G; Botto, GL; Capucci, A; Iori, M; Mancini, M; Mariconti, B; Pacchioni, F; Pasanisi, G; Russo, G, 2010) |
| "Flecainide was discontinued because of adverse effects in 6 patients (4%)." | 5.33 | Long-term results of hybrid therapy in patients with atrial fibrillation who develop atrial flutter during flecainide infusion. ( Astarita, C; De Matteis, C; De Simone, A; Di Napoli, T; El Jamal, B; Greco, L; La Rocca, V; Messina, V; Nocerino, P; Rotunno, R; Stabile, G; Turco, P; Vitale, DF, 2005) |
| "The management of patients with paroxysmal atrial fibrillation (AF) is unsuccessful, because AF recurs in about 50% of patients despite an antiarrhythmic treatment." | 5.30 | [The role of an electropharmacological transesophageal test in the prevention of paroxysmal atrial fibrillation. Experience with flecainide]. ( Accogli, S; Ciolli, A; De Sisti, A; Di Lorenzo, M; Lo Sardo, G; Matteucci, C; Palamara, A; Patrissi, T; Sasdelli, M, 1998) |
| " The administration of flecainide, dosage 1." | 5.28 | [A case of atrial paralysis during the use of intravenous flecainide acetate]. ( Pardini, E; Tognarini, S, 1989) |
| "In this study, we randomly compared single oral doses of flecainide, amiodarone and propafenone versus placebo for the conversion of recent atrial fibrillation (AF) (within 48 hours)." | 5.15 | Pharmacological conversion of recent atrial fibrillation: a randomized, placebo-controlled study of three antiarrhythmic drugs. ( Balla, I; Kondili, A; Petrela, E, 2011) |
| "The mechanism of the action of flecainide in the termination of human atrial fibrillation (AF) is not fully understood." | 5.14 | Increase in organization index predicts atrial fibrillation termination with flecainide post-ablation: spectral analysis of intracardiac electrograms. ( Jeilan, M; Kundu, S; Mantravadi, R; Ng, GA; Osman, F; Stafford, PJ; Tuan, J, 2010) |
| "The beta(1)AR Arg389Arg genotype is associated with increased flecainide potency and higher heart rate during atrial fibrillation." | 5.14 | Beta1-adrenoceptor polymorphism predicts flecainide action in patients with atrial fibrillation. ( Aslan, O; Caglayan, E; Duru, F; Er, F; Erdmann, E; Gassanov, N; Hellmich, M; Nia, AM; Rosenkranz, S; Zimmermann, T, 2010) |
| "Patients received intravenous flecainide, propafenone, or amiodarone on presentation and a second dose after 6 hours if atrial fibrillation persisted." | 5.14 | Management of patients with acute atrial fibrillation in the ED. ( Abbate, R; Conti, A; Del Taglia, B; Gensini, GF; Grifoni, S; Mariannini, Y; Michelucci, A; Padeletti, L; Pepe, G; Vanni, S, 2010) |
| "It has been reported that bepridil is as good as amiodarone in converting persistent atrial fibrillation (AF) to sinus rhythm (SR)." | 5.13 | Use of bepridil in combination with Ic antiarrhythmic agent in converting persistent atrial fibrillation to sinus rhythm. ( Aoyama, H; Enomoto, M; Hirayama, A; Imai, S; Kushiro, T; Saito, F; Takase, H; Yagi, H; Yamaji, S; Yokoyama, K, 2008) |
| "To compare flecainide and dronedarone for sinus rhythm (SR) maintenance following electrocardioversion of persistent atrial fibrillation (AF), in patients with minimal or no structural heart disease." | 5.12 | Comparison of dronedarone vs. flecainide in the maintenance of sinus rhythm, following electrocardioversion in adults with persistent atrial fibrillation: a systematic review and meta-analysis. ( Moore, Z; Nugent, L; O'Connor, T; Patton, D; Wilson, H, 2021) |
| "Flecainide acetate instant release (LI) has been prescribed for years in the prevention of atrial fibrillation (AF) relapse after sinus rate conversion." | 5.12 | [Flecainide controlled-release for prevention of atrial fibrillation relapse]. ( Chatelin, A; Jaillon, P; Mary-Krause, M; Simon, T; Thuault, M, 2006) |
| "The study aimed to report our experience of intravenous flecainide administration in the treatment of paroxysmal atrial fibrillation (PAF) in the Emergency Room (ER)." | 5.12 | [Intravenous flecainide administration for conversion of paroxysmal atrial fibrillation in the emergency room]. ( Antonelli, D; Darawsha, A; Feldman, A; Freedberg, NA; Rosenfeld, T, 2006) |
| "A double-blind, randomized, parallel-group, placebo-controlled trial was conducted in patients with paroxysmal atrial fibrillation or flutter (PAF/PAFL) experiencing 2 or more episodes of symptomatic PAF/PAFL during a 28-day observation period to determine the dose-response effect and safety of flecainide." | 5.12 | Dose-response effect of flecainide in patients with symptomatic paroxysmal atrial fibrillation and/or flutter monitored with trans-telephonic electrocardiography: a multicenter, placebo-controlled, double-blind trial. ( Atarashi, H; Hamada, C; Inoue, H; Ogawa, S, 2007) |
| "The QT/RR relationship was obtained in 45 subjects without heart disease (20 men, 25 women); 20 were taken as controls, and 30 were under antiarrhythmic prophylaxis for lone atrial fibrillation (15 with amiodarone, 15 with flecainide)." | 5.12 | Different effects of antiarrhythmic drugs on the rate-dependency of QT interval: a study with amiodarone and flecainide. ( Facchini, M; Malfatto, G; Zaza, A, 2007) |
| "This study compared the efficacy and safety of intravenous flecainide and ibutilide for immediate cardioversion of atrial fibrillation (AF)." | 5.11 | Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset. ( Aicher, F; Bachleitner, T; Eisserer, G; Gatterer, E; Grander, W; Heinze, G; Kühn, P; Lang, W; Niemeth, C; Reisinger, J; Siostrzonek, P; Vanicek, T, 2004) |
| "We sought to assess the efficacy and safety of ibutilide cardioversion for those with atrial fibrillation (AF) or atrial flutter (AFL) receiving long-term treatmentwith class IC agents." | 5.11 | Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents. ( Bonso, A; Glatter, KA; Hongo, RH; Raviele, A; Rossillo, A; Scheinman, MM; Themistoclakis, S; Yang, Y, 2004) |
| "In-hospital administration of flecainide and propafenone in a single oral loading dose has been shown to be effective and superior to placebo in terminating atrial fibrillation." | 5.11 | Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. ( Alboni, P; Baldi, N; Baroffio, R; Botto, GL; Calzolari, M; Gaggioli, G; Gianfranchi, L; Luzi, M; Marchi, P; Russo, V; Solano, A, 2004) |
| "The objectives were to study the absorption kinetics and pharmacodynamics of two oral formulations of flecainide in patients with atrial fibrillation (AF) and to assess the relationship between pharmacokinetic parameters and the efficacy in restoring sinus rhythm." | 5.11 | Absorption kinetics and pharmacodynamics of two oral dosage forms of flecainide in patients with an episode of paroxysmal atrial fibrillation. ( Brouwers, JR; Deneer, VH; Dunselman, PH; Gossen, SA; Kingma, JH; Lie-A-Huen, L; Proost, JH; Stuurman, A; Uytdehaag, GM, 2004) |
| "Flecainide and sotalol prolong the atrial action potential during atrial fibrillation in humans." | 5.11 | Electrophysiological effects of flecainide and sotalol in the human atrium during persistent atrial fibrillation. ( Breithardt, G; Eckardt, L; Engelen, M; Franz, MR; Haverkamp, W; Kirchhof, P; Ribbing, M; Wasmer, K, 2005) |
| "[corrected] Bepridil, a multiple ion-channel blocker, has been reported to prevent paroxysmal atrial fibrillation (PAF)." | 5.10 | Bepridil prevents paroxysmal atrial fibrillation by a class III antiarrhythmic drug effect. ( Hara, H; Ikeda-Murakami, K; Inuo, K; Izumi, T; Kojima, J; Niwano, S; Saito, J; Yoshida, T, 2003) |
| "To evaluate the impact, on atrial fibrillation (AF) recurrences, of verapamil addition to a class IC or III antiarrhythmic drug in patients, with persistent AF, who underwent an electrical cardioversion (EC)." | 5.10 | VErapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF Study). ( Alfano, F; Campana, A; Canciello, M; De Fabrizio, G; De Matteis, C; De Pasquale, M; De Simone, A; Di Mauro, M; Manzo, M; Sabino, L; Stabile, G; Turco, P; Vitale, DF, 2003) |
| " low-dose flecainide followed by oral pilsicainide might be a promising strategy for the outpatient treatment of paroxysmal atrial fibrillation." | 5.10 | Low-dose flecainide infusion followed by oral pilsicainide is highly effective and safe for paroxysmal atrial fibrillation. ( Kubota, I; Nagai, S; Takeishi, Y, 2003) |
| "In this multicentre randomized controlled trial, 68 patients affected by severely symptomatic paroxysmal atrial fibrillation were assigned, after successful atrioventricular junction ablation and pacing treatment, to antiarrhythmic drug therapy with amiodarone, propafenone, flecainide or sotalol and were compared with 69 patients assigned, after successful AV junction ablation and pacing treatment, to no antiarrhythmic drug therapy." | 5.10 | An evaluation of the strategy of maintenance of sinus rhythm by antiarrhythmic drug therapy after ablation and pacing therapy in patients with paroxysmal atrial fibrillation. ( Alboni, P; Bongiorni, MG; Botto, GL; Brignole, M; Bruna, C; Gasparini, M; Menozzi, C; Ometto, R; Verlato, R; Vincenti, A, 2002) |
| "To investigate whether an oral loading dose of flecainide is as safe and effective as intravenous flecainide for the cardioversion of acute atrial fibrillation." | 5.09 | Randomised double blind trial of oral versus intravenous flecainide for the cardioversion of acute atrial fibrillation. ( Alp, NJ; Bell, JA; Shahi, M, 2000) |
| "In a prospective, single-blind trial, we randomized 150 consecutive symptomatic patients with acute (< or = 48 hours' duration) atrial fibrillation to receive intravenous flecainide, propafenone, or amiodarone." | 5.09 | Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. ( Camacho, C; Fernández-Gómez, JM; García-Garmendia, JL; Martínez-Marcos, FJ; Ortega-Carpio, A; Santos, JM, 2000) |
| "The authors report their experience in recent-onset atrial fibrillation treated with intravenous flecainide and propafenone, in comparison with the placebo group." | 5.09 | [Effectiveness and side effects of the treatment with propafenone and flecainide for recent-onset atrial fibrillation]. ( Caccavale, F; Catanzaro, M; Coppo, A; Corsini, F; Corsini, G; Di Maggio, O; Fattore, L; Iodice, E; Martone, A; Romano, A; Romano, S; Toscano, G, 2001) |
| "We tested the hypothesis that the response to flecainide infusion can identify patients with atrial fibrillation (AF) in whom the hybrid pharmacologic and ablation therapy reduces the recurrences of AF." | 5.09 | Response to flecainide infusion predicts long-term success of hybrid pharmacologic and ablation therapy in patients with atrial fibrillation. ( Astarita, C; De Matteis, C; De Simone, A; Di Napoli, T; La Rocca, V; Maresca, F; Nocerino, P; Stabile, E; Stabile, G; Turco, P; Vitale, DF, 2001) |
| "Aim of the present study was to assess the efficacy and safety of flecainide (F) and sotalol (S) for the prevention of recurrences of paroxysmal atrial fibrillation (PAF)." | 5.08 | [A comparison between flecainide and sotalol in the prevention of recurrences of paroxysmal atrial fibrillation]. ( Burattini, M; Carunchio, A; Ceci, V; Fera, MS; Galati, A; Greco, G; Mazza, A, 1995) |
| "In a randomized, double-blind, controlled study of 98 patients with atrial fibrillation (AF) (present for > or = 30 minutes, < or = 72 hours, and a ventricular response of > or = 100 beats/min), intravenous flecainide (2 mg/kg, maximum 150 mg) was compared with intravenous amiodarone (7 mg/kg) and placebo." | 5.08 | Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. ( Dobb, GJ; Donovan, KD; Hockings, BE; Lee, KY; Power, BM, 1995) |
| "In order to compare the efficacy and long-term tolerability of flecainide acetate versus quinidine, 239 patients with paroxysmal atrial fibrillation were prospectively treated with flecainide (n = 122) or quinidine (n = 117) in an open-label, randomized trial." | 5.08 | Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group. ( Coumel, P; Dorian, P; Hohnloser, SH; Naccarelli, GV, 1996) |
| "To compare the relative safety of flecainide acetate to propafenone HCl during long-term treatment (12 months), we conducted a randomized, open-label, comparative, parallel, multicenter trial in 200 patients with paroxysmal atrial fibrillation (AF) and no history of heart disease." | 5.08 | Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators. ( Casadei, G; Chimienti, M; Cullen, MT, 1996) |
| "To assess the cardiac and extracardiac safety and efficacy of flecainide versus propafenone in patients suffering from episodes of paroxysmal atrial fibrillation (AF) or atrial flutter, 97 patients were enrolled in a randomized, open-label, long-term, parallel, comparative multicenter study." | 5.08 | Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group. ( Aliot, E; Denjoy, I, 1996) |
| "Patients with supraventricular arrhythmias have been safely and effectively treated with flecainide." | 5.08 | Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group. ( Buxton, AE; Heilman, JM; Hopson, JR; Kienzle, MG; Nademanee, K; Rinkenberger, RL, 1996) |
| "In order to compare the long-term safety of flecainide and propafenone, an open label, randomized, parallel group study was performed in 335 patients with paroxysmal atrial fibrillation (n = 200) or paroxysmal supraventricular tachycardia (n = 135), and no history of heart disease." | 5.08 | Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. ( Casadei, G; Chimienti, M; Cullen, MT, 1995) |
| "This study sought to compare the efficacy and safety of intravenous flecainide and sotalol for immediate cardioversion of atrial fibrillation." | 5.08 | Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation. ( Ebner, A; Gatterer, E; Gattermeier, M; Heinze, G; Hohenwallner, W; Kratzer, H; Kuhn, P; Lenz, K; Poelzl, G; Reisinger, J; Slany, J; Wiesinger, K; Zeindlhofer, E, 1998) |
| "The purpose of our study (conducted between August 1995 and September 1996) was to evaluate prospectively the efficacy of intravenous administration (in 10 min) of sotalol, flecainide or the combination of these drugs to restore sinus rhythm in patients (without cardiac/pulmonary failure) who came to the First Heart Aid of our hospital with atrial fibrillation lasting less than 24 h." | 5.08 | Treatment of recent onset atrial fibrillation with intravenous sotalol and/or flecainide. ( Braat, SH; Heymeriks, J; Peters, FP; Wellens, HJ, 1998) |
| "The incidence of fast atrial tachycardias with regular ventricular rhythm was assessed in a population of 243 patients with recent onset (< 72 hours) atrial fibrillation (AF), without heart failure, randomly treated with single loading oral dose of propafenone (600 mg), flecainide (300 mg), digoxin (1 mg), or placebo for acute conversion to sinus rhythm (SR)." | 5.07 | Regular ventricular rhythms before conversion of recent onset atrial fibrillation to sinus rhythm. ( Bonini, W; Botto, GL; Broffoni, T; Cappelletti, G; Falcone, C; Ferrari, G; Lombardi, R; Paulesu, A; Pedraglio, E, 1994) |
| "In this prospective, controlled and randomized cross-over study we tried to establish the efficiency and safety of flecainide vs procainamide for the treatment of acute atrial fibrillation." | 5.07 | Comparison of flecainide and procainamide in cardioversion of atrial fibrillation. ( Costa, A; Madrid, AH; Marín-Huerta, E; Mestre, JL; Moro, C; Novo, L, 1993) |
| "The effects of intravenous flecainide and propafenone (2 mg/kg) administered in random order were compared in 16 patients with Wolff-Parkinson-White syndrome." | 5.07 | Effects of flecainide on atrial electrophysiology in the Wolff-Parkinson-White syndrome. ( Camm, AJ; Katritsis, D; Nunain, SO, 1992) |
| "In order to assess efficacy, safety, and long-term tolerance of flecainide for the prevention of paroxysmal atrial fibrillation (PAF), 944 patients (555 male) were enrolled in an open multicenter study." | 5.07 | Flecainide acetate in the prevention of paroxysmal atrial fibrillation: a nine-month follow-up of more than 500 patients. ( Clementy, J; Denjoy, I; Dos Santos, P; Dulhoste, MN; Laiter, C, 1992) |
| "The efficacy and safety of intravenous flecainide to convert recent-onset atrial fibrillation (AF) (present for greater than or equal to 30 minutes and less than or equal to 72 hours and a ventricular response greater than or equal to 120 beats/min) was investigated." | 5.07 | Efficacy of flecainide for the reversion of acute onset atrial fibrillation. ( Clarke, GM; Coombs, LJ; Dobb, GJ; Donovan, KD; Lee, KY; Murdock, CJ; Weekes, JN, 1992) |
| "Efficacy and safety of intravenous flecainide (2 mg/kg body weight in 10 minutes), verapamil (10 mg in 1 minute), and propafenone (2 mg/kg body weight in 10 minutes) were investigated in 90 consecutive patients with atrial fibrillation (AF) or flutter (AFL)." | 5.07 | Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil. ( Kingma, JH; Suttorp, MJ, 1992) |
| "In 34 patients with a symptomatic accessory atrioventricular connection the reversible protective effect of orally administered flecainide (300 mg/day) and of propafenone (900 mg/day) in control of ventricular response during atrial fibrillation by exercise was assessed." | 5.07 | Reversible protective effect of propafenone or flecainide during atrial fibrillation in patients with an accessory atrioventricular connection. ( Auricchio, A, 1992) |
| "Sixty-two patients with recent-onset (less than or equal to 1 week) atrial fibrillation (New York Heart Association functional class 1 and 2) were randomized in a single-blind study to 1 of the following treatment groups: (1) flecainide (300 mg) as a single oral loading dose; or (2) amiodarone (5 mg/kg) as an intravenous bolus, followed by 1." | 5.07 | Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. ( Binetti, N; Boriani, G; Capucci, A; Cavazza, M; Fontana, G; Lenzi, T; Magnani, B; Trisolino, G, 1992) |
| "We compared the electrophysiological effects of intravenous propafenone and flecainide on accessory pathway conduction by a randomized crossover study in 16 patients with Wolff-Parkinson-White syndrome." | 5.07 | A comparison of intravenous propafenone and flecainide in the treatment of tachycardias associated with the Wolff-Parkinson-White syndrome. ( Camm, AJ; Garratt, CJ; Gill, J; Linker, NJ; O'Nunain, S; Ward, DE, 1991) |
| "The dose-response relations for efficacy and tolerance of the antiarrhythmic drug flecainide acetate were studied in 28 patients with paroxysmal supraventricular tachycardia (Group 1) and 45 patients with paroxysmal atrial fibrillation or flutter (Group 2)." | 5.07 | Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: dose-response studies. The Flecainide Supraventricular Tachycardia Study Group. ( DaTorre, SD; Hougham, AJ; McCarville, SE; Platt, ML; Pritchett, EL, 1991) |
| "To evaluate the efficacy of flecainide acetate in the prevention of paroxysmal atrial fibrillation and flutter, 43 patients (23 men) (mean age 53 years) were randomized blindly to receive either placebo or 150 mg of flecainide twice per day for consecutive periods of 3 months." | 5.07 | Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Danish-Norwegian Flecainide Multicenter Study Group. ( Hellemann, H; Pietersen, AH, 1991) |
| "The efficacy of oral cibenzoline (260 mg/day and 320 mg/day) and flecainide (200 mg/day and 300 mg/day) in the conversion of chronic atrial fibrillation to sinus rhythm were compared in 31 patients in a randomized order." | 5.07 | Randomized comparison of flecainide and cibenzoline in the conversion of atrial fibrillation. ( Kühlkamp, V; Risler, T; Schmid, F; Seipel, L, 1991) |
| "In a single-blind randomized study, the efficacy and safety of intravenous propafenone (2 mg/kg body weight per 10 min) versus flecainide (2 mg/kg per 10 min) were assessed in 50 patients with atrial fibrillation or flutter." | 5.06 | The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. ( Jessurun, ER; Kingma, JH; Lie, KI; Lie-A-Huen, L; Suttorp, MJ; van Hemel, NM, 1990) |
| "In 69 consecutive patients with recent-onset atrial fibrillation, we compared the usefulness of verapamil, flecainide and propafenone for the acute conversion to sinus rhythm within 1 hour of the start of intravenous infusion." | 5.06 | Comparative evaluation of verapamil, flecainide and propafenone for the acute conversion of atrial fibrillation to sinus rhythm. ( Kastrati, A; Kondili, A; Popa, Y, 1990) |
| "Seventy-seven patients with symptomatic atrial fibrillation (AF) received oral flecainide acetate (247 +/- 8 mg/day)." | 5.06 | Clinical efficacy of flecainide acetate in atrial fibrillation. ( Kulbertus, HE; Mary-Rabine, L, 1990) |
| "We compared the efficacy of flecainide versus quinidine in preventing paroxysms of atrial fibrillation in a randomized open crossover study." | 5.06 | Flecainide versus quinidine in the prevention of paroxysms of atrial fibrillation. ( Crijns, HJ; den Heijer, P; Lie, KI; van Gilst, WH; van Wijk, LM, 1989) |
| "In a single-blind randomized study, the efficacy of intravenous flecainide (2 mg/kg/10 minutes) versus verapamil (10 mg/1 minute) was assessed in 40 patients with paroxysmal atrial fibrillation (AF) or atrial flutter (AFI)." | 5.06 | Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. ( Kingma, JH; Lie-A-Huen, L; Mast, EG; Suttorp, MJ, 1989) |
| "The efficacy and safety of flecainide were studied in the maintenance of sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter." | 5.06 | Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. ( Crijns, HJ; Hamer, HP; Lie, KI; Van Gelder, IC; Van Gilst, WH; Van Wijk, LM, 1989) |
| "This study was designed to assess the clinical efficacy of oral flecainide for the prevention of paroxysmal attacks of atrial fibrillation (AF)." | 5.06 | Oral flecainide for prophylaxis of paroxysmal atrial fibrillation. ( Chouty, F; Coumel, P, 1988) |
| "The efficacy and safety of oral (up to 400 mg in 3 h) and intravenous regimens (up to 150 mg in 10 min) of flecainide acetate were compared in the acute conversion of atrial fibrillation to sinus rhythm." | 5.06 | Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate. Comparison of two regimens. ( Crijns, HJ; Kingma, JH; Lie, KI; van Gelder, IC; van Gilst, WH; van Wijk, LM, 1988) |
| "In a prospective study 45 patients with paroxysmal atrial fibrillation were randomly assigned to one of three groups (of 15 patients each): group I received oral digoxin, three times 0." | 5.06 | [Therapy of paroxysmal atrial fibrillation. Cardiac glycosides alone or combined with anti-arrhythmia agents?]. ( Bach, P; Doliwa, R; Steinbeck, G, 1988) |
| "The efficacy and safety of flecainide for long-term prevention of paroxysmal atrial fibrillation (AF) were studied in an open trial." | 5.06 | Long-term efficacy of flecainide in paroxysmal atrial fibrillation. ( Kallryd, A; Nylander, E; Rydén, L; Sonnhag, C, 1988) |
| "The effectiveness and safety of flecainide and quinidine for conversion of atrial fibrillation (AF) to sinus rhythm were compared." | 5.06 | Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. ( Borgeat, A; Goy, JJ; Grbic, M; Kaufmann, U; Maendly, R; Sigwart, U, 1986) |
| "Over the last 35 years, flecainide proved itself one of the most commonly used arrhythmic drugs, expanding its original indication for ventricular arrhythmias and results nowadays as the cornerstone of the rhythm control strategy in atrial fibrillation management of patients without structural heart disease." | 5.01 | Flecainide: Electrophysiological properties, clinical indications, and practical aspects. ( Capucci, A; Guerra, F; Paolini, E; Stronati, G, 2019) |
| "The aim of this review is to evaluate the available data on efficacy and safety of flecainide in all the spectrum of its indications including cardioversion of recent-onset AF, sinus rhythm maintenance in paroxysmal AF and management of ventricular tachyarrhythmias." | 4.89 | Flecainide acetate for the treatment of atrial and ventricular arrhythmias. ( Apostolakis, S; Breithardt, G; Fabritz, L; Kirchhof, P; Oeff, M; Tebbe, U, 2013) |
| "Flecainide is a class Ic antiarrhythmic agent that has an important role as part of rhythm control strategies in patients with atrial fibrillation (AF)." | 4.88 | Safety of flecainide. ( Capucci, A; Mabo, P; Tamargo, J, 2012) |
| "The efficacy and safety of the single oral loading dose of flecainide for cardioversion of recent-onset atrial fibrillation was examined by reviewing the trials on the subject identified through a comprehensive literature search." | 4.82 | Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation. ( Khan, IA, 2003) |
| "A short cut review was carried out to establish whether amiodarone is better than flecainide at restoring sinus rhythm in patients with atrial fibrillation." | 4.82 | Best evidence topic report. Amiodarone or flecainide for cardioversion in acute onset atrial fibrillation. ( Argall, J; Crawford, I, 2004) |
| " Most recently, the introduction of dofetilide has widened the therapeutic options in patients with severe heart disease, and the Canadian Trial of Atrial Fibrillation indicated the superior efficacy of amiodarone at low doses." | 4.82 | Antiarrhythmic drug therapy of atrial fibrillation. ( Mounsey, JP; VerNooy, RA, 2004) |
| " These antiarrhythmics, prescribed to prevent atrial fibrillation (3 patients) and atrial flutter (5 patients), were flecainide in 4 cases, propafenone in 2 cases and cibenzoline and hydroquinidine respectively associated with digitoxine and propranolol." | 4.79 | [Supraventricular tachycardia with wide QRS complexes during Vaughan-Williams class I anti-arrhythmic treatment. Diagnostic and therapeutic implications]. ( Aouate, P; Benassar, A; Fontaine, G; Frank, R; Jacquemin, M; Laborde, JP; Tageddine, R; Tonet, J; Turlure, A, 1995) |
| "Among the drugs recommended to prevent recurrences of atrial fibrillation after external electric shock, antiarrhythmic agents of classes Ia (quinidine, disopyramide), Ic (cibenzoline, flecainide, propafenone) and III (sotalol) seem to have the same effectiveness in maintaining the sinus rhythm in about 50 percent of the cases after 6 months and one year." | 4.78 | [Antiarrhythmic treatment after reduction of atrial fibrillation by external shock]. ( Brechenmacher, C; Chauvin, M; Koenig, A; Theolade, R, 1993) |
| "This report summarizes efficacy and safety data on the use of flecainide acetate for supraventricular arrhythmias." | 4.78 | Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias. ( Hohnloser, SH; Zabel, M, 1992) |
| "The effects of flecainide on electrophysiologic parameters and arrhythmias in the Wolff-Parkinson-White syndrome were reviewed." | 4.78 | Flecainide in the Wolff-Parkinson-White syndrome. ( Crozier, I, 1992) |
| " A 59-year-old woman had a permanent pacemaker implanted after diagnosis of tachycardia-bradycardia syndrome, and her drug regimen of digoxin, verapamil, and warfarin was supplemented with flecainide to prevent paroxysmal atrial fibrillation." | 4.78 | Interference by antiarrhythmic agents with function of electrical cardiac devices. ( Bauman, JL; Ezri, M; Nazari, J; Tworek, DA, 1992) |
| "Flecainide is a benzenacetamide synthesised about a decade ago and only recently introduced into the treatment of arrhythmias." | 4.77 | [Flecainide and anti-arrhythmia therapy]. ( Croce, L; Lomuscio, A; Pozzoni, L; Romano, S, 1988) |
| "Flecainide and propafenone are Class Ic antiarrhythmic drugs that block the cardiac fast inwards Na+ current and are used for rhythm control in patients with atrial fibrillation (AF)." | 4.31 | Medical therapy with flecainide and propafenone in atrial fibrillation: Long-term clinical experience in the tertiary care setting. ( Duru, F; Eriksson, U; Kovacs, B; Krasniqi, N; Yakupoglu, HY, 2023) |
| "Amiodarone, the most effective antiarrhythmic drug in atrial fibrillation, inhibits apixaban and rivaroxaban elimination, thus possibly increasing anticoagulant-related risk for bleeding." | 4.31 | Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial Fibrillation : A Retrospective Cohort Study. ( Chung, CP; Daugherty, JR; Dickson, AL; Dupont, WD; Hung, AM; Murray, KT; Ray, WA; Smalley, W; Stein, CM; Zimmerman, E, 2023) |
| "A 62 year old Caucasian man with a history of paroxysmal atrial fibrillation treated with flecainide, presented with atrial flutter with 1:1 conduction to the ventricles and was cardioverted." | 4.31 | Failure of diltiazem to prevent 1:1 conduction of atrial flutter: a case report. ( Ganesan, AN; Lahiri, A; Martin, DK; Quah, J; Tiver, KD, 2023) |
| "The use of flecainide and propafenone for medical cardioversion of atrial fibrillation (AF) and atrial flutter/intra-atrial reentrant tachycardia (IART) is well-described in adults without congenital heart disease (CHD)." | 4.31 | Medical cardioversion of atrial fibrillation and flutter with class IC antiarrhythmic drugs in young patients with and without congenital heart disease. ( Alexander, ME; Bezzerides, VJ; DeWitt, ES; Dionne, A; Eberly, LM; Mah, DY; O'Leary, ET; Przybylski, R; Triedman, JK; Walsh, EP, 2023) |
| "Oral and intravenous flecainide is recommended for cardioversion of atrial fibrillation." | 4.12 | Open-Label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution for Acute Conversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm. ( Aksoy, I; Al-Windy, N; Badings, E; Belardinelli, L; Camm, AJ; Crijns, HJGM; Elvan, A; Kowey, PR; Madhavapeddi, P; Ruskin, JN; Tuininga, YS; Van Gelder, IC, 2022) |
| "A patient with paroxysmalatrial fibrillation and recently implanted dual chamber pacemaker withresultant atrial latency underwent flecainide treatment resulting in worseningatrial latency, progressive dyspnea, and pacemaker syndrome physiology." | 4.02 | Flecainide-induced AV dyssynchrony and atrial latency progression in a patient with a dual-chamber pacemaker. ( Alston, M; Chang, D; Mitra, R, 2021) |
| "Flecainide, a widely prescribed class IC agent used to treat atrial arrhythmias, can in rare cases cause 1:1 atrial flutter with rapid conduction." | 4.02 | Flecainide-Induced Atrial Flutter With 1:1 Conduction Complicated by Ventricular Fibrillation After Electrical Cardioversion. ( Colangelo, T; Ho, R; Johnson, D, 2021) |
| "We describe a case of a woman in her 80s with persistent atrial fibrillation (AF) despite being on flecainide who was admitted for AF with rapid ventricular response." | 4.02 | Flecainide toxicity with high pacemaker capture thresholds and associated takotsubo syndrome. ( Alqusairi, R; Crass, S; Girard, S; Manley-Casco, D, 2021) |
| "Inhaled flecainide significantly alters atrial electrical properties with the potential to terminate atrial fibrillation (AF) efficiently by optimizing dose and drug formulation." | 3.96 | Multimodal mechanisms and enhanced efficiency of atrial fibrillation cardioversion by pulmonary delivery of a novel flecainide formulation. ( Araujo Silva, B; Belardinelli, L; Bortolotto, AL; Hurrey, M; Madhavapeddi, P; Medeiros, SA; Pedreira, GC; Schuler, C; Tessarolo Silva, F; Verrier, RL, 2020) |
| "Flecainide is a class Ic antidysrhythmic agent used to prevent and treat both ventricular and supraventricular tachycardias, including atrial fibrillation, atrioventricular nodal re-entrant tachycardia, and Wolff-Parkinson-White syndrome." | 3.96 | The Case of Flecainide Toxicity: What to Look for and How to Treat. ( Newson, JM; Santos, CD; Todd, BR; Walters, BL, 2020) |
| "Flecainide pill-in-the-pocket therapy is a pharmacologic treatment option for patients with infrequent episodes of symptomatic atrial fibrillation." | 3.96 | Paroxysmal Atrial Fibrillation on Flecainide Therapy. ( Gavin, JL; Kim, SS; Peigh, GS, 2020) |
| "Vernakalant was safe, more effective and faster than flecainide in the cardioversion of recent-onset atrial fibrillation." | 3.91 | Intravenous vernakalant in comparison with intravenous flecainide in the cardioversion of recent-onset atrial fibrillation. ( Hartikainen, J; Heikkola, A; Hyppölä, H; Lekkala, M; Pohjantähti-Maaroos, H; Sinisalo, E, 2019) |
| "We investigated whether rapid administration of a low dose of flecainide, either intratracheally or intravenously (IV), could accelerate conversion of atrial fibrillation (AF) while reducing adverse ventricular effects." | 3.91 | Optimizing flecainide plasma concentration profile for atrial fibrillation conversion while minimizing adverse ventricular effects by rapid, low-dose intratracheal or intravenous administration. ( Belardinelli, L; Bortolotto, AL; de Antonio, VZ; Marum, AA; Silva, AC; Silva, BA; Verrier, RL, 2019) |
| "OBJECTIVE To compare the efficacy of quinidine and flecainide in treating naturally occurring, recent-onset atrial fibrillation (AF) in Thoroughbred racehorses." | 3.88 | Treatment of recent-onset atrial fibrillation with quinidine and flecainide in Thoroughbred racehorses: 107 cases (1987-2014). ( Ishikawa, Y; Ohmura, H; Takahashi, Y, 2018) |
| "Class Ic antiarrhythmic agents flecainide and propafenone are amongst the drugs most frequently prescribed to control atrial arrhythmias, in particular atrial fibrillation (AF)." | 3.88 | 1:1 atrial flutter induced by flecainide, whilst the patient was at rest. ( Cervellin, G; Comelli, I; Pigna, F, 2018) |
| "Dronedarone was the only anti-arrhythmic drug with significantly lower risk for arrhythmic death, sustained ventricular arrhythmia or ICD implantation than sotalol among patients with atrial fibrillation." | 3.88 | Ventricular arrhythmia and death among atrial fibrillation patients using anti-arrhythmic drugs. ( Friberg, L, 2018) |
| " Herein, through data mining with supportive statistical analyses, we identified and consolidated variables of the Flecainide Short-Long (Flec-SL-AFNET 3) trial dataset that are associated with the primary outcome of the trial, recurrence of persistent atrial fibrillation (AF) or death." | 3.85 | Predictors of sinus rhythm after electrical cardioversion of atrial fibrillation: results from a data mining project on the Flec-SL trial data set. ( Borggrefe, M; Breithardt, G; Goette, A; Güvenir, HA; Karaagaoglu, E; Katircioglu-Öztürk, D; Kirchhof, P; Okutucu, S; Oto, A; Oto, E; Ravens, U; Steinbeck, G; Wegscheider, K, 2017) |
| "The antihistaminic antazoline (ANT) was reported to be highly effective and safe for rapid conversion of atrial fibrillation (AF)." | 3.85 | Effective suppression of atrial fibrillation by the antihistaminic agent antazoline: First experimental insights into a novel antiarrhythmic agent. ( Bögeholz, N; Bogossian, H; Dechering, DG; Eckardt, L; Fehr, M; Frommeyer, G; Kaese, S; Milberg, P; Pott, C; Sterneberg, M, 2017) |
| "A patient taking regular flecainide for paroxysmal atrial fibrillation presented with broad complex tachycardia and circulatory compromise." | 3.81 | Cardiac devices with class 1C antiarrhythmics: a potentially toxic combination. ( Apps, A; Fellows, S; Jones, M; Miller, CP, 2015) |
| "Vernakalant is a new, safe and effective drug used intravenously, which has proved to be more rapid in converting recent onset atrial fibrillation (AF) to sinus rhythm compared to placebo, amiodarone, propafenone, and flecainide in clinical studies." | 3.80 | Vernakalant: Perception of state of health in patients with a recent-onset atrial fibrillation. ( Aragon, M; Conde, D; Costabel, JP; Lambardi, F; Trivi, M, 2014) |
| "Acute atrial fibrillation (AF) is often treated with the administration of intravenous flecainide; however, this treatment may not always be successful and is potentially hazardous." | 3.80 | Tissue velocity imaging of the left atrium predicts response to flecainide in patients with acute atrial fibrillation. ( Blaauw, Y; Crijns, HJ; De Vos, CB; Delhaas, T; Limantoro, I; Marcos, E; Pisters, R; Schotten, U; Tieleman, RG; Van Gelder, IC; Weijs, B, 2014) |
| "Flecainide is recommended as a first-line antiarrhythmic drug to maintain normal sinus rhythm in patients with atrial fibrillation (AF) who have structurally normal hearts or hypertension without left ventricular hypertrophy." | 3.80 | An unusual case of flecainide-induced QT prolongation leading to cardiac arrest. ( Costa, SM; Mixon, TA; Oguayo, KN; Oyetayo, OO, 2014) |
| "An oral single dose of flecainide is used worldwide for conversion of recent onset atrial fibrillation (AF) in hemodynamically stable patients without structural heart disease." | 3.79 | Flecainide versus vernakalant for conversion of recent-onset atrial fibrillation. ( Caro, M; Conde, D; Corrales Barboza, A; Costabel, JP; Ferro, A; Lambardi, F; Lavalle Cobo, A; Trivi, M, 2013) |
| "In several clinical and pre-clinical studies, application of ranolazine (RAN) led to suppression of atrial fibrillation (AF)." | 3.79 | Sodium channel block by ranolazine in an experimental model of stretch-related atrial fibrillation: prolongation of interatrial conduction time and increase in post-repolarization refractoriness. ( Belardinelli, L; Breithardt, G; Eckardt, L; Frommeyer, G; Ghezelbash, S; Milberg, P; Osada, N; Rajamani, S; Razvan, R, 2013) |
| "Blockade of inward-rectifier K+ channels by chloroquine terminates reentry in cholinergic atrial fibrillation (AF)." | 3.78 | Chloroquine terminates stretch-induced atrial fibrillation more effectively than flecainide in the sheep heart. ( Bandaru, K; Berenfeld, O; Calvo, CJ; Ennis, SR; Filgueiras-Rama, D; Jalife, J; Kalifa, J; Martins, RP; Mironov, S; Noujaim, SF; Yamazaki, M, 2012) |
| "To assess the safety of long-term treatment with flecainide in patients with atrial fibrillation (AF), particularly with regard to sudden cardiac death (SCD) and proarrhythmic events." | 3.77 | The safety of flecainide treatment of atrial fibrillation: long-term incidence of sudden cardiac death and proarrhythmic events. ( Almroth, H; Andersson, T; Englund, A; Fengsrud, E; Friberg, L; Linde, P; Rosenqvist, M, 2011) |
| "Flecainide is used as a pill-in-the-pocket treatment for pharmacological cardioversion in patients without structural heart disease and atrial fibrillation (AF)." | 3.76 | Flecainide for cardioversion in patients at elevated cardiovascular risk and persistent atrial fibrillation: a prospective observational study. ( Aslan, O; Caglayan, E; Er, F; Erdmann, E; Gassanov, N; Nia, AM; Rosenkranz, S, 2010) |
| "Flecainide can "organise" atrial fibrillation into atrial flutter with 1:1 conduction, leading to cardiovascular compromise." | 3.76 | Tachycardia due to atrial flutter with rapid 1:1 conduction following treatment of atrial fibrillation with flecainide. ( Gandhi, MM; Lloyd, G; Taylor, R, 2010) |
| "A 62-year-old man presented newly developed tachyarrhythmia diagnosed as paroxysmal atrial fibrillation (PAF) and was treated with flecainide and enalapril." | 3.76 | Paroxysmal atrial fibrillation due to bronchogenic cyst. ( Aoyama, T; Arai, Y; Fujino, S; Hwang, EH; Kaizaki, Y; Sekido, N, 2010) |
| "Oral flecainide was successful in longer-term management of arrhythmia in 74 and 81% of patients with AV nodal and AV reentrant tachycardia, respectively, and in 83% with atrial tachycardia." | 3.76 | Summary of efficacy and safety of flecainide for supraventricular arrhythmias. ( Anderson, JL; Fredell, PA; Jolivette, DM, 1988) |
| " The aim of this study was to determine the effects of IPC versus intravenous (IV) d,l-sotalol and flecainide infusion on transmural atrial electrophysiology and sustained atrial fibrillation (AF) in the goat." | 3.75 | Effects of intrapericardial sotalol and flecainide on transmural atrial electrophysiology and atrial fibrillation. ( Accord, RE; Allessie, MA; Hermans, JJ; Maessen, JG; Schotten, U; Smits, JF; van Brakel, TJ, 2009) |
| "We present a case of flecainide-induced hyponatremia in a 67-year-old woman who was treated for paroxysmal atrial tachycardia." | 3.75 | A case of flecainide-induced hyponatremia. ( Ahmed, M; Akhtar, M; Mortada, ME; Sra, J, 2009) |
| "Between January 2000 and June 2008, all consecutive patients with new-onset AF, who after flecainide exhibited typical Brugada ECG pattern, underwent electrophysiologic, pharmacologic, and genetic testing." | 3.75 | New-onset atrial fibrillation as first clinical manifestation of latent Brugada syndrome: prevalence and clinical significance. ( Ciaccio, C; Ciconte, G; Ferrari, M; Kallergis, EM; Manguso, F; Pappone, C; Radinovic, A; Sacchi, S; Sacco, FM; Sala, S; Santinelli, V; Saviano, M; Sommariva, E; Vicedomini, G, 2009) |
| "A 72-year-old male patient with dilated cardiomyopathy was treated with oral flecainide (100 mg/day) for persistent atrial fibrillation (AF) that could not be converted to sinus rhythm by electrical cardioversion." | 3.74 | Impact of serum flecainide level on control of atrial fibrillation in a case treated with cardiac resynchronization therapy. ( Aonuma, K; Doki, K; Homma, M; Kawano, S; Kohda, Y; Kuga, K; Yamaguchi, I, 2007) |
| "The relation between flecainide's plasma level and its influence on human atrial electrophysiology during acute and maintenance therapy of atrial fibrillation (AF) is unknown." | 3.73 | Pilot study: Noninvasive monitoring of oral flecainide's effects on atrial electrophysiology during persistent human atrial fibrillation using the surface electrocardiogram. ( Binias, KH; Bollmann, A; Geller, C; Husser, D; Klein, HU; Molling, J; Olsson, SB; Sornmo, L; Stridh, M, 2005) |
| "The purpose of this study was to evaluate the hypothesis that presumed reversion of electrical remodeling after cardioversion of atrial fibrillation (AF) restores the efficacy of flecainide." | 3.73 | Does flecainide regain its antiarrhythmic activity after electrical cardioversion of persistent atrial fibrillation? ( Allessie, MA; Bennekers, JH; Bosker, HA; Bracke, FA; Crijns, HJ; Haaksma, J; Kingma, T; Kirchhof, CJ; Tieleman, RG; Van Gelder, IC; Veeger, NJ; Wilde, AA, 2005) |
| "A 37-year-old man with symptomatic acute atrial fibrillation and a low-voltage electrocardiogram was treated with flecainide intravenously." | 3.73 | [Life-threatening ventricular tachycardia during flecainide treatment for symptomatic atrial fibrillation in a patient with a structural cardiac disorder]. ( Rienstra, M; van Gelder, IC; van Veldhuisen, DJ; Wiesfeld, AC, 2006) |
| " By means of telemedicine, it was possible to document the arrhythmia--in this case atrial fibrillation--within 10 days and to start antiarrhythmic drug treatment with flecainide and metoprolol." | 3.73 | Use of telemedicine in the diagnosis of paroxysmal atrial fibrillation and to monitor the effect of antiarrhythmic drug therapy. ( Israel, CW; Klingenheben, T, 2006) |
| "Bepridil, a multi-ion channel blocker, is effective for some types of cardiac arrhythmias, and so its effect on the paroxysmal atrial fibrillation (PAF) was evaluated in the present study, comparing it with class Ic antiarrhythmic drugs." | 3.72 | Evaluation of the effect of bepridil on paroxysmal atrial fibrillation: relationship between efficacy and the f-f interval in surface ECG recordings. ( Hara, H; Ikeda-Murakami, K; Inuo, K; Izumi, T; Kojima, J; Niwano, S; Saito, J; Yoshida, T, 2003) |
| "The basis of the unique effectiveness of amiodarone for atrial fibrillation (AF) is poorly understood." | 3.72 | Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: insights into the mechanism of the superior efficacy of amiodarone. ( Nattel, S; Schram, G; Shinagawa, K; Shiroshita-Takeshita, A, 2003) |
| "The cardiac safety of a once-a-day 200 mg controlled-release formulation of flecainide acetate in the prevention of paroxysmal atrial fibrillation (PAF) was assessed in outpatients." | 3.72 | Safety of a controlled-release flecainide acetate formulation in the prevention of paroxysmal atrial fibrillation in outpatients. ( Aliot, E; Capucci, A; Coumel, P; De Roy, L; Denjoy, I; Hernández, J; Lupoglazoff, JM, 2003) |
| " We describe the case of a 62-year-old male with latent Brugada syndrome in whom the intravenous infusion of flecainide for paroxysmal atrial fibrillation caused ECG abnormalities similar to those of an acute septal myocardial infarction." | 3.72 | [Infusion of flecainide in a patient with atrial fibrillation and latent Brugada's syndrome has determined modifications of the electrocardiogram similar to those of a septal myocardial infarct]. ( Carotenuto, F; Cirillo, R; D'Errico, L; di Palma, F; Fontana, D; Granato, L; Pagano, V; Sestri, C; Vitiello, N, 2003) |
| " flecainide has a high efficacy for the treatment of experimentally-induced acute atrial fibrillation (AF) in horses and that its use is associated with minimal toxic side effects." | 3.72 | Use of intravenous flecainide in horses with naturally-occurring atrial fibrillation. ( Blissitt, KJ; Keen, JA; van Loon, G; Young, LE, 2004) |
| " Pilsicainide (four patients) or flecainide (one patient) were administered orally for the treatment of symptomatic paroxysmal atrial fibrillation or premature atrial contractions." | 3.71 | ST segment elevation in the right precordial leads following administration of class Ic antiarrhythmic drugs. ( Kawano, Y; Mineda, Y; Nakata, Y; Nakazato, K; Nakazato, Y; Sekita, G; Sumiyoshi, M; Tokano, T; Yamashita, H; Yasuda, M, 2001) |
| "To compare the effects of class Ic and III antiarrhythmic agents on the termination and prevention of atrial fibrillation, the present study investigated the use-dependent electrophysiological effects of flecainide, nifekalant and d,l-sotalol on the human atrium." | 3.71 | Frequency-dependent electrophysiological effects of flecainide, nifekalant and d,l-sotalol on the human atrium. ( Kanmatuse, K; Kojima, T; Kunimoto, S; Masaki, R; Nakai, T; Oshikawa, N; Ozawa, Y; Saito, S; Watanabe, H; Watanabe, I, 2001) |
| "24 consecutive patients with atrial fibrillation (age 54 (12) years; 5 female, 19 male) developing atrial flutter while taking propafenone (n = 12) or flecainide (n = 12)." | 3.71 | Class IC antiarrhythmic drug induced atrial flutter: electrocardiographic and electrophysiological findings and their importance for long term outcome after right atrial isthmus ablation. ( Nabar, A; Rodriguez, LM; Timmermans, C; van Mechelen, R; Wellens, HJ, 2001) |
| "We present a case report describing an interaction between topical timolol maleate, verapamil, and flecainide resulting in symptomatic bradycardia." | 3.71 | Symptomatic bradycardia secondary to interaction between topical timolol maleate, verapamil, and flecainide: a case report. ( Herd, A; Minish, T, 2002) |
| "Treatment of paroxysmal atrial fibrillation with flecainide acetate resulted in a 4-fold increase in ventricular capture thresholds." | 3.71 | Documentation of acute rise in ventricular capture thresholds associated with flecainide acetate. ( Fornieles-Pérez, H; Levine, PA; Montoya-García, M; Sanz, O, 2002) |
| "Chronic persistent atrial fibrillation was converted in 13/19 (68%) patients at baseline and in 16/19 (84%) patients after flecainide." | 3.70 | Favorable effects of flecainide in transvenous internal cardioversion of atrial fibrillation. ( Ayers, GM; Biffi, M; Boriani, G; Branzi, A; Bronzetti, G; Capucci, A; Magnani, B; Zannoli, R, 1999) |
| "(1) To investigate the electrophysiological effects of flecainide and propafenone during atrial fibrillation, and their relation to arrhythmia termination; (2) to investigate the effects of isoprenaline on atrial fibrillation in basal conditions and during treatment with class 1C drugs to evaluate the role of adrenergic stimulation on proarrhythmic events occurring during this treatment." | 3.70 | Electrophysiological effects of flecainide and propafenone on atrial fibrillation cycle and relation with arrhythmia termination. ( Biffi, M; Boriani, G; Branzi, A; Bronzetti, G; Capucci, A; Magnani, B, 1999) |
| "To determine a safe and efficacious dose of flecainide acetate for treating equine atrial fibrillation (Af), the safe dosage level was determined by injecting 1, 2, or 3 mg/kg i." | 3.70 | Safe and efficacious dosage of flecainide acetate for treating equine atrial fibrillation. ( Amada, A; Mizuno, Y; Nakayama, T; Nukada, T; Ohmura, H; Yamaya, Y, 2000) |
| "The effects of E-4031, a new class III antiarrhythmic agent, on atrial fibrillation threshold (AFT), atrial effective refractory period (ERP), and interatrial conduction time (ACT) were investigated in Langendorff-perfused guinea pig hearts; the results were then compared with those of the class I agents disopyramide, procainamide, lidocaine, and flecainide." | 3.69 | Effects of E-4031 on atrial fibrillation threshold in guinea pig atria: comparative study with class I antiarrhythmic drugs. ( Asayama, J; Inoue, D; Inoue, M; Ishibashi, K; Nakagawa, M; Sakai, R; Shirayama, T, 1994) |
| "This study sought to determine the mechanisms of idiopathic atrial fibrillation and the atrial antifibrillatory action of flecainide in dogs." | 3.69 | Idiopathic atrial fibrillation in dogs: electrophysiologic determinants and mechanisms of antiarrhythmic action of flecainide. ( Feng, J; Nattel, S; Wang, Z, 1995) |
| "In order to determine the efficacy of type 1C agents (flecainide, encainide, propafenone) in patients with atrial fibrillation who have failed to maintain sinus rhythm with type 1A agents (quinidine, procainamide, disopyramide), 147 patients, that were admitted into the John Dempsey Hospital with new or recurrent atrial fibrillation between 1987-1991, were studied retrospectively." | 3.68 | Efficacy of type 1C antiarrhythmic agents for treatment of resistant atrial fibrillation. ( Grey, E; Silverman, DI, 1993) |
| "The effects of pilsicainide, a new class Ic antiarrhythmic agent, on the atrial fibrillation threshold (AFT), the atrial effective refractory period (ERP), and the interatrial conduction time (ACT) in Langendorff-perfused guinea pig hearts were investigated." | 3.68 | Effects of pilsicainide on the atrial fibrillation threshold in guinea pig atria. A comparative study with disopyramide, lidocaine and flecainide. ( Asayama, J; Inoue, D; Inoue, M; Ishibashi, K; Nakagawa, M; Omori, I; Sakai, R; Yamahara, Y, 1993) |
| "Flecainide (100 mg twice daily) was used for prevention of paroxysmal atrial fibrillation (PAF) in 52 patients with frequent symptomatic attacks that were resistant or intolerant to quinidine (600-900 mg/day)." | 3.68 | Flecainide in quinidine-resistant atrial fibrillation. ( Chouty, F; Coumel, P; Denjoy, I; Leclercq, JF; Slama, R, 1992) |
| "Twenty-eight patients with atrial fibrillation of less than 1 month's duration were given a single intravenous bolus of flecainide (2 mg/kg)." | 3.68 | Cardioversion of atrial fibrillation of recent onset with flecainide. ( Carr, B; Channer, KS; Hawley, K, 1991) |
| "The arrhythmogenic effects of flecainide in atrial fibrillation and flutter were assessed in a consecutive material of 100 patients without severe heart failure (NYHA class I or II)." | 3.68 | Flecainide acetate in atrial flutter and fibrillation. The arrhythmogenic effects. ( Hansen, FA; Pedersen, AK; Rasmussen, J; Sihm, I; Thygesen, K, 1990) |
| "Intravenous flecainide (2 mg/Kg for 15 min) was used in 30 patients (18 men and 12 women aged 23 to 85 years: mean 62) with recent or paroxysmal atrial fibrillation: 5 patients returned to sinus rhythm during flecainide administration while other 23 patients did it not later than 2 hours." | 3.67 | [Effects of intravenous flecainide in the treatment of paroxysmal or recent-onset atrial fibrillations]. ( Bolognesi, R; Manca, C; Tsialtas, D; Visioli, O, 1989) |
| "Flecainide acetate has a recognized proarrhythmic effect in patients treated for ventricular tachycardia." | 3.67 | Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. ( Falk, RH, 1989) |
| "The action of intravenous flecainide was studied in patients presenting a tachyarrhythmia secondary to a permanent atrial fibrillation of recent onset." | 3.67 | [Flecainide by the intravenous route: a new method for decreasing auricular fibrillation]. ( Assyag, P; Brechenmacher, C; Chauvin, M; Fass, H; Klein, JM, 1987) |
| "Thirty-nine patients with symptomatic ectopic atrial tachycardia (9 paroxysmal, of which 5 were incessant) and atrial fibrillation (AF) (25 paroxysmal, 5 chronic) were treated with oral flecainide acetate (100 to 400 mg/day)." | 3.67 | Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillation. ( Berns, E; Dougherty, AH; Jeang, MK; Jenkins, M; Naccarelli, GV; Rinkenberger, RL, 1987) |
| "Fifty-one consecutive patients with atrial tachycardia [atrial fibrillation (FA) 37, atrial flutter (Fl) 10, tachycardia (TSA) 4] received a single 2 mg/kg dose of flecainide injected intravenously over 5 to 10 minutes." | 3.67 | [Reduction of auricular fibrillation and tachycardia using intravenous flecainide]. ( Aumont, MC; Boujon, B; Charlier, P; Cohen-Solal, A; Dahan, M; Farinotti, P; Jaeger, P; Juliard, JM, 1987) |
| "Sixteen consecutive patients who had ventricular preexcitation complicated by atrial fibrillation or flutter were treated with intravenous flecainide acetate after treatment with as many as 5 unsuccessful trial regimens with other drugs." | 3.67 | Treatment of atrial tachyarrhythmias and preexcitation syndrome with flecainide acetate. ( Kim, SS; Ruffy, R; Smith, P, 1988) |
| "The efficacy of flecainide acetate for conversion of atrial fibrillation into sinus rhythm was assessed in 69 patients (mean age of 63 +/- 14 years)." | 3.67 | Restoration of sinus rhythm with flecainide in patients with atrial fibrillation. ( Goy, JJ; Kappenberger, L; Kaufmann, U; Sigwart, U, 1988) |
| "A 42-year old man with non-obstructive myocardiopathy complicated by paroxysmal atrial fibrillation treated with amiodarone (200 mg per day) received flecainide in daily doses of 400 mg for undocumented palpitations." | 3.67 | [Bundle branch reentry tachycardia: a possible mechanism of flecainide proarrhythmia effect]. ( Berland, J; Cribier, A; Letac, B; Saoudi, N, 1988) |
| "A population of 50 patients suffering from paroxysmal attacks of atrial fibrillation was studied prospectively to evaluate the prognostic value of 20 variables: 6 clinical variables: sex, age, cardiopathy, number of arrhythmic attacks, "vagal" triggering, failure of class IA antiarrhythmic agents; 3 echocardiographic variables: left ventricular diastolic diameter and percentage of fibre shortening, left atrial diameter; 6 basic electrophysiological data: threshold, refractory periods at 110 and 150/min, modalities of induction of a sustained arrhythmia; 4 results observed with an infusion of flecainide in doses of 2 mg/kg: arrest or persistence of the arrhythmia, whether or not it could be reinduced and value of refractory periods; doses of flecainide administered orally." | 3.67 | [Predictive factors of the therapeutic result in the prevention of auricular fibrillation. Role of electrophysiological studies]. ( Commenges, D; Dulhoste, MN; Haissaguerre, M; Lemetayer, P; Salamon, R; Warin, JF, 1988) |
| "Flecainide was given to a patient in a dose of 150 mg twice daily to convert a newly developed atrial fibrillation; concomitant therapy was unchanged." | 3.67 | [Flecainide-induced hepatitis]. ( Haasis, R; Kühlkamp, V; Seipel, L, 1988) |
| "Flecainide is reported to be effective in patients with paroxysmal tachycardias, but its effect on rapid ventricular response over accessory atrioventricular pathway during atrial fibrillation is not known." | 3.67 | Evaluation of flecainide acetate in rapid atrial fibrillation complicating Wolff-Parkinson-White syndrome. ( Fromer, MA; Gloor, HO; Kappenberger, LJ; Shenasa, M, 1985) |
| "Flecainide has been tested with variable efficacy." | 2.87 | Time-dependent antiarrhythmic effects of flecainide on induced atrial fibrillation in horses. ( Buhl, R; Carstensen, H; Fenner, M; Flethøj, M; Hesselkilde, EZ; Jespersen, T; Kanters, JK; Loft-Andersen, AV; Pehrson, S; Sattler, SM; Tfelt-Hansen, J, 2018) |
| "Pregnancy is associated with a greater risk of arrhythmias, and patients with a history of arrhythmias are at significant risk of arrhythmia recurrence during pregnancy." | 2.82 | Arrhythmias in Pregnancy. ( Briller, JE; Elkayam, U; Lakkireddy, DR; Mason, PK; Merchant, FM; Patel, H; Pillarisetti, J; Russo, AM; Tamirisa, KP; Vaseghi, M; Volgman, AS, 2022) |
| "In order to prevent AF recurrences, many anti-arrhythmic drugs are currently available, but most of them are burdened by serious side effects and suboptimal efficacy." | 2.82 | Flecainide-metoprolol combination reduces atrial fibrillation clinical recurrences and improves tolerability at 1-year follow-up in persistent symptomatic atrial fibrillation. ( Capucci, A; Gabrielli, D; Guerra, F; Piangerelli, L; Ricciotti, J, 2016) |
| "Strokes are rare in this large, prospectively followed cohort of patients undergoing cardioversion for AF and receiving antithrombotic therapy following local routine." | 2.78 | Low stroke risk after elective cardioversion of atrial fibrillation: an analysis of the Flec-SL trial. ( Andresen, D; Apostolakis, S; Borggrefe, M; Breithardt, G; Haeusler, KG; Kirchhof, P; Lip, GY; Meinertz, T; Oeff, M; Parade, U; Samol, A; Steinbeck, G; Treszl, A; Wegscheider, K, 2013) |
| "Eligible patients were adults with persistent atrial fibrillation undergoing planned cardioversion." | 2.77 | Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. ( Andresen, D; Borggrefe, M; Bosch, R; Breithardt, G; Kirchhof, P; Meinertz, T; Parade, U; Ravens, U; Samol, A; Steinbeck, G; Treszl, A; Wegscheider, K, 2012) |
| "We randomly assigned 294 patients with paroxysmal atrial fibrillation and no history of antiarrhythmic drug use to an initial treatment strategy of either radiofrequency catheter ablation (146 patients) or therapy with class IC or class III antiarrhythmic agents (148 patients)." | 2.77 | Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. ( Cosedis Nielsen, J; Englund, A; Hansen, PS; Hartikainen, J; Hindricks, G; Johannessen, A; Kongstad, O; Mortensen, LS; Pehrson, S; Raatikainen, P; Walfridsson, H, 2012) |
| "To identify a possible relationship with subjective symptoms, we reviewed 6319 trans-telephonic electrocardiographic strips (ECGs) recorded from 123 patients in a double-blind, placebo-controlled trial examining dose-response effects of flecainide." | 2.73 | Relationship between subjective symptoms and trans-telephonic ECG findings in patients with symptomatic paroxysmal atrial fibrillation and flutter. ( Atarashi, H; Inoue, H; Ogawa, S, 2008) |
| " Despite careful precautions, serious proarrhythmias, the major limiting side effect of dofetilide, still occurred during long-term follow-up." | 2.73 | Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function. ( Bauman, JL; Kehoe, RF; Leal, S; Mykytsey, A; Razminia, M; Saleem, M; Wang, T; Zheutlin, T, 2007) |
| "Sudden cardiac death was observed in 16 patients, 8 patients in each group." | 2.72 | Determinants of sudden cardiac death in patients with persistent atrial fibrillation in the rate control versus electrical cardioversion (RACE) study. ( Crijns, HJ; Hagens, VE; Rienstra, M; Van Gelder, IC; Van Veldhuisen, DJ, 2006) |
| "The pharmacodynamic equivalence of flecainide acetate immediate-release (IR) and controlled-release (CR) formulations was assessed from QRS duration in patients currently treated with the IR formulation." | 2.71 | Pharmacodynamic equivalence of two flecainide acetate formulations in patients with paroxysmal atrial fibrillation by QRS analysis of ambulatory electrocardiogram. ( Coumel, P; Leenhardt, A; Maison-Blanche, P; Milliez, P; Périer, A; Tarral, E, 2003) |
| "The short QT syndrome is characterized by familial sudden death, short refractory periods, and inducible ventricular fibrillation." | 2.71 | Short QT Syndrome: a familial cause of sudden death. ( Bianchi, F; Borggrefe, M; Gaita, F; Giustetto, C; Grossi, S; Riccardi, R; Richiardi, E; Schimpf, R; Wolpert, C, 2003) |
| "amiodarone was not different from placebo until 8 hours when it was associated with 57% of conversions; (3) conversion to sinus rhythm at 8 hours was observed in 37% of the placebo treated patients." | 2.69 | Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different drug protocols. ( Biffi, M; Boriani, G; Botto, G; Branzi, A; Broffoni, T; Capucci, A; Magnani, B; Ongari, M; Rubino, I; Sanguinetti, M; Trisolino, G, 1998) |
| "Seventeen patients had documented recurrence of atrial arrhythmia (9 in the cibenzoline group, 8 in the flecainide group) during the study." | 2.68 | Cibenzoline versus flecainide in the prevention of paroxysmal atrial arrhythmias: a double-blind randomized study. ( Babuty, D; D'Hautefeuille, B; Mycinsky, C; Peraudeau, P; Pruvost, P; Scheck, F, 1995) |
| " There were no deaths and no reports of major proarrhythmic events or other major adverse effects." | 2.68 | Efficacy and safety of long-term oral flecainide acetate in patients with responsive supraventricular tachycardia. ( Hellestrand, KJ, 1996) |
| "In the not-responders, the mean time to recurrence was 75 +/- 48 days in group C and 75 +/- 62 days in group F(NS)." | 2.68 | [Comparative study of cibenzoline and flecainide by oral route for preventing recurrence of paroxysmal atrial tachyarrhythmias]. ( Babuty, D; Brembilla-Perrot, B; Breuillac, JC; Fauchier, JP; Funck, F; Garnier, LF; Maison-Blanche, P; Medvedowsky, JL; Peraudeau, P; Rouesnel, P; Scheck, F, 1997) |
| "In case of PAF recurrence pts withdrew from the study." | 2.68 | [Comparison of anti-arrhythmic therapy guided by the transesophageal electropharmacologic test and emperic therapy in the prophylaxis of atrial fibrillation recurrence]. ( Burattini, M; Carunchio, A; Ceci, V; Coletta, C; Fera, MS; Galati, A; Mazza, A, 1997) |
| " Only 3 (5%) of 66 patients discontinued therapy due to possible noncardiac adverse effects." | 2.67 | Long-term safety and efficacy of flecainide in the treatment of supraventricular tachyarrhythmias: the United States experience. The Flecainide Supraventricular Tachyarrhythmia Investigators. ( Anderson, JL, 1992) |
| "Patients with paroxysmal atrial fibrillation (PAF) are prone to recurrence." | 2.67 | A randomized double-blind crossover study comparing the efficacy and tolerability of flecainide and quinidine in the control of patients with symptomatic paroxysmal atrial fibrillation. ( Lau, CP; Leung, WH; Wong, CK, 1992) |
| "In the acute treatment of paroxysmal atrial fibrillation several drugs can be used." | 2.67 | [The efficacy of oral treatment with flecainide for paroxysmal atrial fibrillation: correlation with plasma concentration]. ( Arruzzoli, S; Dieci, G; Gandolfini, A; Gazzola, U; Groppi, F; Groppi, M; Piepoli, M; Rosi, A; Villani, GQ, 1990) |
| "Flecainide was replaced with encainide (153 mg/day; range, 50-225 mg/day) for a mean duration of 6." | 2.67 | Encainide versus flecainide in the treatment of chronic resistant paroxysmal atrial tachyarrhythmias. ( Coumel, P, 1990) |
| "Amiodarone was associated with the highest rate of patients experiencing at least one serious adverse event (OR 2." | 2.47 | Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. ( Eckert, L; Freemantle, N; Lafuente-Lafuente, C; Mitchell, S; Reynolds, M, 2011) |
| "Atrial flutter is most often arising from a macroreentry circuit in the right atrium or around scar tissue in case or previous cardiothoracic surgery." | 2.43 | [Atrial flutter and fibrillation]. ( Scharf, C, 2005) |
| "Amiodarone has been demonstrated to be more efficacious than propafenone or sotalol in the Canadian Trial of Atrial Fibrillation." | 2.42 | Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. ( Bhatta, L; Hynes, J; Khan, M; Luck, J; Naccarelli, GV; Samii, S; Wolbrette, DL, 2003) |
| "Flecainide is a Class IC antiarrhythmic agent whose primary electrophysiologic effect is a slowing of conduction in a wide range of cardiac tissues." | 2.39 | Flecainide. ( Falk, RH; Fogel, RI, 1994) |
| "The nature of an arrhythmia and of individual patient factors change over time, requiring a flexible approach to long-term treatment that may be defined only after months or years." | 2.39 | Atrial fibrillation: maintenance of sinus rhythm versus rate control. ( Camm, AJ; Sopher, SM, 1996) |
| "This study suggests that flecainide and beta-blockers association is complementary to implantable cardioverter-defibrillator and catheter ablation and is safe for treating persistent symptomatic VA in patients with ARVC." | 1.72 | Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy. ( Badenco, N; Duthoit, G; Frank, R; Gandjbakhch, E; Hidden-Lucet, F; Himbert, C; Laredo, M; Maupain, C; Rolland, T; Waintraub, X, 2022) |
| "Guidelines recommend that initial trial of a "pill-in-the-pocket" (PIP) Class 1C antiarrhythmic drug (AAD) for cardioversion of atrial fibrillation (AF) be performed in a monitored setting because of the potential for adverse reactions." | 1.72 | Safety of Pill-in-the-Pocket Class 1C Antiarrhythmic Drugs for Atrial Fibrillation. ( Arkles, JS; Callans, DJ; Deo, R; Dixit, S; Epstein, AE; Frankel, DS; Guandalini, GS; Hyman, MC; Jarrah, AA; Lin, D; Marchlinski, FE; Markman, TM; Mustin, E; Nazarian, S; Riley, M; Santangeli, P; Schaller, RD; Supple, GE; Tian, Y, 2022) |
| "Flecainide was used most frequently (26." | 1.62 | Limited duration of antiarrhythmic drug use for newly diagnosed atrial fibrillation in a nationwide population under age 65. ( D'Angelo, RN; Goldstein, L; Kalsekar, I; Khanna, R; Rahman, M; Tung, P; Yadalam, S; Yeh, RW; Zimetbaum, PJ, 2021) |
| "Flecainide is a class 1C antiarrhythmic, which is known to cause several cardiac and non-cardiac adverse reactions." | 1.62 | Flecainide-induced myalgias and weakness: a rare adverse reaction. ( Kumar, D; Mersfelder, T; Patel, P; Rehman, ME, 2021) |
| "Treatment with flecainide CR significantly improves QoL in both paroxysmal as well as persistent AF patients, with an excellent safety profile and associated patient compliance." | 1.56 | Beneficial Effect of Flecainide Controlled Release on the Quality of Life of Patients with Atrial Fibrillation-the REFLEC-CR Study. ( Asvestas, D; Gavriilidou, M; Giannakoulas, G; Kapetanios, K; Karlis, D; Koufaki, P; Kourouklis, S; Kouskos, G; Papadimitriou, G; Patsourakos, F; Taxiarchou, E; Tsiachris, D; Tzeis, S; Vatkalis, N, 2020) |
| " It is associated with a potent adverse effect profile; however, the effects of flecainide toxicity in the setting of a pacemaker have not been well described." | 1.51 | Flecainide Toxicity Resulting in Pacemaker Latency and Intermittent Failure to Capture. ( Akpunonu, P; Baum, R; Catanzaro, J; Elayi, CS; Rutland, J; Suffredini, JM, 2019) |
| " We analysed the differences between amiodarone and class IC group in terms of efficacy and safety that is conversion to sinus rhythm rates within 12 and 48 h after starting treatment, time to conversion, and adverse drug effects." | 1.46 | Efficacy and safety in pharmacological cardioversion of recent-onset atrial fibrillation: a propensity score matching to compare amiodarone vs class IC antiarrhythmic drugs. ( Bonora, A; Dilda, A; Franchi, E; Maccagnani, A; Olivieri, O; Pistorelli, C; Taioli, G; Turcato, G; Zerman, G, 2017) |
| "Dronedarone has failed to make an impact on AAD prescribing." | 1.43 | The evolving landscape of oral anti-arrhythmic prescriptions for atrial fibrillation in England: 1998-2014. ( Ahsan, SY; Di Mario, C; Hayward, C; Lyon, AR; Patel, HC; Patel, K; Rowland, E, 2016) |
| "In all, 374 (53." | 1.42 | The epidemiology and management of recent-onset atrial fibrillation and flutter presenting to the Emergency Department. ( Clark, D; Cragg, A; Gray, A; Grubb, N; Hamilton, A, 2015) |
| "Flecainide was anti-arrhythmic in RyR2(S/S) but pro-arrhythmic in WT." | 1.42 | Flecainide exerts paradoxical effects on sodium currents and atrial arrhythmia in murine RyR2-P2328S hearts. ( Chandrasekharan, KH; Fraser, JA; Guzadhur, L; Huang, CL; Jafferji, DI; King, JH; Matthews, HR; Salvage, SC, 2015) |
| "Amiodarone was the most widely used active compound (82%) and apparently the most effective." | 1.39 | [Predictors of reversion to sinus rhythm previous to electrical cardioversion in patients with persistent atrial fibrillation treated with anti-arrhythmic drugs]. ( Alegret, JM; Freire, F; Romero-Menor, C; Viñolas, X, 2013) |
| "Pill-in-the-pocket treatment should be prescribed only if the administration of a loading oral dose of flecainide or propafenone has been proved safe in hospital, since major adverse effects have been reported in 5% of patients during in-hospital treatment." | 1.36 | Intravenous administration of flecainide or propafenone in patients with recent-onset atrial fibrillation does not predict adverse effects during 'pill-in-the-pocket' treatment. ( Alboni, P; Boriani, G; Botto, GL; Capucci, A; Iori, M; Mancini, M; Mariconti, B; Pacchioni, F; Pasanisi, G; Russo, G, 2010) |
| " Rhythm control agents are associated with clinically important adverse events." | 1.36 | Rhythm control agents and adverse events in patients with atrial fibrillation. ( Hobbs, FD; Hodgkinson, J; Taylor, CJ, 2010) |
| "Flecainide is an antiarrhythmic drug that blocks sodium channels during phase 0 of cardiac action potential, delaying conduction and reducing contractility." | 1.36 | [Flecainide poisoning]. ( Bobillo, B; Diz Gómez, JC; Doniz Campos, M; Filgueira, P; Illodo Miramontes, G; Otero Amoedo, T; Rey López, F, 2010) |
| "Flecainide was used in two patients for LQT-3 diagnosis and therapeutic treatment of AF." | 1.35 | A mutation in the sodium channel is responsible for the association of long QT syndrome and familial atrial fibrillation. ( Benito, B; Berruezo, A; Brugada, J; Brugada, P; Brugada, R; Cinca, J; Freixa, X; Lizotte, E; Mont, L; Perich, RM; Tolosana, JM, 2008) |
| "Flecainide is a sodium channel blocker used mainly in the treatment of supraventricular arrhythmias." | 1.35 | Paranoid psychosis and myoclonus: flecainide toxicity in renal failure. ( Lee, D; Maclean, D; Sheerin, NS; Ting, SM, 2008) |
| "Flecainide was discontinued because of adverse effects in 6 patients (4%)." | 1.33 | Long-term results of hybrid therapy in patients with atrial fibrillation who develop atrial flutter during flecainide infusion. ( Astarita, C; De Matteis, C; De Simone, A; Di Napoli, T; El Jamal, B; Greco, L; La Rocca, V; Messina, V; Nocerino, P; Rotunno, R; Stabile, G; Turco, P; Vitale, DF, 2005) |
| "Flecainide was prescribed with a median posology of 150 mg per day, mostly as LP form (64%)." | 1.33 | [Flecainide acetate utilisation review among general practitioners and hospital or office-based cardiologists in France. Obepine: observational study of flecainide]. ( Danchin, N; Jaillon, P; Le Heuzey, JY; Liard, F; Lièvre, M, 2006) |
| "Ibutilide (I) has been reported to block I(k) and to delay inactivation of the slow Na(+) current (S-Na)." | 1.31 | The actions of ibutilide and class Ic drugs on the slow sodium channel: new insights regarding individual pharmacologic effects elucidated through combination therapies. ( Blitzer, M; Reiffel, JA, 2000) |
| "Average follow up at first AF recurrence was 18." | 1.31 | Atrial fibrillation recurrence after internal cardioversion: prognostic importance of electrophysiological parameters. ( Bacchi Reggiani, L; Bartolotti, M; Biffi, M; Boriani, G; Branzi, A; Zannoli, R, 2002) |
| "The management of patients with paroxysmal atrial fibrillation (AF) is unsuccessful, because AF recurs in about 50% of patients despite an antiarrhythmic treatment." | 1.30 | [The role of an electropharmacological transesophageal test in the prevention of paroxysmal atrial fibrillation. Experience with flecainide]. ( Accogli, S; Ciolli, A; De Sisti, A; Di Lorenzo, M; Lo Sardo, G; Matteucci, C; Palamara, A; Patrissi, T; Sasdelli, M, 1998) |
| " In this study, we prospectively investigated the effects of AFI ablation and continuation of drug therapy in patients with AF who developed AFI due to long-term administration of class IC antiarrhythmic drugs." | 1.30 | Radiofrequency ablation of atrial flutter due to administration of class IC antiarrhythmic drugs for atrial fibrillation. ( Jung, W; Lewalter, T; Lüderitz, B; Schumacher, B; Vahlhaus, C; Wolpert, C, 1999) |
| "Patient 1 had frequent episodes of paroxysmal atrial fibrillation resistant to Class IA drugs." | 1.30 | ST segment elevation in the right precordial leads induced with class IC antiarrhythmic drugs: insight into the mechanism of Brugada syndrome. ( Fujiki, A; Hayashi, H; Inoue, H; Mizumaki, K; Nagasawa, H; Usui, M, 1999) |
| "Flecainide-induced VF was antagonized by glibenclamide." | 1.29 | Antifibrillatory and profibrillatory actions of selected class I antiarrhythmic agents. ( Chi, L; Fagbemi, SO; Lucchesi, BR, 1993) |
| " Daily flecainide dosage was 200 (100-400) mg." | 1.28 | Antiarrhythmic treatment with flecainide (Tambocor). Clinical experience from 107 patients. ( Frandsen, F; Mickley, H; Møller, M; Pless, P, 1990) |
| "When amiodarone was not employed, as a first choice, in conformity with a specific protocol, it was utilized as a second choice after verapamil or flecainide." | 1.28 | [Supraventricular tachyarrhythmia of recent onset in the absence of documented cardiac pathology: different therapeutic approaches]. ( Bechi, S; Cordoni, M; Franchini, C; Mazza, F; Micheli, G; Scalzini, A, 1989) |
| " The administration of flecainide, dosage 1." | 1.28 | [A case of atrial paralysis during the use of intravenous flecainide acetate]. ( Pardini, E; Tognarini, S, 1989) |
| "Flecainide acetate is an effective antiarrhythmic agent for the acute termination of recent onset paroxysmal atrial and ventricular tachyarrhythmias." | 1.27 | Intravenous flecainide acetate for the clinical management of paroxysmal tachycardias. ( Bexton, RS; Camm, AJ; Hellestrand, KJ; Nathan, AW, 1987) |
| " It allows a reduction in the dosage of amiodarone when both drugs are combined." | 1.27 | Long term evaluation of flecainide acetate in supraventricular tachyarrhythmias. ( Mary-Rabine, L; Telerman, M, 1988) |
| "Flecainide was administered during SVT to 9 patients with atrial flutter, 11 with atrial fibrillation, 7 with atrial tachycardia, 38 with AV reentrant tachycardia and 34 with AV nodal reentrant tachycardia." | 1.27 | Intravenous flecainide acetate for supraventricular tachycardias. ( Hellestrand, KJ, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 39 (10.32) | 18.7374 |
| 1990's | 95 (25.13) | 18.2507 |
| 2000's | 108 (28.57) | 29.6817 |
| 2010's | 98 (25.93) | 24.3611 |
| 2020's | 38 (10.05) | 2.80 |
| Authors | Studies |
|---|---|
| Plouvier, B | 1 |
| Beatch, GN | 1 |
| Jung, GL | 1 |
| Zolotoy, A | 1 |
| Sheng, T | 1 |
| Clohs, L | 1 |
| Barrett, TD | 1 |
| Fedida, D | 1 |
| Wang, WQ | 1 |
| Zhu, JJ | 1 |
| Liu, Y | 1 |
| Abraham, S | 1 |
| Lynn, L | 1 |
| Dong, Y | 1 |
| Wall, RA | 1 |
| Walker, MJ | 1 |
| Rolland, T | 1 |
| Badenco, N | 1 |
| Maupain, C | 1 |
| Duthoit, G | 1 |
| Waintraub, X | 1 |
| Laredo, M | 1 |
| Himbert, C | 1 |
| Frank, R | 2 |
| Hidden-Lucet, F | 1 |
| Gandjbakhch, E | 1 |
| Burnham, TS | 1 |
| May, HT | 1 |
| Bair, TL | 1 |
| Anderson, JA | 1 |
| Crandall, BG | 1 |
| Cutler, MJ | 1 |
| Day, JD | 1 |
| Freedman, RA | 1 |
| Knowlton, KU | 1 |
| Muhlestein, JB | 1 |
| Navaravong, L | 1 |
| Ranjan, RA | 1 |
| Steinberg, BA | 1 |
| Bunch, TJ | 1 |
| Tamirisa, KP | 1 |
| Elkayam, U | 1 |
| Briller, JE | 1 |
| Mason, PK | 1 |
| Pillarisetti, J | 1 |
| Merchant, FM | 1 |
| Patel, H | 1 |
| Lakkireddy, DR | 1 |
| Russo, AM | 1 |
| Volgman, AS | 1 |
| Vaseghi, M | 1 |
| O' Brien, S | 1 |
| Holmes, AP | 5 |
| Johnson, DM | 1 |
| Kabir, SN | 4 |
| O' Shea, C | 1 |
| O' Reilly, M | 1 |
| Avezzu, A | 1 |
| Reyat, JS | 4 |
| Hall, AW | 1 |
| Apicella, C | 2 |
| Ellinor, PT | 1 |
| Niederer, S | 1 |
| Tucker, NR | 1 |
| Fabritz, L | 7 |
| Kirchhof, P | 12 |
| Pavlovic, D | 5 |
| Tsiachris, D | 3 |
| Doundoulakis, I | 2 |
| Tsioufis, P | 1 |
| Pagkalidou, E | 2 |
| Antoniou, CK | 1 |
| Zafeiropoulos, SM | 1 |
| Gatzoulis, KA | 2 |
| Tsioufis, K | 2 |
| Stefanadis, C | 2 |
| Crijns, HJGM | 2 |
| Elvan, A | 1 |
| Al-Windy, N | 1 |
| Tuininga, YS | 1 |
| Badings, E | 1 |
| Aksoy, I | 1 |
| Van Gelder, IC | 11 |
| Madhavapeddi, P | 2 |
| Camm, AJ | 12 |
| Kowey, PR | 3 |
| Ruskin, JN | 2 |
| Belardinelli, L | 6 |
| Reiffel, JA | 4 |
| Kartalis, A | 3 |
| Afendoulis, D | 3 |
| Moutafi, M | 3 |
| Voutas, P | 3 |
| Papagiannis, N | 3 |
| Garoufalis, S | 3 |
| Kartalis, N | 3 |
| Smyrnioudis, N | 3 |
| Andrikopoulos, G | 3 |
| Didagelos, M | 3 |
| O'Reilly, M | 3 |
| Sommerfeld, LC | 2 |
| O'Shea, C | 3 |
| Broadway-Stringer, S | 2 |
| Andaleeb, S | 2 |
| Stastny, D | 2 |
| Malinova, A | 2 |
| Delbue, D | 2 |
| Fortmueller, L | 2 |
| Gehmlich, K | 2 |
| Skryabin, BV | 2 |
| Kovacs, B | 2 |
| Yakupoglu, HY | 2 |
| Eriksson, U | 2 |
| Krasniqi, N | 2 |
| Duru, F | 3 |
| Markman, TM | 2 |
| Jarrah, AA | 1 |
| Tian, Y | 1 |
| Mustin, E | 1 |
| Guandalini, GS | 1 |
| Lin, D | 2 |
| Epstein, AE | 2 |
| Hyman, MC | 1 |
| Deo, R | 1 |
| Supple, GE | 1 |
| Arkles, JS | 1 |
| Dixit, S | 1 |
| Schaller, RD | 1 |
| Santangeli, P | 1 |
| Nazarian, S | 1 |
| Riley, M | 1 |
| Callans, DJ | 1 |
| Marchlinski, FE | 2 |
| Frankel, DS | 2 |
| Basza, M | 1 |
| Maciejewski, C | 1 |
| Bojanowicz, W | 1 |
| Balsam, P | 1 |
| Grabowski, M | 1 |
| Mitkowski, P | 1 |
| Kempa, M | 1 |
| Kowalski, O | 1 |
| Kalarus, Z | 1 |
| Jaguszewski, M | 1 |
| Lubiński, A | 1 |
| Daniłowicz-Szymanowicz, L | 1 |
| Szumowski, Ł | 1 |
| Sterliński, M | 1 |
| Kołtowski, Ł | 1 |
| Burashnikov, A | 1 |
| Antzelevitch, C | 1 |
| Ray, WA | 1 |
| Chung, CP | 1 |
| Stein, CM | 1 |
| Smalley, W | 1 |
| Zimmerman, E | 1 |
| Dupont, WD | 1 |
| Hung, AM | 1 |
| Daugherty, JR | 1 |
| Dickson, AL | 1 |
| Murray, KT | 1 |
| Orso, D | 1 |
| Santangelo, S | 1 |
| Guglielmo, N | 1 |
| Bove, T | 1 |
| Cilenti, F | 1 |
| Cristiani, L | 1 |
| Copetti, R | 1 |
| Tiver, KD | 1 |
| Martin, DK | 1 |
| Quah, J | 1 |
| Lahiri, A | 1 |
| Ganesan, AN | 1 |
| Przybylski, R | 1 |
| Eberly, LM | 1 |
| Alexander, ME | 1 |
| Bezzerides, VJ | 1 |
| DeWitt, ES | 1 |
| Dionne, A | 1 |
| Mah, DY | 1 |
| Triedman, JK | 1 |
| Walsh, EP | 1 |
| O'Leary, ET | 1 |
| Suffredini, JM | 1 |
| Rutland, J | 1 |
| Akpunonu, P | 1 |
| Baum, R | 1 |
| Catanzaro, J | 1 |
| Elayi, CS | 1 |
| Paolini, E | 1 |
| Stronati, G | 1 |
| Guerra, F | 2 |
| Capucci, A | 13 |
| Hesselkilde, EZ | 4 |
| Carstensen, H | 4 |
| Flethøj, M | 3 |
| Fenner, M | 2 |
| Kruse, DD | 1 |
| Sattler, SM | 2 |
| Tfelt-Hansen, J | 2 |
| Pehrson, S | 6 |
| Braunstein, TH | 1 |
| Carlson, J | 2 |
| Platonov, PG | 2 |
| Jespersen, T | 6 |
| Buhl, R | 5 |
| Tessarolo Silva, F | 1 |
| Pedreira, GC | 1 |
| Medeiros, SA | 1 |
| Bortolotto, AL | 3 |
| Araujo Silva, B | 1 |
| Hurrey, M | 1 |
| Schuler, C | 1 |
| Verrier, RL | 4 |
| Ornelas-Loredo, A | 1 |
| Kany, S | 1 |
| Abraham, V | 1 |
| Alzahrani, Z | 1 |
| Darbar, FA | 1 |
| Sridhar, A | 1 |
| Ahmed, M | 2 |
| Alamar, I | 1 |
| Menon, A | 1 |
| Zhang, M | 1 |
| Chen, Y | 1 |
| Hong, L | 1 |
| Konda, S | 1 |
| Darbar, D | 1 |
| Echt, DS | 1 |
| Bai, J | 1 |
| Lo, A | 1 |
| Gladding, PA | 1 |
| Stiles, MK | 1 |
| Fedorov, VV | 1 |
| Zhao, J | 1 |
| Wilson, H | 1 |
| Patton, D | 1 |
| Moore, Z | 1 |
| O'Connor, T | 1 |
| Nugent, L | 1 |
| Tzeis, S | 1 |
| Asvestas, D | 1 |
| Kourouklis, S | 1 |
| Patsourakos, F | 1 |
| Karlis, D | 1 |
| Kouskos, G | 1 |
| Papadimitriou, G | 1 |
| Gavriilidou, M | 1 |
| Vatkalis, N | 1 |
| Kapetanios, K | 1 |
| Koufaki, P | 1 |
| Taxiarchou, E | 1 |
| Giannakoulas, G | 1 |
| Newson, JM | 1 |
| Santos, CD | 1 |
| Walters, BL | 1 |
| Todd, BR | 1 |
| Gavin, JL | 1 |
| Peigh, GS | 1 |
| Kim, SS | 2 |
| Kordalis, A | 1 |
| Deftereos, S | 1 |
| Saljic, A | 1 |
| Saxena, P | 1 |
| Kuhlmann, SM | 2 |
| Gupta, S | 1 |
| Fobian, D | 1 |
| Syeda, F | 2 |
| Smith, GL | 1 |
| Workman, AJ | 1 |
| D'Angelo, RN | 1 |
| Rahman, M | 1 |
| Khanna, R | 1 |
| Yeh, RW | 1 |
| Goldstein, L | 1 |
| Yadalam, S | 1 |
| Kalsekar, I | 1 |
| Tung, P | 1 |
| Zimetbaum, PJ | 1 |
| Kumar, D | 1 |
| Rehman, ME | 1 |
| Mersfelder, T | 1 |
| Patel, P | 1 |
| Alston, M | 1 |
| Chang, D | 1 |
| Mitra, R | 1 |
| Colangelo, T | 1 |
| Johnson, D | 1 |
| Ho, R | 1 |
| Ferrante, JA | 1 |
| Rizvi, M | 1 |
| Sakaan, S | 1 |
| Eick, J | 1 |
| Cutshall, BT | 1 |
| Manley-Casco, D | 1 |
| Crass, S | 1 |
| Alqusairi, R | 1 |
| Girard, S | 1 |
| De Bortoli, A | 2 |
| Shi, LB | 2 |
| Ohm, OJ | 2 |
| Hoff, PI | 2 |
| Schuster, P | 1 |
| Solheim, E | 2 |
| Chen, J | 2 |
| Cars, T | 1 |
| Lindhagen, L | 1 |
| Malmström, RE | 1 |
| Neovius, M | 1 |
| Schwieler, J | 1 |
| Wettermark, B | 1 |
| Sundström, J | 1 |
| Pohjantähti-Maaroos, H | 1 |
| Hyppölä, H | 1 |
| Lekkala, M | 1 |
| Sinisalo, E | 1 |
| Heikkola, A | 1 |
| Hartikainen, J | 3 |
| Zeemering, S | 1 |
| Lankveld, TAR | 1 |
| Bonizzi, P | 1 |
| Limantoro, I | 2 |
| Bekkers, SCAM | 1 |
| Schotten, U | 5 |
| Haugaard, MM | 2 |
| Markey, GC | 1 |
| Salter, N | 1 |
| Ryan, J | 1 |
| Wu, C | 1 |
| Tcherny-Lessenot, S | 1 |
| Dai, W | 1 |
| Wang, Y | 1 |
| Kechemir, H | 1 |
| Gandhi, S | 1 |
| Lin, S | 1 |
| Juhaeri, J | 1 |
| Liberman, L | 1 |
| Starc, TJ | 1 |
| Silver, ES | 1 |
| Takahashi, Y | 1 |
| Ishikawa, Y | 1 |
| Ohmura, H | 2 |
| Silva, BA | 2 |
| Marum, AA | 2 |
| Stocco, FG | 1 |
| Evaristo, E | 1 |
| de Antonio, VZ | 2 |
| Silva, AC | 2 |
| Comelli, I | 1 |
| Pigna, F | 1 |
| Cervellin, G | 1 |
| Loft-Andersen, AV | 1 |
| Kanters, JK | 1 |
| Mills, LD | 1 |
| Friberg, L | 2 |
| Banavalikar, B | 1 |
| Shenthar, J | 1 |
| Padmanabhan, D | 1 |
| Bucklew, EA | 1 |
| Reis, SE | 1 |
| Kancharla, K | 1 |
| Roguera Sopena, M | 1 |
| Sabidó Sánchez, L | 1 |
| Villuendas Sabaté, R | 1 |
| Del Alcázar Muñoz, R | 1 |
| Conde, D | 4 |
| Costabel, JP | 3 |
| Aragon, M | 2 |
| Caro, M | 2 |
| Ferro, A | 2 |
| Klein, A | 1 |
| Trivi, M | 3 |
| Giniger, A | 1 |
| Lambardi, F | 2 |
| Corrales Barboza, A | 1 |
| Lavalle Cobo, A | 1 |
| Ravens, U | 3 |
| Kagal, DR | 1 |
| Crystal, E | 1 |
| Lashevsky, I | 1 |
| Tiong, I | 1 |
| Lau, C | 1 |
| Vitali, AC | 1 |
| Newman, D | 1 |
| Thelle, DS | 1 |
| Selmer, R | 1 |
| Gjesdal, K | 1 |
| Sakshaug, S | 1 |
| Jugessur, A | 1 |
| Graff-Iversen, S | 1 |
| Tverdal, A | 1 |
| Nystad, W | 1 |
| Apostolakis, S | 2 |
| Haeusler, KG | 1 |
| Oeff, M | 2 |
| Treszl, A | 2 |
| Andresen, D | 2 |
| Borggrefe, M | 4 |
| Lip, GY | 5 |
| Meinertz, T | 6 |
| Parade, U | 2 |
| Samol, A | 2 |
| Steinbeck, G | 6 |
| Wegscheider, K | 3 |
| Breithardt, G | 9 |
| Sivalingam, SK | 1 |
| Gadiraju, VT | 1 |
| Hariharan, MV | 1 |
| Atreya, AR | 1 |
| Flack, JE | 1 |
| Aziz, H | 1 |
| De Vos, CB | 1 |
| Delhaas, T | 1 |
| Marcos, E | 1 |
| Blaauw, Y | 3 |
| Weijs, B | 2 |
| Tieleman, RG | 3 |
| Pisters, R | 1 |
| Crijns, HJ | 12 |
| Oguayo, KN | 1 |
| Oyetayo, OO | 1 |
| Costa, SM | 1 |
| Mixon, TA | 1 |
| Eggertson, L | 1 |
| Hayashi, M | 1 |
| Miyauchi, Y | 1 |
| Iwasaki, YK | 1 |
| Yodogawa, K | 1 |
| Tsuboi, I | 1 |
| Uetake, S | 1 |
| Hayashi, H | 2 |
| Takahashi, K | 1 |
| Shimizu, W | 1 |
| Yamamoto, W | 1 |
| Hashimoto, N | 1 |
| Matsuura, J | 1 |
| Machida, T | 1 |
| Ogino, Y | 1 |
| Kobayashi, T | 1 |
| Yamanaka, Y | 1 |
| Ishiwata, N | 1 |
| Yamashita, T | 1 |
| Tanimoto, K | 1 |
| Miyoshi, S | 1 |
| Fukuda, K | 1 |
| Nakaya, H | 1 |
| Ogawa, S | 3 |
| Seyler, C | 1 |
| Schweizer, PA | 1 |
| Zitron, E | 1 |
| Katus, HA | 1 |
| Thomas, D | 1 |
| Hamilton, A | 1 |
| Clark, D | 1 |
| Gray, A | 1 |
| Cragg, A | 1 |
| Grubb, N | 1 |
| Praestegaard, KF | 1 |
| Diness, JG | 2 |
| Grunnet, M | 2 |
| Allen LaPointe, NM | 1 |
| Dai, D | 1 |
| Thomas, L | 1 |
| Piccini, JP | 2 |
| Peterson, ED | 1 |
| Al-Khatib, SM | 1 |
| Kirchhoff, JE | 1 |
| Sheykhzade, M | 1 |
| Kapoor, M | 1 |
| Greenough, G | 1 |
| Walfridsson, H | 2 |
| Walfridsson, U | 1 |
| Nielsen, JC | 1 |
| Johannessen, A | 2 |
| Raatikainen, P | 2 |
| Janzon, M | 1 |
| Levin, LA | 1 |
| Aronsson, M | 1 |
| Hindricks, G | 2 |
| Kongstad, O | 2 |
| Englund, A | 3 |
| Mortensen, LS | 2 |
| Hansen, PS | 2 |
| Salvage, SC | 1 |
| King, JH | 1 |
| Chandrasekharan, KH | 1 |
| Jafferji, DI | 1 |
| Guzadhur, L | 1 |
| Matthews, HR | 1 |
| Huang, CL | 2 |
| Fraser, JA | 1 |
| Wang, YC | 1 |
| Ramos-Rúa, L | 1 |
| Álvarez-Fernández, L | 1 |
| Nogueira-Fernández, V | 1 |
| da Silva-Franca, CF | 1 |
| Brañas-Fernández, FM | 1 |
| Pego-Reigosa, R | 1 |
| Cortés-Laíño, JA | 1 |
| Curran, J | 1 |
| Louch, WE | 1 |
| Apps, A | 1 |
| Miller, CP | 1 |
| Fellows, S | 1 |
| Jones, M | 1 |
| Lewis, G | 1 |
| Currie, P | 1 |
| Hegde, S | 1 |
| Kumar, V | 1 |
| Piangerelli, L | 1 |
| Ricciotti, J | 1 |
| Gabrielli, D | 1 |
| Fauchier, L | 1 |
| Freedman, SB | 1 |
| Van Gelder, I | 2 |
| Natale, A | 1 |
| Gianni, C | 1 |
| Nattel, S | 6 |
| Potpara, T | 1 |
| Rienstra, M | 4 |
| Tse, HF | 1 |
| Lane, DA | 1 |
| Oto, E | 1 |
| Okutucu, S | 1 |
| Katircioglu-Öztürk, D | 1 |
| Güvenir, HA | 1 |
| Karaagaoglu, E | 1 |
| Goette, A | 2 |
| Oto, A | 1 |
| Bonora, A | 1 |
| Turcato, G | 1 |
| Franchi, E | 1 |
| Taioli, G | 1 |
| Dilda, A | 1 |
| Zerman, G | 1 |
| Maccagnani, A | 1 |
| Pistorelli, C | 1 |
| Olivieri, O | 1 |
| Hayward, C | 1 |
| Patel, HC | 1 |
| Patel, K | 1 |
| Di Mario, C | 1 |
| Lyon, AR | 1 |
| Ahsan, SY | 1 |
| Rowland, E | 2 |
| Yu, TY | 1 |
| Tull, S | 1 |
| Betney, D | 1 |
| Riley, G | 1 |
| Kucera, JP | 1 |
| Jousset, F | 1 |
| de Groot, JR | 1 |
| Rohr, S | 1 |
| Brown, NA | 1 |
| Tessitore, E | 1 |
| Ramlawi, M | 1 |
| Tobler, O | 1 |
| Sunthorn, H | 1 |
| Dudink, E | 1 |
| Essers, B | 1 |
| Holvoet, W | 1 |
| Luermans, J | 1 |
| Ramanna, H | 1 |
| Liem, A | 1 |
| van Opstal, J | 1 |
| Dekker, L | 1 |
| van Dijk, V | 1 |
| Lenderink, T | 1 |
| Kamp, O | 1 |
| Kulker, L | 1 |
| Kietselaer, B | 1 |
| Alings, M | 1 |
| Widdershoven, J | 1 |
| Meeder, J | 1 |
| Prins, M | 1 |
| Crijns, H | 2 |
| Frommeyer, G | 2 |
| Sterneberg, M | 1 |
| Dechering, DG | 1 |
| Kaese, S | 2 |
| Bögeholz, N | 1 |
| Pott, C | 1 |
| Fehr, M | 1 |
| Bogossian, H | 1 |
| Milberg, P | 2 |
| Eckardt, L | 3 |
| Tsai, TF | 1 |
| Garcia, RT | 1 |
| Bui, JQ | 1 |
| Thinda, A | 1 |
| Amsterdam, EA | 1 |
| Atarashi, H | 2 |
| Inoue, H | 3 |
| Benito, B | 1 |
| Brugada, R | 1 |
| Perich, RM | 1 |
| Lizotte, E | 1 |
| Cinca, J | 1 |
| Mont, L | 1 |
| Berruezo, A | 1 |
| Tolosana, JM | 1 |
| Freixa, X | 1 |
| Brugada, P | 1 |
| Brugada, J | 1 |
| Drewitz, I | 1 |
| Rostock, T | 1 |
| Hoffmann, B | 1 |
| Steven, D | 1 |
| Servatius, H | 1 |
| Willems, S | 1 |
| van Brakel, TJ | 1 |
| Hermans, JJ | 1 |
| Accord, RE | 1 |
| Smits, JF | 1 |
| Allessie, MA | 5 |
| Maessen, JG | 1 |
| Dautova, Y | 1 |
| Zhang, Y | 1 |
| Sabir, I | 1 |
| Grace, AA | 1 |
| Sra, J | 3 |
| Akhtar, M | 3 |
| Mortada, ME | 1 |
| Psaty, BM | 1 |
| Psaty, SE | 1 |
| Mattson-DiCecca, AA | 1 |
| Reynolds, E | 1 |
| Pappone, C | 2 |
| Radinovic, A | 2 |
| Manguso, F | 2 |
| Vicedomini, G | 2 |
| Sala, S | 2 |
| Sacco, FM | 1 |
| Ciconte, G | 1 |
| Saviano, M | 1 |
| Ferrari, M | 1 |
| Sommariva, E | 1 |
| Sacchi, S | 1 |
| Ciaccio, C | 1 |
| Kallergis, EM | 1 |
| Santinelli, V | 2 |
| Tuan, J | 1 |
| Osman, F | 1 |
| Jeilan, M | 1 |
| Kundu, S | 1 |
| Mantravadi, R | 1 |
| Stafford, PJ | 1 |
| Ng, GA | 2 |
| Guédon-Moreau, L | 1 |
| Denjoy, I | 5 |
| Morgan, CC | 1 |
| Périer, A | 2 |
| Leplège, A | 1 |
| Kacet, S | 1 |
| Hunter, RJ | 1 |
| Schilling, RJ | 1 |
| Er, F | 2 |
| Aslan, O | 2 |
| Caglayan, E | 2 |
| Gassanov, N | 2 |
| Nia, AM | 2 |
| Erdmann, E | 2 |
| Rosenkranz, S | 2 |
| Taylor, R | 1 |
| Gandhi, MM | 1 |
| Lloyd, G | 1 |
| Camm, J | 1 |
| Dorian, P | 3 |
| Le Heuzey, JY | 2 |
| Pedrazzini, L | 1 |
| Prystowsky, EN | 1 |
| Salette, G | 1 |
| Schwartz, PJ | 1 |
| Torp-Pedersen, C | 1 |
| Weintraub, W | 1 |
| Alboni, P | 4 |
| Botto, GL | 6 |
| Boriani, G | 8 |
| Russo, G | 1 |
| Pacchioni, F | 1 |
| Iori, M | 1 |
| Pasanisi, G | 1 |
| Mancini, M | 1 |
| Mariconti, B | 1 |
| Stiefelhagen, P | 2 |
| Taylor, CJ | 1 |
| Hodgkinson, J | 1 |
| Hobbs, FD | 1 |
| Zimmermann, T | 1 |
| Hellmich, M | 1 |
| Anusionwu, O | 1 |
| Wali, A | 1 |
| Blana, A | 1 |
| Fortmüller, L | 1 |
| Laakmann, S | 1 |
| Damke, D | 1 |
| van Bragt, K | 1 |
| Eckstein, J | 1 |
| Piccini, I | 1 |
| Kirchhefer, U | 1 |
| Carmeliet, P | 1 |
| Carmeliet, E | 1 |
| Verheule, S | 1 |
| Bond, R | 1 |
| Augustine, D | 1 |
| Walker, S | 1 |
| Hirschl, MM | 1 |
| Wollmann, C | 1 |
| Globits, S | 1 |
| Conti, A | 1 |
| Del Taglia, B | 1 |
| Mariannini, Y | 1 |
| Pepe, G | 1 |
| Vanni, S | 1 |
| Grifoni, S | 1 |
| Abbate, R | 1 |
| Michelucci, A | 1 |
| Padeletti, L | 1 |
| Gensini, GF | 1 |
| Fujino, S | 1 |
| Hwang, EH | 1 |
| Sekido, N | 1 |
| Kaizaki, Y | 1 |
| Arai, Y | 1 |
| Aoyama, T | 1 |
| Aliot, E | 4 |
| Tamargo, J | 2 |
| Doniz Campos, M | 1 |
| Illodo Miramontes, G | 1 |
| Bobillo, B | 1 |
| Otero Amoedo, T | 1 |
| Filgueira, P | 1 |
| Rey López, F | 1 |
| Diz Gómez, JC | 1 |
| Freemantle, N | 1 |
| Lafuente-Lafuente, C | 1 |
| Mitchell, S | 1 |
| Eckert, L | 1 |
| Reynolds, M | 1 |
| Kong, DF | 1 |
| Ector, H | 1 |
| Almroth, H | 1 |
| Andersson, T | 1 |
| Fengsrud, E | 1 |
| Linde, P | 1 |
| Rosenqvist, M | 1 |
| Daniell, HW | 1 |
| Balla, I | 1 |
| Petrela, E | 1 |
| Kondili, A | 2 |
| Bash, LD | 1 |
| Buono, JL | 1 |
| Davies, GM | 1 |
| Martin, A | 1 |
| Fahrbach, K | 1 |
| Phatak, H | 1 |
| Avetisyan, R | 1 |
| Mwamburi, M | 1 |
| Landy, C | 1 |
| Schaeffer, E | 1 |
| Raynaud, L | 1 |
| Favier, JC | 1 |
| Plancade, D | 1 |
| Mabo, P | 1 |
| Filgueiras-Rama, D | 1 |
| Martins, RP | 1 |
| Mironov, S | 1 |
| Yamazaki, M | 1 |
| Calvo, CJ | 1 |
| Ennis, SR | 1 |
| Bandaru, K | 1 |
| Noujaim, SF | 1 |
| Kalifa, J | 2 |
| Berenfeld, O | 1 |
| Jalife, J | 1 |
| Savelieva, I | 2 |
| Bosch, R | 1 |
| Kiblboeck, D | 1 |
| Braeuer-Mocker, M | 1 |
| Siostrzonek, P | 2 |
| Reisinger, J | 3 |
| Viñolas, X | 1 |
| Freire, F | 1 |
| Romero-Menor, C | 1 |
| Alegret, JM | 1 |
| Cosedis Nielsen, J | 1 |
| Smit, MD | 1 |
| Moes, ML | 1 |
| Schwab, M | 1 |
| Moerike, K | 1 |
| Vallakati, A | 1 |
| Sharma, A | 1 |
| Lakkireddy, D | 1 |
| Tebbe, U | 1 |
| Ghezelbash, S | 1 |
| Rajamani, S | 1 |
| Osada, N | 1 |
| Razvan, R | 1 |
| Bollmann, A | 4 |
| Binias, KH | 2 |
| Toepffer, I | 1 |
| Molling, J | 2 |
| Geller, C | 3 |
| Klein, HU | 4 |
| Shirayama, T | 3 |
| Shiraishi, H | 1 |
| Yoshida, S | 1 |
| Matoba, Y | 1 |
| Imai, H | 1 |
| Nakagawa, M | 4 |
| Yoshida, T | 2 |
| Niwano, S | 2 |
| Inuo, K | 2 |
| Saito, J | 2 |
| Kojima, J | 2 |
| Ikeda-Murakami, K | 2 |
| Hara, H | 2 |
| Izumi, T | 2 |
| Khan, IA | 2 |
| Shinagawa, K | 1 |
| Shiroshita-Takeshita, A | 2 |
| Schram, G | 2 |
| Naccarelli, GV | 4 |
| Wolbrette, DL | 2 |
| Khan, M | 1 |
| Bhatta, L | 1 |
| Hynes, J | 1 |
| Samii, S | 1 |
| Luck, J | 1 |
| Yan, GX | 1 |
| Winkel, E | 1 |
| Kao, W | 1 |
| De Roy, L | 1 |
| Hernández, J | 1 |
| Lupoglazoff, JM | 1 |
| Coumel, P | 8 |
| Maison-Blanche, P | 2 |
| Tarral, E | 1 |
| Milliez, P | 1 |
| Leenhardt, A | 2 |
| Yoshiga, Y | 1 |
| Shimizu, A | 1 |
| Yamagata, T | 1 |
| Esato, M | 1 |
| Ueyama, T | 1 |
| Ohmura, M | 1 |
| Itagaki, K | 1 |
| Kimura, M | 1 |
| Kakugawa, H | 1 |
| Doi, M | 1 |
| Matsuzaki, M | 1 |
| Kokkonen, L | 1 |
| Majahalme, S | 1 |
| Vitiello, N | 1 |
| Cirillo, R | 1 |
| Fontana, D | 1 |
| Granato, L | 1 |
| Sestri, C | 1 |
| Pagano, V | 1 |
| D'Errico, L | 1 |
| Carotenuto, F | 1 |
| di Palma, F | 1 |
| De Simone, A | 3 |
| De Pasquale, M | 1 |
| De Matteis, C | 3 |
| Canciello, M | 1 |
| Manzo, M | 1 |
| Sabino, L | 1 |
| Alfano, F | 1 |
| Di Mauro, M | 1 |
| Campana, A | 1 |
| De Fabrizio, G | 1 |
| Vitale, DF | 3 |
| Turco, P | 3 |
| Stabile, G | 3 |
| Nagai, S | 1 |
| Takeishi, Y | 1 |
| Kubota, I | 1 |
| Gaita, F | 1 |
| Giustetto, C | 1 |
| Bianchi, F | 1 |
| Wolpert, C | 2 |
| Schimpf, R | 1 |
| Riccardi, R | 1 |
| Grossi, S | 1 |
| Richiardi, E | 1 |
| Siaplaouras, S | 1 |
| Jung, J | 1 |
| Buob, A | 1 |
| Heisel, A | 1 |
| Husser, D | 3 |
| Stridh, M | 3 |
| Soernmo, L | 1 |
| Majic, M | 1 |
| Olsson, SB | 3 |
| Argall, J | 1 |
| Crawford, I | 1 |
| VerNooy, RA | 1 |
| Mounsey, JP | 1 |
| Climent, VE | 1 |
| Marin, F | 1 |
| Mainar, L | 1 |
| Gomez-Aldaravi, R | 1 |
| Martinez, JG | 1 |
| Chorro, FJ | 2 |
| Roman, P | 1 |
| Sogorb, F | 1 |
| Merckx, KL | 1 |
| Gatterer, E | 2 |
| Lang, W | 1 |
| Vanicek, T | 1 |
| Eisserer, G | 1 |
| Bachleitner, T | 1 |
| Niemeth, C | 1 |
| Aicher, F | 1 |
| Grander, W | 1 |
| Heinze, G | 2 |
| Kühn, P | 2 |
| Hongo, RH | 1 |
| Themistoclakis, S | 2 |
| Raviele, A | 2 |
| Bonso, A | 2 |
| Rossillo, A | 1 |
| Glatter, KA | 1 |
| Yang, Y | 1 |
| Scheinman, MM | 1 |
| Humphries, KH | 1 |
| Kerr, CR | 1 |
| Steinbuch, M | 1 |
| Beldner, S | 1 |
| Bertaglia, E | 1 |
| Zoppo, F | 1 |
| Proclemer, A | 1 |
| Verlato, R | 2 |
| Corò, L | 1 |
| Mantovan, R | 1 |
| Pascotto, P | 1 |
| Freestone, B | 2 |
| Baldi, N | 2 |
| Luzi, M | 1 |
| Russo, V | 1 |
| Gianfranchi, L | 1 |
| Marchi, P | 1 |
| Calzolari, M | 1 |
| Solano, A | 1 |
| Baroffio, R | 1 |
| Gaggioli, G | 1 |
| van Loon, G | 1 |
| Blissitt, KJ | 1 |
| Keen, JA | 1 |
| Young, LE | 1 |
| Deneer, VH | 1 |
| Lie-A-Huen, L | 3 |
| Kingma, JH | 5 |
| Proost, JH | 1 |
| Gossen, SA | 1 |
| Stuurman, A | 1 |
| Uytdehaag, GM | 1 |
| Dunselman, PH | 1 |
| Brouwers, JR | 1 |
| La Rocca, V | 2 |
| El Jamal, B | 1 |
| Nocerino, P | 2 |
| Astarita, C | 2 |
| Messina, V | 1 |
| Greco, L | 1 |
| Rotunno, R | 1 |
| Di Napoli, T | 2 |
| Sornmo, L | 2 |
| Engelen, M | 1 |
| Franz, MR | 1 |
| Ribbing, M | 1 |
| Wasmer, K | 1 |
| Haverkamp, W | 1 |
| Konety, SH | 1 |
| Olshansky, B | 1 |
| Morady, F | 1 |
| Bosker, HA | 1 |
| Kingma, T | 1 |
| Wilde, AA | 1 |
| Kirchhof, CJ | 1 |
| Bennekers, JH | 1 |
| Bracke, FA | 1 |
| Veeger, NJ | 1 |
| Haaksma, J | 1 |
| Sedrakyan, A | 1 |
| Treasure, T | 1 |
| Browne, J | 1 |
| Krumholz, H | 1 |
| Sharpin, C | 1 |
| van der Meulen, J | 1 |
| Duytschaever, M | 2 |
| Allessie, M | 1 |
| Martínez-Sellés, M | 1 |
| Castillo, I | 1 |
| Montenegro, P | 1 |
| Martín, ML | 1 |
| Almendral, J | 1 |
| Sanjurjo, M | 1 |
| Wyse, DG | 1 |
| Fetsch, T | 1 |
| Hanrath, P | 1 |
| Lehmacher, W | 1 |
| Scharf, C | 1 |
| Simon, T | 1 |
| Mary-Krause, M | 1 |
| Chatelin, A | 1 |
| Thuault, M | 1 |
| Jaillon, P | 2 |
| Janko, S | 1 |
| Hoffmann, E | 1 |
| Wiesfeld, AC | 1 |
| van Veldhuisen, DJ | 2 |
| Liard, F | 1 |
| Lièvre, M | 1 |
| Danchin, N | 1 |
| Antonelli, D | 1 |
| Feldman, A | 1 |
| Freedberg, NA | 1 |
| Darawsha, A | 1 |
| Rosenfeld, T | 1 |
| Eijsbouts, S | 1 |
| Ausma, J | 1 |
| Anderson, ME | 1 |
| Narayan, G | 1 |
| Hagens, VE | 1 |
| Augello, G | 1 |
| Gugliotta, F | 1 |
| Gulletta, S | 1 |
| Paglino, G | 1 |
| Mazzone, P | 1 |
| Sora, N | 1 |
| Greiss, I | 1 |
| Santagostino, A | 1 |
| LiVolsi, L | 1 |
| Pappone, N | 1 |
| Klingenheben, T | 1 |
| Israel, CW | 1 |
| Rivard, L | 1 |
| Sinno, H | 1 |
| Leung, TK | 1 |
| Hamada, C | 1 |
| Bernard, M | 1 |
| Gout, B | 1 |
| Bril, A | 1 |
| Cozma, D | 1 |
| Laurent, P | 1 |
| Chalvidan, T | 1 |
| Deharo, JC | 1 |
| Djiane, P | 1 |
| Cozzone, P | 1 |
| Maixent, JM | 1 |
| Walsh, CA | 1 |
| Manias, T | 1 |
| Patient, C | 1 |
| Mykytsey, A | 1 |
| Bauman, JL | 2 |
| Razminia, M | 1 |
| Zheutlin, T | 1 |
| Wang, T | 1 |
| Saleem, M | 1 |
| Leal, S | 1 |
| Kehoe, RF | 1 |
| Doki, K | 1 |
| Homma, M | 1 |
| Kuga, K | 1 |
| Kawano, S | 1 |
| Aonuma, K | 1 |
| Yamaguchi, I | 1 |
| Kohda, Y | 1 |
| Birettoni, F | 1 |
| Porciello, F | 1 |
| Rishniw, M | 1 |
| della Rocca, G | 1 |
| Di Salvo, A | 1 |
| Sgorbini, M | 1 |
| Airaksinen, KE | 1 |
| Koistinen, MJ | 1 |
| Malfatto, G | 1 |
| Zaza, A | 1 |
| Facchini, M | 1 |
| Tamargo Menéndez, J | 1 |
| Gulizia, M | 1 |
| Mangiameli, S | 1 |
| Orazi, S | 1 |
| Chiarandà, G | 1 |
| Piccione, G | 1 |
| Di Giovanni, N | 1 |
| Colletti, A | 1 |
| Pensabene, O | 1 |
| Lisi, F | 1 |
| Vasquez, L | 1 |
| Grammatico, A | 1 |
| Robinet, S | 1 |
| Melon, R | 1 |
| Piérard, L | 1 |
| Ting, SM | 1 |
| Lee, D | 1 |
| Maclean, D | 1 |
| Sheerin, NS | 1 |
| Imai, S | 1 |
| Saito, F | 1 |
| Takase, H | 1 |
| Enomoto, M | 1 |
| Aoyama, H | 1 |
| Yamaji, S | 1 |
| Yokoyama, K | 1 |
| Yagi, H | 1 |
| Kushiro, T | 1 |
| Hirayama, A | 1 |
| Liakishev, AA | 1 |
| Hellestrand, KJ | 4 |
| Burnett, PJ | 1 |
| Milne, JR | 1 |
| Bexton, RS | 2 |
| Nathan, AW | 3 |
| Orning, OM | 1 |
| Pop, T | 1 |
| Treese, N | 1 |
| Kang, JC | 1 |
| Kasper, W | 1 |
| Grey, E | 1 |
| Silverman, DI | 1 |
| Inoue, M | 3 |
| Inoue, D | 3 |
| Ishibashi, K | 2 |
| Sakai, R | 3 |
| Asayama, J | 3 |
| Carunchio, A | 2 |
| Fera, MS | 2 |
| Mazza, A | 2 |
| Burattini, M | 2 |
| Greco, G | 1 |
| Galati, A | 2 |
| Ceci, V | 2 |
| Babuty, D | 2 |
| D'Hautefeuille, B | 1 |
| Scheck, F | 2 |
| Mycinsky, C | 1 |
| Pruvost, P | 1 |
| Peraudeau, P | 2 |
| Zarembski, DG | 1 |
| Nolan, PE | 1 |
| Slack, MK | 1 |
| Caruso, AC | 1 |
| Fagbemi, SO | 1 |
| Chi, L | 1 |
| Lucchesi, BR | 1 |
| Wang, JA | 1 |
| Lau, CP | 3 |
| Tai, YT | 1 |
| Wu, BZ | 1 |
| Lee, CY | 1 |
| Teo, WS | 1 |
| Wang, Z | 2 |
| Feng, J | 1 |
| Panagides, D | 1 |
| Bory, M | 1 |
| Bonnet, JL | 1 |
| Yvorra, S | 1 |
| Desfossez, L | 1 |
| Savin, B | 1 |
| Ebagosti, A | 1 |
| Van de Walle, JP | 1 |
| Bonini, W | 1 |
| Broffoni, T | 2 |
| Cappelletti, G | 1 |
| Falcone, C | 2 |
| Lombardi, R | 1 |
| Paulesu, A | 1 |
| Pedraglio, E | 1 |
| Ferrari, G | 1 |
| Knez, A | 1 |
| Haberl, R | 1 |
| Falk, RH | 2 |
| Fogel, RI | 1 |
| Donovan, KD | 3 |
| Power, BM | 1 |
| Hockings, BE | 1 |
| Dobb, GJ | 3 |
| Lee, KY | 3 |
| Lenzi, T | 2 |
| Rubino, I | 2 |
| Trisolino, G | 3 |
| Della Casa, S | 1 |
| Binetti, N | 2 |
| Cavazza, M | 2 |
| Said, SA | 1 |
| Somer, ST | 1 |
| Oude Luttikhuis, HA | 1 |
| Cowan, JC | 1 |
| Manz, M | 1 |
| Lüderitz, B | 2 |
| Koenig, A | 1 |
| Theolade, R | 1 |
| Chauvin, M | 2 |
| Brechenmacher, C | 2 |
| Madrid, AH | 1 |
| Moro, C | 1 |
| Marín-Huerta, E | 1 |
| Mestre, JL | 1 |
| Novo, L | 1 |
| Costa, A | 1 |
| Omori, I | 2 |
| Yamahara, Y | 2 |
| Sanchis, J | 1 |
| López-Merino, V | 1 |
| Burguera, M | 1 |
| Martínez-Mas, ML | 1 |
| Such, L | 1 |
| Sopher, SM | 1 |
| Hohnloser, SH | 2 |
| Chimienti, M | 2 |
| Cullen, MT | 3 |
| Casadei, G | 2 |
| Hopson, JR | 1 |
| Buxton, AE | 1 |
| Rinkenberger, RL | 2 |
| Nademanee, K | 1 |
| Heilman, JM | 1 |
| Kienzle, MG | 1 |
| Katritsis, D | 2 |
| O'Nunain, S | 2 |
| Shakespeare, CF | 1 |
| Poloniecki, J | 1 |
| Reeb, T | 1 |
| de Chillou, C | 1 |
| Sadoul, N | 1 |
| Lacour, JC | 1 |
| Ducrocq, X | 1 |
| Debouverie, M | 1 |
| Weber, M | 1 |
| Aouate, P | 1 |
| Fontaine, G | 1 |
| Tonet, J | 1 |
| Tageddine, R | 1 |
| Benassar, A | 1 |
| Turlure, A | 1 |
| Jacquemin, M | 1 |
| Laborde, JP | 1 |
| Jung, F | 1 |
| DiMarco, JP | 1 |
| Oltrona, L | 1 |
| Broccolino, M | 1 |
| Merlini, PA | 1 |
| Spinola, A | 1 |
| Pezzano, A | 1 |
| Mannucci, PM | 1 |
| Brembilla-Perrot, B | 1 |
| Fauchier, JP | 1 |
| Garnier, LF | 1 |
| Rouesnel, P | 1 |
| Breuillac, JC | 1 |
| Funck, F | 1 |
| Medvedowsky, JL | 1 |
| Thomas, O | 1 |
| Coletta, C | 1 |
| Okreglicki, AM | 1 |
| Millar, RN | 1 |
| Lawson-Matthew, PJ | 1 |
| Ionescu, A | 1 |
| McHugh, P | 1 |
| Channer, KS | 2 |
| Bellandi, F | 1 |
| Dabizzi, RP | 1 |
| Mugnaioni, G | 1 |
| Cantini, F | 1 |
| Palchetti, R | 1 |
| Matsuo, K | 1 |
| Kumagai, K | 1 |
| Annoura, M | 1 |
| Ideishi, M | 1 |
| Arakawa, K | 1 |
| Huang, DT | 1 |
| Monahan, KM | 1 |
| Zimetbaum, P | 1 |
| Papageorgiou, P | 1 |
| Epstein, LM | 1 |
| Josephson, ME | 2 |
| Wiesinger, K | 1 |
| Zeindlhofer, E | 1 |
| Gattermeier, M | 1 |
| Poelzl, G | 1 |
| Kratzer, H | 1 |
| Ebner, A | 1 |
| Hohenwallner, W | 1 |
| Lenz, K | 1 |
| Slany, J | 1 |
| Meurin, P | 1 |
| Larrazet, F | 1 |
| Weber, H | 1 |
| Bourmayan, C | 1 |
| Peters, FP | 1 |
| Braat, SH | 1 |
| Heymeriks, J | 1 |
| Wellens, HJ | 3 |
| Biffi, M | 4 |
| Botto, G | 1 |
| Ongari, M | 1 |
| Sanguinetti, M | 1 |
| Branzi, A | 4 |
| Magnani, B | 4 |
| Krishnan, SC | 1 |
| Sarubbi, B | 1 |
| Ducceschi, V | 1 |
| D'Andrea, A | 1 |
| Liccardo, B | 1 |
| Santangelo, L | 1 |
| Iacono, A | 1 |
| De Sisti, A | 2 |
| Matteucci, C | 1 |
| Patrissi, T | 1 |
| Accogli, S | 1 |
| Di Lorenzo, M | 1 |
| Sasdelli, M | 1 |
| Ciolli, A | 2 |
| Lo Sardo, G | 2 |
| Palamara, A | 2 |
| Montenero, AS | 1 |
| Sanna, T | 1 |
| Villani, GQ | 2 |
| Piepoli, MF | 1 |
| Aschieri, D | 1 |
| Bronzetti, G | 2 |
| Ayers, GM | 1 |
| Zannoli, R | 2 |
| Schumacher, B | 1 |
| Jung, W | 1 |
| Lewalter, T | 1 |
| Vahlhaus, C | 1 |
| Nabar, A | 2 |
| Rodriguez, LM | 2 |
| Timmermans, C | 2 |
| Smeets, JL | 1 |
| Wijffels, MC | 2 |
| Dorland, R | 2 |
| Fujiki, A | 1 |
| Usui, M | 1 |
| Nagasawa, H | 1 |
| Mizumaki, K | 1 |
| Rankin, AC | 1 |
| Tuinenburg, AE | 1 |
| Van Den Berg, MP | 1 |
| Brügemann, J | 1 |
| De Kam, PJ | 1 |
| Schwartz, M | 1 |
| Maglio, C | 1 |
| Boccadamo, R | 1 |
| Dell'Orfano, JT | 1 |
| Patel, HM | 1 |
| Luck, JC | 1 |
| Alp, NJ | 1 |
| Bell, JA | 1 |
| Shahi, M | 1 |
| Mast, F | 1 |
| Nukada, T | 1 |
| Mizuno, Y | 1 |
| Yamaya, Y | 1 |
| Nakayama, T | 1 |
| Amada, A | 1 |
| Martínez-Marcos, FJ | 1 |
| García-Garmendia, JL | 1 |
| Ortega-Carpio, A | 1 |
| Fernández-Gómez, JM | 1 |
| Santos, JM | 1 |
| Camacho, C | 1 |
| Yasuda, M | 1 |
| Nakazato, Y | 1 |
| Yamashita, H | 1 |
| Sekita, G | 1 |
| Kawano, Y | 1 |
| Mineda, Y | 1 |
| Nakazato, K | 1 |
| Tokano, T | 1 |
| Sumiyoshi, M | 1 |
| Nakata, Y | 1 |
| Gasparini, M | 2 |
| Coltorti, F | 1 |
| Mantica, M | 1 |
| Galimberti, P | 1 |
| Ceriotti, C | 1 |
| Beatty, G | 1 |
| Blitzer, M | 1 |
| Watanabe, H | 1 |
| Watanabe, I | 1 |
| Nakai, T | 1 |
| Oshikawa, N | 1 |
| Kunimoto, S | 1 |
| Masaki, R | 1 |
| Kojima, T | 1 |
| Saito, S | 1 |
| Ozawa, Y | 1 |
| Kanmatuse, K | 1 |
| Romano, S | 2 |
| Fattore, L | 1 |
| Toscano, G | 1 |
| Corsini, F | 1 |
| Coppo, A | 1 |
| Catanzaro, M | 1 |
| Romano, A | 1 |
| Martone, A | 1 |
| Caccavale, F | 1 |
| Iodice, E | 1 |
| Di Maggio, O | 1 |
| Corsini, G | 1 |
| Wirth, KJ | 1 |
| Knobloch, K | 1 |
| Ohki, R | 1 |
| Takahashi, M | 1 |
| Mizuno, O | 1 |
| Fujikawa, H | 1 |
| Mitsuhashi, T | 1 |
| Katsuki, T | 1 |
| Ikeda, U | 1 |
| Shimada, K | 1 |
| van Mechelen, R | 1 |
| Maresca, F | 1 |
| Stabile, E | 1 |
| Minish, T | 1 |
| Herd, A | 1 |
| Antonielli, E | 1 |
| Pizzuti, A | 1 |
| Pálinkás, A | 1 |
| Tanga, M | 1 |
| Gruber, N | 1 |
| Michelassi, C | 1 |
| Varga, A | 1 |
| Bonzano, A | 1 |
| Gandolfo, N | 1 |
| Halmai, L | 1 |
| Bassignana, A | 1 |
| Imran, MB | 1 |
| Delnevo, F | 1 |
| Csanády, M | 1 |
| Picano, E | 1 |
| Bartolotti, M | 1 |
| Bacchi Reggiani, L | 1 |
| Brignole, M | 1 |
| Menozzi, C | 1 |
| Bongiorni, MG | 1 |
| Ometto, R | 1 |
| Bruna, C | 1 |
| Vincenti, A | 1 |
| Fornieles-Pérez, H | 1 |
| Montoya-García, M | 1 |
| Levine, PA | 1 |
| Sanz, O | 1 |
| Zabel, M | 1 |
| Matsumoto, T | 1 |
| Katsume, H | 1 |
| Anderson, JL | 4 |
| Crozier, I | 2 |
| Nunain, SO | 1 |
| Clementy, J | 1 |
| Dulhoste, MN | 2 |
| Laiter, C | 1 |
| Dos Santos, P | 1 |
| Coombs, LJ | 2 |
| Weekes, JN | 2 |
| Murdock, CJ | 2 |
| Clarke, GM | 2 |
| Suttorp, MJ | 3 |
| Leclercq, JF | 2 |
| Chouty, F | 3 |
| Slama, R | 1 |
| Leung, WH | 1 |
| Wong, CK | 1 |
| Auricchio, A | 1 |
| Fontana, G | 1 |
| Pagé, P | 1 |
| Bhandari, AK | 2 |
| Gilbert, EM | 2 |
| Alpert, BL | 2 |
| Henthorn, RW | 2 |
| Waldo, AL | 2 |
| Hawkinson, RW | 2 |
| Pritchett, EL | 3 |
| Wiseman, MN | 1 |
| Elstob, JE | 1 |
| Frandsen, F | 1 |
| Pless, P | 1 |
| Mickley, H | 1 |
| Møller, M | 1 |
| Guarnieri, T | 1 |
| Tomaselli, G | 1 |
| Griffith, LS | 1 |
| Brinker, J | 1 |
| Garratt, CJ | 1 |
| Linker, NJ | 1 |
| Gill, J | 1 |
| Ward, DE | 1 |
| Tworek, DA | 1 |
| Nazari, J | 1 |
| Ezri, M | 1 |
| Hughes, MM | 1 |
| Trohman, RG | 1 |
| Simmons, TW | 1 |
| Castle, LW | 1 |
| Wilkoff, BL | 1 |
| Morant, VA | 1 |
| Maloney, JD | 1 |
| DaTorre, SD | 1 |
| Platt, ML | 1 |
| McCarville, SE | 1 |
| Hougham, AJ | 1 |
| Pietersen, AH | 1 |
| Hellemann, H | 1 |
| Kühlkamp, V | 2 |
| Schmid, F | 1 |
| Risler, T | 1 |
| Seipel, L | 2 |
| Van Gilst, WH | 5 |
| Hillege, H | 1 |
| Gosselink, AM | 1 |
| Lie, KI | 7 |
| Carr, B | 1 |
| Hawley, K | 1 |
| Sihm, I | 1 |
| Hansen, FA | 1 |
| Rasmussen, J | 1 |
| Pedersen, AK | 1 |
| Thygesen, K | 1 |
| Marcus, FI | 1 |
| Rosi, A | 1 |
| Piepoli, M | 1 |
| Gandolfini, A | 1 |
| Groppi, F | 1 |
| Groppi, M | 1 |
| Arruzzoli, S | 1 |
| Dieci, G | 1 |
| Gazzola, U | 1 |
| Bashir, Y | 1 |
| Jessurun, ER | 1 |
| van Hemel, NM | 1 |
| Kastrati, A | 1 |
| Popa, Y | 1 |
| Mary-Rabine, L | 2 |
| Kulbertus, HE | 1 |
| van Wijk, LM | 5 |
| den Heijer, P | 2 |
| De Langen, CD | 1 |
| Mast, EG | 1 |
| Bolognesi, R | 1 |
| Tsialtas, D | 1 |
| Manca, C | 1 |
| Visioli, O | 1 |
| Cordoni, M | 1 |
| Scalzini, A | 1 |
| Bechi, S | 1 |
| Franchini, C | 1 |
| Mazza, F | 1 |
| Micheli, G | 1 |
| Hamer, HP | 1 |
| Tognarini, S | 1 |
| Pardini, E | 1 |
| Borgeat, A | 2 |
| Grbic, M | 3 |
| Assyag, P | 1 |
| Fass, H | 1 |
| Klein, JM | 1 |
| Berns, E | 1 |
| Jeang, MK | 1 |
| Dougherty, AH | 1 |
| Jenkins, M | 1 |
| Davies, DW | 1 |
| Mehta, D | 1 |
| Ward, DW | 1 |
| Cohen-Solal, A | 1 |
| Juliard, JM | 1 |
| Jaeger, P | 1 |
| Farinotti, P | 1 |
| Dahan, M | 1 |
| Charlier, P | 1 |
| Boujon, B | 1 |
| Aumont, MC | 1 |
| Croce, L | 1 |
| Pozzoni, L | 1 |
| Lomuscio, A | 1 |
| Telerman, M | 1 |
| Marwick, TH | 1 |
| Woodhouse, SP | 1 |
| Smith, P | 1 |
| Ruffy, R | 1 |
| Goy, JJ | 3 |
| Kaufmann, U | 2 |
| Kappenberger, L | 1 |
| Sigwart, U | 3 |
| Jolivette, DM | 1 |
| Fredell, PA | 1 |
| Saoudi, N | 1 |
| Berland, J | 1 |
| Cribier, A | 1 |
| Letac, B | 1 |
| Doliwa, R | 1 |
| Bach, P | 1 |
| Haissaguerre, M | 1 |
| Commenges, D | 1 |
| Salamon, R | 1 |
| Lemetayer, P | 1 |
| Warin, JF | 1 |
| Sonnhag, C | 1 |
| Kallryd, A | 1 |
| Nylander, E | 1 |
| Rydén, L | 1 |
| Haasis, R | 1 |
| Maendly, R | 2 |
| Rae, BG | 1 |
| Ilsley, CD | 1 |
| Ablett, MB | 1 |
| Ikram, H | 1 |
| Finci, L | 1 |
| Kappenberger, LJ | 1 |
| Fromer, MA | 1 |
| Shenasa, M | 1 |
| Gloor, HO | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Randomized Multicenter Study of Flecainide Acetate Oral Inhalation Solution in Single and Repeat Dose Regimens for Acute Conversion to Sinus Rhythm in Subjects With Recent Onset of Symptomatic Paroxysmal Atrial Fibrillation[NCT03539302] | Phase 2 | 170 participants (Actual) | Interventional | 2018-05-29 | Completed | ||
| Cryoballoon Pulmonary Vein Isolation as First Line Treatment for Typical Atrial Flutter[NCT03401099] | 113 participants (Actual) | Interventional | 2018-08-17 | Completed | |||
| Targeted Pharmacological Reversal of Electrical Remodeling After Cardioversion.[NCT00215774] | 760 participants (Actual) | Interventional | 2005-03-31 | Completed | |||
| Medical Antiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation: A Randomized Prospective Multicentre Study (MANTRA-PAF)[NCT00133211] | Phase 3 | 294 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| A Single Site, Interventional, Comparative Study to Evaluate the Safety and Efficacy of Ranolazine Plus Metoprolol Combination vs. FlecainidE pluS Metoprolol Combination in ATrial Fibrillation Recurrences[NCT03162120] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2018-09-01 | Withdrawn (stopped due to new study type, it will be re-organiZed as an Investigator Initiated Study (IIS)) | ||
| Acute Cardioversion Versus Wait And See-approach for Symptomatic Atrial Fibrillation in the Emergency Department (RACE 7 ACWAS-trial)[NCT02248753] | 437 participants (Actual) | Interventional | 2014-10-31 | Completed | |||
| Can Global Peak Longitudinal Strain Measurements in Combination With Non-invasive ECG Parameters Predict the Success or Failure of Flecainide Treatment for Atrial Fibrillation Patients?[NCT05084495] | 100 participants (Anticipated) | Observational | 2022-02-01 | Recruiting | |||
| Using Time-dependent Intravenous Infusions of Amiodarone for Conversions to Sinus Rhythms in Patients With Paroxysmal Atrial Fibrillation[NCT03432663] | Phase 4 | 60 participants (Actual) | Interventional | 2008-08-01 | Completed | ||
| Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study[NCT02932007] | Phase 2 | 40 participants (Anticipated) | Interventional | 2017-03-28 | Recruiting | ||
| Efficacy and Safety of Dual Direct Current Cardioversion Versus Single Direct Current Cardioversion as an Initial Treatment Strategy in Obese Patients[NCT04539158] | 200 participants (Anticipated) | Interventional | 2020-08-07 | Recruiting | |||
| Dual Shock Versus Single Shock Synchronized External Direct Current Cardioversion for Atrial Fibrillation - A Double-blinded Randomized Trial[NCT03943693] | Phase 4 | 100 participants (Actual) | Interventional | 2019-04-01 | Terminated (stopped due to Poor enrollment) | ||
| Inhibition of Atrial Fibrillation by Elimination of Transitional Mechanisms[NCT02758002] | 0 participants (Actual) | Interventional | 2016-01-28 | Withdrawn | |||
| Radiofrequency vs Cryoballoon Catheter Ablation for Pulmonary Vein Isolation in Patients With Atrial Fibrillation - Effect on Atrial Fibrillation Burden Assessed by Implantable Cardiac Monitor (RACE-AF Trial)[NCT03805555] | 105 participants (Actual) | Interventional | 2015-06-30 | Completed | |||
| First-line Cryoablation for Early Treatment of Persistent Atrial Fibrillation - a Randomized Study Comparing Early Trigger Isolation Using the Cryoballoon Versus Antiarrhythmic Medication[NCT05939076] | Phase 3 | 220 participants (Anticipated) | Interventional | 2023-08-21 | Not yet recruiting | ||
| Randomized Clinical Trial to Study Pharmacological Cardioversion of Paroxysmal Atrial Fibrillation by Vernakalant and Flecainide[NCT03005366] | Phase 4 | 50 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| Home-based Videoplethysmographic Detection of Atrial Fibrillation[NCT04267133] | 256 participants (Actual) | Interventional | 2018-05-24 | Completed | |||
| A Controlled Randomized Trial of Circumferential Pulmonary Vein Ablation Versus Antiarrhythmic Drug Therapy in Treating Paroxysmal Atrial Fibrillation. The Ablation for Paroxysmal Atrial Fibrillation (APAF2) Trial[NCT00340314] | Phase 4 | 198 participants | Interventional | 2005-01-31 | Completed | ||
| Hybrid Ablation Plus Medical Therapy for Persistent Atrial Fibrillation (HYBRID AF)[NCT04190186] | 90 participants (Anticipated) | Interventional | 2020-06-25 | Recruiting | |||
| Risk Factors That Contribute to the Maintenance of Sinus Rhythm: A Prospective Study to Create a Prediction Model for Atrial Fibrillation Patients to Maintain Sinus Rhythm.[NCT04655443] | 77 participants (Actual) | Observational | 2017-08-29 | Terminated (stopped due to due to COVID-19) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The outcome measure is the AUC of the curve obtained from the ROC analysis. The curve is a combination of specificity and sensitivity of detecting atrial fibrillation. The range of the curve is 0.5-1.0 where 0.5 would be random detection of atrial fibrillation and 1.0 would be perfect performance. (NCT04267133)
Timeframe: 2 weeks
| Intervention | probability (Number) |
|---|---|
| All Participants | 0.74 |
49 reviews available for flecainide and Auricular Fibrillation
| Article | Year |
|---|---|
Arrhythmias in Pregnancy.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Flecainide; Humans; Pregnancy; Sotalol; Tachyca | 2022 |
Reappraising the role of class Ic antiarrhythmics in atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Flecainide; Humans; Propafenone; | 2022 |
Flecainide in clinical practice.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Child; Female; Flecainide; Humans; Pregnancy; Propafeno | 2023 |
Bayesian Network Meta-analysis of Randomized Controlled Trials on the Efficacy of Antiarrhythmics in the Pharmacological Cardioversion of Paroxysmal Atrial Fibrillation.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Flecainide; H | 2023 |
Flecainide: Electrophysiological properties, clinical indications, and practical aspects.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Flecainide; Humans | 2019 |
Pulmonary Delivery of Antiarrhythmic Drugs for Rapid Conversion of New-Onset Atrial Fibrillation.
Topics: Administration, Inhalation; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, An | 2020 |
Use of Flecainide for the Treatment of Atrial Fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Flecainide; Heart Rate; Humans; Quality of Life | 2020 |
Comparison of dronedarone vs. flecainide in the maintenance of sinus rhythm, following electrocardioversion in adults with persistent atrial fibrillation: a systematic review and meta-analysis.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Dronedarone; Flecainide; Humans | 2021 |
Pharmacologic Cardioversion in Patients with Paroxysmal Atrial Fibrillation: A Network Meta-Analysis.
Topics: Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Flecainide; Humans; Pyrrolidines; Randomized | 2021 |
Anti-arrhythmic investigations in large animal models of atrial fibrillation.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dogs; Flecainide; Horses; Mammals; Models, Ani | 2022 |
Intravenous Flecainide for Emergency Department Management of Acute Atrial Fibrillation.
Topics: Administration, Intravenous; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Elec | 2018 |
[Paroxysmal atrial fibrillation within the context of cluster headaches].
Topics: Amiodarone; Anti-Inflammatory Agents, Non-Steroidal; Atrial Fibrillation; Autonomic Nervous System D | 2015 |
Atrial fibrillation.
Topics: Ablation Techniques; Anticoagulants; Aspirin; Atrial Fibrillation; Dizziness; Dyspnea; Electric Coun | 2016 |
[Current strategies in the treatment of atrial fibrillation].
Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Cardiac Pacing, Artificial; Catheter Ab | 2008 |
Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Flecainide; Humans; Prevalence; Treatment Outcome | 2011 |
Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Flecainide; Humans; Prevalence; Treatment Outcome | 2011 |
Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Flecainide; Humans; Prevalence; Treatment Outcome | 2011 |
Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Flecainide; Humans; Prevalence; Treatment Outcome | 2011 |
Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Female; Flecainide; Huma | 2011 |
Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation.
Topics: Aged; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Bayes Theorem; Electric Countershock; F | 2012 |
Safety of flecainide.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Interactions; Flecainide; He | 2012 |
Flecainide acetate for the treatment of atrial and ventricular arrhythmias.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Flecainide; Humans; Prac | 2013 |
Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Atrial Fibrillation; Biological Availability; Controlled Clinical | 2003 |
Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Australia; Canada; Controlled Clinical Tria | 2003 |
Pharmacologic and nonpharmacologic options to maintain sinus rhythm: guideline-based and new approaches.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Catheter Ablati | 2003 |
[Postoperative atrial fibrillation].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Flecainide; Hemodynamics; | 2003 |
Best evidence topic report. Amiodarone or flecainide for cardioversion in acute onset atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Flecainide; Humans; Middle Aged | 2004 |
Antiarrhythmic drug therapy of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disopyramide; Flecainide; Humans; Phenethyl | 2004 |
Atrial fibrillation (acute).
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Diltiazem; Flecainide; Humans; Pro | 2003 |
Atrial fibrillation (acute).
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Diltiazem; Flecainide; Humans; Pro | 2004 |
Pharmacologic prophylaxis for postoperative atrial tachyarrhythmia in general thoracic surgery: evidence from randomized clinical trials.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial F | 2005 |
[Atrial flutter and fibrillation].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia | 2005 |
Atrial fibrillation (recent onset).
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Diltiazem; Flecainide; Humans; Pro | 2005 |
[Drug treatment of atrial fibrillation].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti | 2006 |
Some patients with paroxysmal atrial fibrillation should carry flecainide or propafenone to self treat.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Flecainide; Humans; Propafenone; Self Care | 2007 |
[New strategies in the treatment of atrial fibrillation].
Topics: Action Potentials; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anim | 2007 |
Treatment of resistant atrial fibrillation. A meta-analysis comparing amiodarone and flecainide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; | 1995 |
Flecainide.
Topics: Atrial Fibrillation; Electrocardiography; Flecainide; Heart; Hemodynamics; Humans; Tachycardia, Vent | 1994 |
Supraventricular tachycardia and pre-excitation syndromes: pharmacological therapy.
Topics: Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Disopyramide; Fle | 1993 |
[Antiarrhythmic treatment after reduction of atrial fibrillation by external shock].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Disopyramide; El | 1993 |
Atrial fibrillation: maintenance of sinus rhythm versus rate control.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Calc | 1996 |
[Supraventricular tachycardia with wide QRS complexes during Vaughan-Williams class I anti-arrhythmic treatment. Diagnostic and therapeutic implications].
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Drug Th | 1995 |
Antiarrhythmic drug therapy in the treatment of atrial fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Electrop | 1996 |
[Pharmacological treatment of atrial fibrillation].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibril | 1997 |
Atrial fibrillation: what are the effects of drug therapy on the effectiveness and complications of electrical cardioversion?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Digoxin; Electri | 1998 |
The role of oral 1C antiarrhythmic drugs in terminating atrial fibrillation.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Flecainide; | 1999 |
Cost-effective management of acute atrial fibrillation: role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy.
Topics: Algorithms; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cost-Benefit An | 2000 |
Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Flecainide; Humans; Meta-Analysis as Topi | 1992 |
Flecainide in the Wolff-Parkinson-White syndrome.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Flecainide; Heart Conduction Syst | 1992 |
Interference by antiarrhythmic agents with function of electrical cardiac devices.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Death, Sudden, Cardiac; Digoxin; Drug Interactions; Ele | 1992 |
[Flecainide and anti-arrhythmia therapy].
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Electrocardiography; Flecainide; Heart Ventricles; Humans | 1988 |
Summary of efficacy and safety of flecainide for supraventricular arrhythmias.
Topics: Atrial Fibrillation; Atrial Flutter; Clinical Trials as Topic; Flecainide; Humans; Tachycardia, Supr | 1988 |
94 trials available for flecainide and Auricular Fibrillation
| Article | Year |
|---|---|
Time-dependent antiarrhythmic effects of flecainide on induced atrial fibrillation in horses.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Flecainide; Horse Diseases; Horses; Pa | 2018 |
Low stroke risk after elective cardioversion of atrial fibrillation: an analysis of the Flec-SL trial.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Electric Count | 2013 |
Three-month lower-dose flecainide after catheter ablation of atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Drug Administration Schedule; | 2014 |
Antiarrhythmic and electrophysiologic effects of flecainide on acutely induced atrial fibrillation in healthy horses.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Female; Flecainide | 2015 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation: results on health-related quality of life and symptom burden. The MANTRA-PAF trial.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Cost of Illness; Female | 2015 |
Flecainide-metoprolol combination reduces atrial fibrillation clinical recurrences and improves tolerability at 1-year follow-up in persistent symptomatic atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Therapy, Combination; Electrocardiography; F | 2016 |
Acute cardioversion vs a wait-and-see approach for recent-onset symptomatic atrial fibrillation in the emergency department: Rationale and design of the randomized ACWAS trial.
Topics: Adult; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Electric Countershock; Electroca | 2017 |
Relationship between subjective symptoms and trans-telephonic ECG findings in patients with symptomatic paroxysmal atrial fibrillation and flutter.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Electrocardiograph | 2008 |
Increase in organization index predicts atrial fibrillation termination with flecainide post-ablation: spectral analysis of intracardiac electrograms.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrophysiologic Techniques, Cardiac; Fe | 2010 |
Physician stated atrial fibrillation management in light of treatment guidelines: data from an international, observational prospective survey.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channe | 2010 |
Beta1-adrenoceptor polymorphism predicts flecainide action in patients with atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Echocardiography; Female; Flecainide; Genotype; H | 2010 |
Management of patients with acute atrial fibrillation in the ED.
Topics: Acute Disease; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; | 2010 |
Pharmacological conversion of recent atrial fibrillation: a randomized, placebo-controlled study of three antiarrhythmic drugs.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; | 2011 |
Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Female; Flecainide; Humans; Male | 2012 |
Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Female; Flecainide; Humans; Male | 2012 |
Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Female; Flecainide; Humans; Male | 2012 |
Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Female; Flecainide; Humans; Male | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Bepridil prevents paroxysmal atrial fibrillation by a class III antiarrhythmic drug effect.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Electrocardiography; Female; Flecainide; Huma | 2003 |
Pharmacodynamic equivalence of two flecainide acetate formulations in patients with paroxysmal atrial fibrillation by QRS analysis of ambulatory electrocardiogram.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Circadian Rhythm; Dosage Forms; Double-Bli | 2003 |
VErapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF Study).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; | 2003 |
Low-dose flecainide infusion followed by oral pilsicainide is highly effective and safe for paroxysmal atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Therapy, Combination; Female; Flecainide; Humans; | 2003 |
Short QT Syndrome: a familial cause of sudden death.
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Complexes, Premature; Ch | 2003 |
Frequency measures obtained from the surface electrocardiogram in atrial fibrillation research and clinical decision-making.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Data Interpretation, St | 2003 |
Effects of pretreatment with intravenous flecainide on efficacy of external cardioversion of persistent atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Output; Double-Blind Method; Electric Cou | 2004 |
Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cost-Benefit Analysis; Female; Flecaini | 2004 |
Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Drug Administration Schedule; Dru | 2004 |
Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach.
Topics: Administration, Oral; Ambulatory Care; Anti-Arrhythmia Agents; Atrial Fibrillation; Feasibility Stud | 2004 |
Absorption kinetics and pharmacodynamics of two oral dosage forms of flecainide in patients with an episode of paroxysmal atrial fibrillation.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Anti-Ulcer Agents; Area Under Curve; Atrial Fibrillati | 2004 |
Electrophysiological effects of flecainide and sotalol in the human atrium during persistent atrial fibrillation.
Topics: Action Potentials; Adult; Aged; Anti-Arrhythmia Agents; Atrial Appendage; Atrial Fibrillation; Elect | 2005 |
[Outpatient treatment of recurrent atrial fibrillation with the "pill-in-the-pocket" approach: practical aspects].
Topics: Administration, Oral; Adolescent; Adult; Aged; Ambulatory Care; Anti-Arrhythmia Agents; Atrial Fibri | 2005 |
[Flecainide controlled-release for prevention of atrial fibrillation relapse].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Delayed-Action Preparations; Elec | 2006 |
[Intravenous flecainide administration for conversion of paroxysmal atrial fibrillation in the emergency room].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Emergencies; Female; Flecainide; Humans; Hypotens | 2006 |
Determinants of sudden cardiac death in patients with persistent atrial fibrillation in the rate control versus electrical cardioversion (RACE) study.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2006 |
A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study.
Topics: Age Factors; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Diseases; | 2006 |
Dose-response effect of flecainide in patients with symptomatic paroxysmal atrial fibrillation and/or flutter monitored with trans-telephonic electrocardiography: a multicenter, placebo-controlled, double-blind trial.
Topics: Aged; Atrial Fibrillation; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiograph | 2007 |
Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut | 2007 |
Treatment of chronic atrial fibrillation in the horse with flecainide: personal observation.
Topics: Animals; Anti-Arrhythmia Agents; Area Under Curve; Atrial Fibrillation; Chronic Disease; Flecainide; | 2007 |
Different effects of antiarrhythmic drugs on the rate-dependency of QT interval: a study with amiodarone and flecainide.
Topics: Action Potentials; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Pressure; El | 2007 |
A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the Prevention Investigation and Treatment: A Group for Observation and Research on Atrial arrhythmias (PITAGORA
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmia, Sinus; Atrial Fibrillation; | 2008 |
Use of bepridil in combination with Ic antiarrhythmic agent in converting persistent atrial fibrillation to sinus rhythm.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Natriuretic Factor; Bepridil; Drug | 2008 |
[Circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation. Results of the APAF trial].
Topics: Adolescent; Adult; Aged; Amiodarone; Angina, Unstable; Anti-Arrhythmia Agents; Atrial Fibrillation; | 2008 |
[A comparison between flecainide and sotalol in the prevention of recurrences of paroxysmal atrial fibrillation].
Topics: Adult; Aged; Atrial Fibrillation; Female; Flecainide; Follow-Up Studies; Humans; Male; Middle Aged; | 1995 |
Cibenzoline versus flecainide in the prevention of paroxysmal atrial arrhythmias: a double-blind randomized study.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Drug Toleran | 1995 |
Effects of flecainide on exercise hemodynamics and electrocardiography in patients without structural heart disease.
Topics: Atrial Fibrillation; Blood Pressure; Cross-Over Studies; Double-Blind Method; Electrocardiography; E | 1995 |
Regular ventricular rhythms before conversion of recent onset atrial fibrillation to sinus rhythm.
Topics: Atrial Fibrillation; Digoxin; Electrocardiography; Electrocardiography, Ambulatory; Female; Flecaini | 1994 |
[The use of digitalis glycosides in atrial fibrillation].
Topics: Administration, Oral; Adult; Aged; Atrial Fibrillation; Digoxin; Dose-Response Relationship, Drug; D | 1994 |
Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation.
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Confidence Intervals; Double-Blind Method; Flecainide; | 1995 |
Comparison of flecainide and procainamide in cardioversion of atrial fibrillation.
Topics: Adult; Aged; Atrial Fibrillation; Atrial Function, Left; Echocardiography; Electrocardiography; Fema | 1993 |
Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Female; Flecainid | 1996 |
Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Flecainide; Follow-Up | 1996 |
Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group.
Topics: Adult; Aged; Ambulatory Care; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Female; F | 1996 |
Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Arrhythmia | 1996 |
Efficacy and safety of long-term oral flecainide acetate in patients with responsive supraventricular tachycardia.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; A | 1996 |
Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Dose-Res | 1995 |
[Comparative study of cibenzoline and flecainide by oral route for preventing recurrence of paroxysmal atrial tachyarrhythmias].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Flecainide; Humans | 1997 |
[Comparison of anti-arrhythmic therapy guided by the transesophageal electropharmacologic test and emperic therapy in the prophylaxis of atrial fibrillation recurrence].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Echocardiography, Transesophageal; Female; Flecainide; | 1997 |
Mechanism of antiarrhythmic effects of class Ic drugs in paroxysmal atrial fibrillation in man.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Arti | 1998 |
Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation.
Topics: Age Factors; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Administration Schedule; Female | 1998 |
Treatment of recent onset atrial fibrillation with intravenous sotalol and/or flecainide.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Thera | 1998 |
Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different drug protocols.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Electroca | 1998 |
Randomised double blind trial of oral versus intravenous flecainide for the cardioversion of acute atrial fibrillation.
Topics: Acute Disease; Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Chi-Square Distrib | 2000 |
Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm.
Topics: Aged; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; Confidence Inte | 2000 |
Noncontact system-guided simplified right atrial linear lesions using radiofrequency transcatheter ablation for treatment of refractory atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Electrocardiography; Female; Flecain | 2000 |
[Effectiveness and side effects of the treatment with propafenone and flecainide for recent-onset atrial fibrillation].
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Flecainide; Hum | 2001 |
Response to flecainide infusion predicts long-term success of hybrid pharmacologic and ablation therapy in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; Atria | 2001 |
Clinical value of left atrial appendage flow for prediction of long-term sinus rhythm maintenance in patients with nonvalvular atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Flow Velocity; Echocardiography, Doppler, P | 2002 |
An evaluation of the strategy of maintenance of sinus rhythm by antiarrhythmic drug therapy after ablation and pacing therapy in patients with paroxysmal atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular Node; Catheter Ablat | 2002 |
Long-term safety and efficacy of flecainide in the treatment of supraventricular tachyarrhythmias: the United States experience. The Flecainide Supraventricular Tachyarrhythmia Investigators.
Topics: Atrial Fibrillation; Drug Evaluation; Drug Tolerance; Female; Flecainide; Follow-Up Studies; Humans; | 1992 |
Effects of flecainide on atrial electrophysiology in the Wolff-Parkinson-White syndrome.
Topics: Atrial Fibrillation; Atrial Function; Cardiac Catheterization; Cardiac Pacing, Artificial; Flecainid | 1992 |
Flecainide acetate in the prevention of paroxysmal atrial fibrillation: a nine-month follow-up of more than 500 patients.
Topics: Atrial Fibrillation; Drug Evaluation; Drug Tolerance; Electrocardiography, Ambulatory; Female; Fleca | 1992 |
Efficacy of flecainide for the reversion of acute onset atrial fibrillation.
Topics: Acute Disease; Arrhythmias, Cardiac; Atrial Fibrillation; Digoxin; Double-Blind Method; Drug Evaluat | 1992 |
Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil.
Topics: Atrial Fibrillation; Atrial Flutter; Drug Evaluation; Female; Flecainide; Humans; Male; Middle Aged; | 1992 |
A randomized double-blind crossover study comparing the efficacy and tolerability of flecainide and quinidine in the control of patients with symptomatic paroxysmal atrial fibrillation.
Topics: Adult; Aged; Atrial Fibrillation; Chi-Square Distribution; Double-Blind Method; Electrocardiography, | 1992 |
Reversible protective effect of propafenone or flecainide during atrial fibrillation in patients with an accessory atrioventricular connection.
Topics: Adult; Atrial Fibrillation; Atrioventricular Node; Cardiac Pacing, Artificial; Exercise; Exercise Te | 1992 |
Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension.
Topics: Administration, Oral; Adult; Aged; Amiodarone; Atrial Fibrillation; Electrocardiography, Ambulatory; | 1992 |
A comparison of intravenous propafenone and flecainide in the treatment of tachycardias associated with the Wolff-Parkinson-White syndrome.
Topics: Adult; Atrial Fibrillation; Cardiac Pacing, Artificial; Female; Flecainide; Humans; Male; Propafenon | 1991 |
Reversion of recent-onset atrial fibrillation to sinus rhythm by intravenous flecainide.
Topics: Atrial Fibrillation; Coronary Care Units; Digoxin; Double-Blind Method; Drug Therapy, Combination; E | 1991 |
Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: dose-response studies. The Flecainide Supraventricular Tachycardia Study Group.
Topics: Adult; Atrial Fibrillation; Atrial Flutter; Dose-Response Relationship, Drug; Double-Blind Method; F | 1991 |
Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Danish-Norwegian Flecainide Multicenter Study Group.
Topics: Adult; Aged; Atrial Fibrillation; Atrial Flutter; Drug Evaluation; Electrocardiography; Female; Flec | 1991 |
Randomized comparison of flecainide and cibenzoline in the conversion of atrial fibrillation.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Chi-Square Distribution; Female; Flecainid | 1991 |
[The efficacy of oral treatment with flecainide for paroxysmal atrial fibrillation: correlation with plasma concentration].
Topics: Adult; Atrial Fibrillation; Echocardiography; Female; Flecainide; Humans; Male; Middle Aged; Thyroid | 1990 |
Clinical trials of flecainide acetate in the management of supraventricular arrhythmias.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Flecainide; Humans; | 1990 |
The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm.
Topics: Atrial Fibrillation; Atrial Flutter; Electrocardiography; Female; Flecainide; Humans; Male; Middle A | 1990 |
Comparative evaluation of verapamil, flecainide and propafenone for the acute conversion of atrial fibrillation to sinus rhythm.
Topics: Adult; Aged; Atrial Fibrillation; Electrocardiography; Female; Flecainide; Heart Rate; Humans; Infus | 1990 |
Encainide versus flecainide in the treatment of chronic resistant paroxysmal atrial tachyarrhythmias.
Topics: Adult; Anilides; Anti-Arrhythmia Agents; Atrial Fibrillation; Encainide; Female; Flecainide; Humans; | 1990 |
Clinical efficacy of flecainide acetate in atrial fibrillation.
Topics: Adult; Aged; Atrial Fibrillation; Electrocardiography; Female; Flecainide; Humans; Male; Middle Aged | 1990 |
Flecainide versus quinidine in the prevention of paroxysms of atrial fibrillation.
Topics: Adult; Aged; Atrial Fibrillation; Female; Flecainide; Humans; Male; Middle Aged; Quinidine; Random A | 1989 |
Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm.
Topics: Adult; Aged; Atrial Fibrillation; Atrial Flutter; Clinical Trials as Topic; Female; Flecainide; Hear | 1989 |
Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutte | 1989 |
Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventri
Topics: Atrial Fibrillation; Double-Blind Method; Female; Flecainide; Humans; Male; Middle Aged; Monitoring, | 1989 |
Oral flecainide for prophylaxis of paroxysmal atrial fibrillation.
Topics: Amiodarone; Atrial Fibrillation; Clinical Trials as Topic; Drug Therapy, Combination; Female; Flecai | 1988 |
Summary of efficacy and safety of flecainide for supraventricular arrhythmias.
Topics: Atrial Fibrillation; Atrial Flutter; Clinical Trials as Topic; Flecainide; Humans; Tachycardia, Supr | 1988 |
Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate. Comparison of two regimens.
Topics: Administration, Oral; Adolescent; Adult; Aged; Atrial Fibrillation; Drug Administration Schedule; El | 1988 |
[Therapy of paroxysmal atrial fibrillation. Cardiac glycosides alone or combined with anti-arrhythmia agents?].
Topics: Administration, Oral; Aged; Atrial Fibrillation; Clinical Trials as Topic; Digoxin; Drug Therapy, Co | 1988 |
Long-term efficacy of flecainide in paroxysmal atrial fibrillation.
Topics: Adult; Aged; Atrial Fibrillation; Clinical Trials as Topic; Female; Flecainide; Humans; Male; Middle | 1988 |
Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Fema | 1986 |
236 other studies available for flecainide and Auricular Fibrillation
| Article | Year |
|---|---|
Synthesis and biological studies of novel 2-aminoalkylethers as potential antiarrhythmic agents for the conversion of atrial fibrillation.
Topics: Administration, Oral; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Biological Availability; | 2007 |
Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy.
Topics: Arrhythmogenic Right Ventricular Dysplasia; Atrial Fibrillation; Defibrillators, Implantable; Flecai | 2022 |
Long-term outcomes in patients treated with flecainide for atrial fibrillation with stable coronary artery disease.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Disease; Flecainide; Humans; Prospectiv | 2022 |
Increased atrial effectiveness of flecainide conferred by altered biophysical properties of sodium channels.
Topics: Action Potentials; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Flecainide; Heart Atria; Human | 2022 |
Open-Label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution for Acute Conversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electric Countershock; Flecainide; Huma | 2022 |
The safety of flecainide for atrial fibrillation in patients with stable coronary artery disease - Fact or fallacy.
Topics: Atrial Fibrillation; Coronary Artery Disease; Flecainide; Heart Atria; Humans | 2022 |
Acute management of paroxysmal atrial fibrillation with beta-blockers plus intravenous flecainide using the real-world Chios registry (BETAFLEC-CHIOS).
Topics: Administration, Intravenous; Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillatio | 2023 |
Acute management of paroxysmal atrial fibrillation with beta-blockers plus intravenous flecainide using the real-world Chios registry (BETAFLEC-CHIOS).
Topics: Administration, Intravenous; Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillatio | 2023 |
Acute management of paroxysmal atrial fibrillation with beta-blockers plus intravenous flecainide using the real-world Chios registry (BETAFLEC-CHIOS).
Topics: Administration, Intravenous; Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillatio | 2023 |
Acute management of paroxysmal atrial fibrillation with beta-blockers plus intravenous flecainide using the real-world Chios registry (BETAFLEC-CHIOS).
Topics: Administration, Intravenous; Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillatio | 2023 |
Familial atrial fibrillation mutation M1875T-SCN5A increases early sodium current and dampens the effect of flecainide.
Topics: Animals; Atrial Fibrillation; Flecainide; Heart Atria; Mice; Mutation; NAV1.5 Voltage-Gated Sodium C | 2023 |
Familial atrial fibrillation mutation M1875T-SCN5A increases early sodium current and dampens the effect of flecainide.
Topics: Animals; Atrial Fibrillation; Flecainide; Heart Atria; Mice; Mutation; NAV1.5 Voltage-Gated Sodium C | 2023 |
Familial atrial fibrillation mutation M1875T-SCN5A increases early sodium current and dampens the effect of flecainide.
Topics: Animals; Atrial Fibrillation; Flecainide; Heart Atria; Mice; Mutation; NAV1.5 Voltage-Gated Sodium C | 2023 |
Familial atrial fibrillation mutation M1875T-SCN5A increases early sodium current and dampens the effect of flecainide.
Topics: Animals; Atrial Fibrillation; Flecainide; Heart Atria; Mice; Mutation; NAV1.5 Voltage-Gated Sodium C | 2023 |
Medical therapy with flecainide and propafenone in atrial fibrillation: Long-term clinical experience in the tertiary care setting.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular Node; Flecainide; Humans; | 2023 |
Medical therapy with flecainide and propafenone in atrial fibrillation: Long-term clinical experience in the tertiary care setting.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular Node; Flecainide; Humans; | 2023 |
Medical therapy with flecainide and propafenone in atrial fibrillation: Long-term clinical experience in the tertiary care setting.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular Node; Flecainide; Humans; | 2023 |
Medical therapy with flecainide and propafenone in atrial fibrillation: Long-term clinical experience in the tertiary care setting.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular Node; Flecainide; Humans; | 2023 |
Safety of Pill-in-the-Pocket Class 1C Antiarrhythmic Drugs for Atrial Fibrillation.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Female; Flecainide; Humans; H | 2022 |
Pill-in-the-Pocket Therapy for Atrial Fibrillation: Is There More to Say?
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Flecainide; Humans | 2022 |
Reply: Pill-in-the-Pocket Therapy for Atrial Fibrillation: Is There More to Say?
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Flecainide; Humans | 2022 |
Mild elevation of extracellular potassium greatly potentiates the effect of sodium channel block to cardiovert atrial fibrillation: The Lankenau approach.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dogs; Flecainide; Heart Atria; Sodium Channels | 2023 |
Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial Fibrillation : A Retrospective Cohort Study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; | 2023 |
Failure of diltiazem to prevent 1:1 conduction of atrial flutter: a case report.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Atrioventricular Block; Diltiazem; Elec | 2023 |
Medical cardioversion of atrial fibrillation and flutter with class IC antiarrhythmic drugs in young patients with and without congenital heart disease.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electric Countershoc | 2023 |
Flecainide Toxicity Resulting in Pacemaker Latency and Intermittent Failure to Capture.
Topics: Acute Kidney Injury; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; El | 2019 |
Longitudinal study of electrical, functional and structural remodelling in an equine model of atrial fibrillation.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function, Left; Atri | 2019 |
Multimodal mechanisms and enhanced efficiency of atrial fibrillation cardioversion by pulmonary delivery of a novel flecainide formulation.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Action Potentials; Administration, Inhalation; Animals; Anti-Arrh | 2020 |
Association Between Obesity-Mediated Atrial Fibrillation and Therapy With Sodium Channel Blocker Antiarrhythmic Drugs.
Topics: Aged; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Diet, High-Fat; Disease Models, Animal; | 2020 |
In silico investigation of the mechanisms underlying atrial fibrillation due to impaired Pitx2.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Remodeling; Calcium; | 2020 |
Beneficial Effect of Flecainide Controlled Release on the Quality of Life of Patients with Atrial Fibrillation-the REFLEC-CR Study.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Delayed-Action Preparations; Female; Flecainide; | 2020 |
The Case of Flecainide Toxicity: What to Look for and How to Treat.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Female; Flecainide; Humans; Middle | 2020 |
Paroxysmal Atrial Fibrillation on Flecainide Therapy.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electrocardiography; Flecainide; Humans | 2020 |
Atrial resting membrane potential confers sodium current sensitivity to propafenone, flecainide and dronedarone.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Dro | 2021 |
Limited duration of antiarrhythmic drug use for newly diagnosed atrial fibrillation in a nationwide population under age 65.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; | 2021 |
Flecainide-induced myalgias and weakness: a rare adverse reaction.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Flecainide; Humans; Middle Aged; Myalgia | 2021 |
Flecainide-induced AV dyssynchrony and atrial latency progression in a patient with a dual-chamber pacemaker.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Flecainide; Heart Atria; Humans; Pacemaker, Artificial | 2021 |
Flecainide-Induced Atrial Flutter With 1:1 Conduction Complicated by Ventricular Fibrillation After Electrical Cardioversion.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electric Countershock; Electrocardiogra | 2021 |
Consequences of AV blockade omission in flecainide therapy.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Flecainide; Heart Block; Humans | 2021 |
Flecainide toxicity with high pacemaker capture thresholds and associated takotsubo syndrome.
Topics: Atrial Fibrillation; Cardiac Pacing, Artificial; Catheter Ablation; Female; Flecainide; Humans; Pace | 2021 |
Incidence and clinical predictors of subsequent atrial fibrillation requiring additional ablation after cavotricuspid isthmus ablation for typical atrial flutter.
Topics: Aged; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Atrial Flutter; Catheter Ablation | 2017 |
Effectiveness of Drugs in Routine Care: A Model for Sequential Monitoring of New Medicines Using Dronedarone as Example.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Computer Syste | 2018 |
Intravenous vernakalant in comparison with intravenous flecainide in the cardioversion of recent-onset atrial fibrillation.
Topics: Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Resynchronization Therapy; Dose-Respo | 2019 |
The electrocardiogram as a predictor of successful pharmacological cardioversion and progression of atrial fibrillation.
Topics: Action Potentials; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Databases, Factual; Dis | 2018 |
Effect of flecainide on atrial fibrillatory rate in a large animal model with induced atrial fibrillation.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; | 2017 |
Assessing the Risk for Peripheral Neuropathy in Patients Treated With Dronedarone Compared With That in Other Antiarrhythmics.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Stud | 2018 |
Usefulness of High-Dose Oral Flecainide for Termination of Recent-Onset Atrial Fibrillation in Children.
Topics: Adolescent; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Child; Child, Preschool; Fe | 2018 |
Treatment of recent-onset atrial fibrillation with quinidine and flecainide in Thoroughbred racehorses: 107 cases (1987-2014).
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Flecainide; Horse Diseases; Horses; Ma | 2018 |
Accelerated conversion of atrial fibrillation to normal sinus rhythm by pulmonary delivery of flecainide acetate in a porcine model.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Dose-Response Relation | 2018 |
1:1 atrial flutter induced by flecainide, whilst the patient was at rest.
Topics: Atrial Fibrillation; Atrial Flutter; Electrocardiography; Emergency Service, Hospital; Flecainide; H | 2018 |
Atrial Fibrillation: How Long Has It Been?
Topics: Atrial Fibrillation; Catheter Ablation; Emergency Service, Hospital; Flecainide; Humans | 2018 |
Optimizing flecainide plasma concentration profile for atrial fibrillation conversion while minimizing adverse ventricular effects by rapid, low-dose intratracheal or intravenous administration.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Biomarkers; Disease Models, Animal; Dose-Respo | 2019 |
Ventricular arrhythmia and death among atrial fibrillation patients using anti-arrhythmic drugs.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cause of Death; Dronedarone; Female; Flecainide; | 2018 |
Unusual Wide Complex Tachycardia During Rhythm Control for Atrial Fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Female; Flecainide; Heart Ra | 2018 |
Wide QRS Tachycardia in a Man With a Medical History of Atrial Fibrillation.
Topics: Aged; Atrial Fibrillation; Catheter Ablation; Electrocardiography; Flecainide; Heart Conduction Syst | 2019 |
[Atrial fibrillation. A presentation of 2 cases].
Topics: Adolescent; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Flecainide; Humans; Ma | 2020 |
Flecainide or propafenone vs. vernakalant for conversion of recent-onset atrial fibrillation.
Topics: Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Europe; Flecainide; Huma | 2013 |
Flecainide versus vernakalant for conversion of recent-onset atrial fibrillation.
Topics: Aged; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Flecainide; Humans; Male; Middl | 2013 |
[Antiarrhythmic agents].
Topics: Atrial Fibrillation; Evidence-Based Medicine; Flecainide; Humans; Risk Factors; Treatment Outcome | 2013 |
Amiodarone plus Flecainide combination therapy in patients with Amiodarone refractory paroxysmal atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Therapy, Combination; Female; Fl | 2013 |
Resting heart rate and physical activity as risk factors for lone atrial fibrillation: a prospective study of 309,540 men and women.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Early Diagnosis; Exercise; Female; Flecainide; H | 2013 |
Conversion of recent onset atrial fibrillation: which drug is faster?
Topics: Administration, Oral; Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Flecainide; | 2013 |
Vernakalant: Perception of state of health in patients with a recent-onset atrial fibrillation.
Topics: Administration, Oral; Aged; Anisoles; Atrial Fibrillation; Dose-Response Relationship, Drug; Drug Th | 2014 |
Flecainide toxicity--treatment with intravenous fat emulsion and extra corporeal life support.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Extracorporeal Circulation; Fat Em | 2013 |
Tissue velocity imaging of the left atrium predicts response to flecainide in patients with acute atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Echocardiography; Electrocardiography; Female; Flecaini | 2014 |
An unusual case of flecainide-induced QT prolongation leading to cardiac arrest.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Defibrillators; Flecainide; Heart Arrest; Humans | 2014 |
Three heart medications in short supply in Canada.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Flecainide; Humans; Phenethylamines; Propafenon | 2014 |
Effects of the selective KACh channel blocker NTC-801 on atrial fibrillation in a canine model of atrial tachypacing: comparison with class Ic and III drugs.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Dogs; Electrocardi | 2014 |
Vernakalant activates human cardiac K(2P)17.1 background K(+) channels.
Topics: Action Potentials; Animals; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; CHO Cells; Cricet | 2014 |
The epidemiology and management of recent-onset atrial fibrillation and flutter presenting to the Emergency Department.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut | 2015 |
Antiarrhythmic drug use in patients <65 years with atrial fibrillation and without structural heart disease.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Databases, Factual; Droneda | 2015 |
Synergistic antiarrhythmic effect of combining inhibition of Ca²⁺-activated K⁺ (SK) channels and voltage-gated Na⁺ channels in an isolated heart model of atrial fibrillation.
Topics: Acetanilides; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Drug Syn | 2015 |
A 42-year-old female with well-controlled atrial fibrillation and mild obstructive sleep apnea.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Diltiazem; Drug Therapy, Combination; Female; Fl | 2015 |
Flecainide exerts paradoxical effects on sodium currents and atrial arrhythmia in murine RyR2-P2328S hearts.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Flecainide; Ion Channel Gating; Membrane Poten | 2015 |
Effect of flecainide on the extension and localization of complex fractionated electrogram during atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Electrocardiography; Electroph | 2015 |
Linking ryanodine receptor Ca(2+) leak and Na(+) current in heart: a day in the life of flecainide.
Topics: Animals; Atrial Fibrillation; Flecainide; Membrane Potentials; NAV1.5 Voltage-Gated Sodium Channel; | 2015 |
Cardiac devices with class 1C antiarrhythmics: a potentially toxic combination.
Topics: Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electric Countershoc | 2015 |
Atrial fibrillation during pregnancy: cardioversion with flecainide.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Flecainide; Humans; Pregnancy; Pregnancy | 2015 |
Wide Complex Tachycardia in a Patient With a History of Atrial Fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Electrocardiography; Female; Fle | 2016 |
Predictors of sinus rhythm after electrical cardioversion of atrial fibrillation: results from a data mining project on the Flec-SL trial data set.
Topics: Action Potentials; Algorithms; Anti-Arrhythmia Agents; Area Under Curve; Atrial Fibrillation; Data M | 2017 |
Efficacy and safety in pharmacological cardioversion of recent-onset atrial fibrillation: a propensity score matching to compare amiodarone vs class IC antiarrhythmic drugs.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countersh | 2017 |
The evolving landscape of oral anti-arrhythmic prescriptions for atrial fibrillation in England: 1998-2014.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Prescriptions; Drug Utili | 2016 |
PITX2 Modulates Atrial Membrane Potential and the Antiarrhythmic Effects of Sodium-Channel Blockers.
Topics: Adult; Aged; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrophysiological Phenomena; F | 2016 |
Brugada Pattern Caused by a Flecainide Overdose.
Topics: Atrial Fibrillation; Bipolar Disorder; Brugada Syndrome; Consciousness Disorders; Drug Overdose; Ele | 2017 |
Effective suppression of atrial fibrillation by the antihistaminic agent antazoline: First experimental insights into a novel antiarrhythmic agent.
Topics: Acetylcholine; Action Potentials; Animals; Antazoline; Anti-Arrhythmia Agents; Atrial Fibrillation; | 2017 |
Confused and Too Long: Neurotoxicity and Cardiac Toxicity of Flecainide.
Topics: Aged; Anti-Arrhythmia Agents; Ataxia; Atrial Fibrillation; Atrioventricular Block; Cardiotoxicity; E | 2017 |
A mutation in the sodium channel is responsible for the association of long QT syndrome and familial atrial fibrillation.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Child; Child, Preschool; Female; Flecainid | 2008 |
Effects of intrapericardial sotalol and flecainide on transmural atrial electrophysiology and atrial fibrillation.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Stimulation; Electrocardiography; Ele | 2009 |
Atrial arrhythmogenesis in wild-type and Scn5a+/delta murine hearts modelling LQT3 syndrome.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Flecainide; Heart Rate | 2009 |
A case of flecainide-induced hyponatremia.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Flecainide; Humans; Hyponatremia | 2009 |
Flecainide toxicity in an older adult.
Topics: Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Echocardiography; Flecainide; Humans | 2009 |
Update: A 60-year-old woman with atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Decision Making; Electric Countershock; | 2009 |
New-onset atrial fibrillation as first clinical manifestation of latent Brugada syndrome: prevalence and clinical significance.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Brugada Syndrome; Electrocardiography; Female; F | 2009 |
Impact of the control of symptomatic paroxysmal atrial fibrillation on health-related quality of life.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Cost of Illness; Female; Fleca | 2010 |
Termination of atrial fibrillation by flecainide: mechanistic insights from spectral analysis.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electrophysiologic Techniques, Cardiac; Flecainide; Hum | 2010 |
Flecainide for cardioversion in patients at elevated cardiovascular risk and persistent atrial fibrillation: a prospective observational study.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Female; Flecainide; Humans | 2010 |
Tachycardia due to atrial flutter with rapid 1:1 conduction following treatment of atrial fibrillation with flecainide.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Female; Flecainide; Heart Block; Humans | 2010 |
Intravenous administration of flecainide or propafenone in patients with recent-onset atrial fibrillation does not predict adverse effects during 'pill-in-the-pocket' treatment.
Topics: Administration, Oral; Adolescent; Adult; Aged; Ambulatory Care; Anti-Arrhythmia Agents; Atrial Fibri | 2010 |
[Instead of long-term antiarrhythmia drug treatment--stand-by therapy for atrial fibrillation].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Diagnosis, Differential; D | 2010 |
Rhythm control agents and adverse events in patients with atrial fibrillation.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Case-Control Studies; Female; | 2010 |
'Pill-in-the-pocket' treatment for recent-onset atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Flecainide; Humans; Infusions, Intravenous; Mal | 2010 |
Knock-in gain-of-function sodium channel mutation prolongs atrial action potentials and alters atrial vulnerability.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Echocardiography, Doppler; | 2010 |
Iatrogenic Flecainide toxicity.
Topics: Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Confusion; Female; Flecainide; Hallu | 2010 |
A 2-year survey of treatment of acute atrial fibrillation in an ED.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillati | 2011 |
Paroxysmal atrial fibrillation due to bronchogenic cyst.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bronchogenic Cyst; Electrocardiography; Enalapril; Flec | 2010 |
[Flecainide poisoning].
Topics: Aged; Amiodarone; Atrial Fibrillation; Cholecystectomy; Cholecystitis; Electrocardiography; Emergenc | 2010 |
Mixed treatment comparisons for atrial fibrillation: evidence network or bewildering entanglement?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Evidence-Based Medicine; Fleca | 2011 |
Flecainide.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Flecainide; Humans; Treatment | 2011 |
The safety of flecainide treatment of atrial fibrillation: long-term incidence of sudden cardiac death and proarrhythmic events.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiovascular Agents; Coho | 2011 |
Does a Brugada pattern ECG precipitated by excessive-dose flecainide provide a diagnosis of a Brugada syndrome patient and/or contraindicate its use? A case study.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Brugada Syndrome; Catheter Ablation; Contraindications; | 2011 |
Syncope following 'pill-in-the-pocket' treatment of atrial fibrillation with propafenone plus quinidine.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Flecainide; Humans; Propafenone | 2011 |
Convulsions after normal dose of lidocaine: a probable drug interaction.
Topics: Adrenergic alpha-Agonists; Aged; Anesthetics, Local; Anti-Arrhythmia Agents; Atrial Fibrillation; Br | 2012 |
Chloroquine terminates stretch-induced atrial fibrillation more effectively than flecainide in the sheep heart.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Antirheumatic Agents; Atrial Fibrillation; Chlor | 2012 |
The long and short of antiarrhythmic drug treatment.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Flecainide; Humans; Male | 2012 |
[Supraventricular extrasystole after cardioversion with amiodarone].
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Premature Complex | 2012 |
A misguided 'pill in the pocket' approach with flecainide leading to cardiac arrest.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular Block; Cardiopulmonary Resuscita | 2012 |
[Predictors of reversion to sinus rhythm previous to electrical cardioversion in patients with persistent atrial fibrillation treated with anti-arrhythmic drugs].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Body Mass Index; Comorbidity; Diabete | 2013 |
Antiarrhythmic drug treatment after cardioversion of atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Flecainide; Humans; Male | 2012 |
Antiarrhythmic drug treatment after cardioversion of atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Flecainide; Humans; Male | 2012 |
Antiarrhythmic drug treatment after cardioversion of atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Flecainide; Humans; Male | 2012 |
Sodium channel block by ranolazine in an experimental model of stretch-related atrial fibrillation: prolongation of interatrial conduction time and increase in post-repolarization refractoriness.
Topics: Acetanilides; Administration, Oral; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Fl | 2013 |
Importance of left atrial diameter and atrial fibrillatory frequency for conversion of persistent atrial fibrillation with oral flecainide.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Evaluation; Echocardio | 2002 |
Atrial fibrillation threshold predicted long-term efficacy of pharmacological treatment of patients without structural heart disease.
Topics: Aged; Anti-Arrhythmia Agents; Aprindine; Atrial Fibrillation; Disopyramide; Electrophysiologic Techn | 2002 |
Evaluation of the effect of bepridil on paroxysmal atrial fibrillation: relationship between efficacy and the f-f interval in surface ECG recordings.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Calcium Channel Blockers; Electrocardio | 2003 |
Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: insights into the mechanism of the superior efficacy of amiodarone.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channels, L-Type; Dogs; El | 2003 |
Safety of a controlled-release flecainide acetate formulation in the prevention of paroxysmal atrial fibrillation in outpatients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Delayed-Ac | 2003 |
Effects of flecainide on the electrophysiological properties of atrial vulnerability in humans.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Electrophysiology; Female; Flecain | 2003 |
[Infusion of flecainide in a patient with atrial fibrillation and latent Brugada's syndrome has determined modifications of the electrocardiogram similar to those of a septal myocardial infarct].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Death, Sudden, Cardiac; Echocardiography; Electrocardio | 2003 |
Incidence and management of early recurrent atrial fibrillation (ERAF) after transthoracic electrical cardioversion.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Flecainide; Humans; Inject | 2004 |
Atrial fibrillation: rate control often better than rhythm control.
Topics: Adult; Aged; Amiodarone; Anticoagulants; Arrhythmia, Sinus; Atrial Fibrillation; Canada; Disopyramid | 2004 |
Cardioversion threshold, IRAF and beyond.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Flecainide; Humans; | 2004 |
Pharmacological cardioversion of recent onset atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Flecainide; Humans; Sulfonamides | 2004 |
Limitations to antiarrhythmic drug use in patients with atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Contraindications; Female; Fl | 2004 |
Flecainide and propafenone induced ST-segment elevation in patients with atrial fibrillation: clue to specificity of Brugada-type electrocardiographic changes.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bundle-Branch Block; Dose-Response Relationship, Drug; | 2004 |
Different clinical courses and predictors of atrial fibrillation occurrence after transisthmic ablation in patients with preablation lone atrial flutter, coexistent atrial fibrillation, and drug induced atrial flutter.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Co | 2004 |
Use of intravenous flecainide in horses with naturally-occurring atrial fibrillation.
Topics: Acute Disease; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Chronic D | 2004 |
Long-term results of hybrid therapy in patients with atrial fibrillation who develop atrial flutter during flecainide infusion.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Combined Modality Th | 2005 |
Time-frequency analysis of the surface electrocardiogram for monitoring antiarrhythmic drug effects in atrial fibrillation.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Monitoring; Elec | 2005 |
The "pill-in-the-pocket" approach to atrial fibrillation.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Control Groups; Flecainide; Human | 2005 |
Pilot study: Noninvasive monitoring of oral flecainide's effects on atrial electrophysiology during persistent human atrial fibrillation using the surface electrocardiogram.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Electrocardiography; Electrophys | 2005 |
Wide QRS complexes during atrial fibrillation: what is the mechanism?
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electrophysiology; Flecainide; Humans; Male; Middle Age | 2004 |
Does flecainide regain its antiarrhythmic activity after electrical cardioversion of persistent atrial fibrillation?
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Female; Flecainide; Humans | 2005 |
Consequences of atrial electrical remodeling for the anti-arrhythmic action of class IC and class III drugs.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Electric Countershock; Electr | 2005 |
[Pharmacogenetic study of the response to flecainide and propafenone in patients with atrial fibrillation].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cytochrome P-450 CYP2D6; Female; Flecainid | 2005 |
Can recent-onset atrial fibrillation be safely and successfully treated with self-administered antiarrhythmic drugs?
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Flecainid | 2005 |
Targeted pharmacological reversal of electrical remodeling after cardioversion--rationale and design of the Flecainide Short-Long (Flec-SL) trial.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Electrocardiography; Flecainide; | 2005 |
[Life-threatening ventricular tachycardia during flecainide treatment for symptomatic atrial fibrillation in a patient with a structural cardiac disorder].
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Flecainide; Humans; Male; T | 2006 |
[Flecainide acetate utilisation review among general practitioners and hospital or office-based cardiologists in France. Obepine: observational study of flecainide].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Output, Low; Cardiology; Coronary Disease | 2006 |
Serial cardioversion by class IC Drugs during 4 months of persistent atrial fibrillation in the goat.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, | 2006 |
Too little, too late: chasing atrial fibrillation with sodium channel antagonists.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Flecainide; Heart Conductio | 2006 |
Combined use of 1C and III agents for highly symptomatic, refractory atrial fibrillation.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Drug Combinations; Female | 2006 |
Use of telemedicine in the diagnosis of paroxysmal atrial fibrillation and to monitor the effect of antiarrhythmic drug therapy.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography, Ambulatory; Female; Flecainide; Hu | 2006 |
The pharmacological response of ischemia-related atrial fibrillation in dogs: evidence for substrate-specific efficacy.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channel B | 2007 |
Anti-arrhythmic effects of I (Na), I (Kr), and combined I (Kr)-I (CaL) blockade in an experimental model of acute stretch-related atrial fibrillation.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Benzamides; Dose-Response Rel | 2007 |
Atrial fibrillation in pregnancy.
Topics: Adult; Anti-Arrhythmia Agents; Aspirin; Atrial Fibrillation; Electrocardiography; Female; Flecainide | 2008 |
Impact of serum flecainide level on control of atrial fibrillation in a case treated with cardiac resynchronization therapy.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Cardiomyopathy, Dilat | 2007 |
ECG findings in fatal flecainide intoxication.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Fatal Outcome; Flecainide; | 2007 |
[Clinical case of the month. Atrial flutter with rapid ventricular response (1:1 atrioventricular conduction) caused by flecaïnide].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Atrioventricular Node; Electric Counter | 2007 |
Paranoid psychosis and myoclonus: flecainide toxicity in renal failure.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Diabetes Mellitus, Type 2; Dose-Response Relationship, | 2008 |
Effect of the antiarrhythmic agent flecainide acetate on acute and chronic pacing thresholds.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Dose-Res | 1983 |
The use of tocainide, encainide, lorcainide and flecainide for supraventricular arrhythmias.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrioventricular Node; | 1984 |
Effect of intravenous flecainide on atrial vulnerability in man.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing | 1983 |
Efficacy of type 1C antiarrhythmic agents for treatment of resistant atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Disopyramide; Encainide; Female; Flecainide; Hear | 1993 |
Effects of E-4031 on atrial fibrillation threshold in guinea pig atria: comparative study with class I antiarrhythmic drugs.
Topics: Acetylcholine; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Disopyramide; | 1994 |
Antifibrillatory and profibrillatory actions of selected class I antiarrhythmic agents.
Topics: Adenosine Triphosphate; Animals; Anti-Arrhythmia Agents; Aprindine; Atrial Fibrillation; Blood Gas A | 1993 |
Electrocardiographic case. Irregular broad complex tachycardia. Wolff-Parkinson-White syndrome with atrial flutter-fibrillation.
Topics: Atrial Fibrillation; Atrial Flutter; Diagnosis, Differential; Electrocardiography; Flecainide; Human | 1994 |
Idiopathic atrial fibrillation in dogs: electrophysiologic determinants and mechanisms of antiarrhythmic action of flecainide.
Topics: Action Potentials; Animals; Atrial Fibrillation; Dogs; Electrophysiology; Flecainide; Heart Atria | 1995 |
[Flecainide exercise induced left bundle branch with chest pain].
Topics: Aged; Angina Pectoris; Atrial Fibrillation; Bundle-Branch Block; Coronary Angiography; Exercise; Fem | 1994 |
Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide.
Topics: Administration, Oral; Aged; Atrial Fibrillation; Female; Flecainide; Humans; Male; Middle Aged; Prop | 1994 |
Flecainide-induced JT prolongation, T wave inversion and ventricular tachycardia during treatment for symptomatic atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Electric Countershock; Electrocardiography; Female; Flecainide; Heart Con | 1994 |
Antiarrhythmic drugs in the management of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Flecainide; Heart; Humans; Propafe | 1993 |
Effects of pilsicainide on the atrial fibrillation threshold in guinea pig atria. A comparative study with disopyramide, lidocaine and flecainide.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disopyramide; Electrophysiology; Female; Fleca | 1993 |
Radiofrequency versus pharmacologic modification of the atrioventricular node.
Topics: Amiodarone; Animals; Atrial Fibrillation; Atrioventricular Node; Dogs; Electrophysiology; Flecainide | 1993 |
A symposium: Supraventricular Arrhythmias: Update 1995. Boston, Massachusetts, May 6, 1995.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Flecainide; Humans; Tachycardia, Supraventricular | 1996 |
Effect of flecainide on atrial and ventricular refractoriness and conduction in patients with normal left ventricle. Implications for possible antiarrhythmic and proarrhythmic mechanisms.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing, Artificial; Dose | 1995 |
[Atrial electrophysiological study of unexplained ischemic cerebrovascular disorders].
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing, Artificial; Cere | 1995 |
Activation of the hemostatic mechanism after pharmacological cardioversion of acute nonvalvular atrial fibrillation.
Topics: Acute Disease; Amiodarone; Anti-Arrhythmia Agents; Antithrombin III; Atrial Fibrillation; Biomarkers | 1997 |
Selective catheter ablation of the slow atrioventricular nodal pathway for atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular Node; Catheter Ablation; Flecainide; H | 1997 |
Evaluation of a protocol to select patients of all ages for cardioversion from atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Coronar | 1997 |
[Pharmacological cardioversion of isolated atrial fibrillation: recovery of atrial mechanical function and correlation with duration of arrhythmia].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Data Interpretation, Stat | 1997 |
Hybrid pharmacologic and ablative therapy: a novel and effective approach for the management of atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut | 1998 |
[Iatrogenic acute renal failure caused by overdosage of flecainide acetate].
Topics: Acute Kidney Injury; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Anti-In | 1998 |
ST segment elevation induced by class IC antiarrhythmic agents: underlying electrophysiologic mechanisms and insights into drug-induced proarrhythmia.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiomyopathy, Dilated; Electroc | 1998 |
[The role of an electropharmacological transesophageal test in the prevention of paroxysmal atrial fibrillation. Experience with flecainide].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Chi-Square Dis | 1998 |
[Idiopathic atrial fibrillation of recent onset and atrial stunning: the echocardiographic evidence after pharmacological cardioversion].
Topics: Adult; Aged; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; Echocardiography, Do | 1998 |
Favorable effects of flecainide in transvenous internal cardioversion of atrial fibrillation.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Catheterization; Chronic Disease; | 1999 |
Radiofrequency ablation of atrial flutter due to administration of class IC antiarrhythmic drugs for atrial fibrillation.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation | 1999 |
Radiofrequency ablation of "class IC atrial flutter" in patients with resistant atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cath | 1999 |
Pharmacologic cardioversion of chronic atrial fibrillation in the goat by class IA, IC, and III drugs: a comparison between hydroquinidine, cibenzoline, flecainide, and d-sotalol.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Disease Models, Animal; Elect | 1999 |
ST segment elevation in the right precordial leads induced with class IC antiarrhythmic drugs: insight into the mechanism of Brugada syndrome.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Flecainide; Follow-Up Studies; Hea | 1999 |
Electrophysiological effects of flecainide and propafenone on atrial fibrillation cycle and relation with arrhythmia termination.
Topics: Adrenergic beta-Agonists; Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; F | 1999 |
Ablation of a left-sided accessory pathway during atrial fibrillation facilitated by intravenous flecainide.
Topics: Anesthesia, General; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Electrocardiogr | 1999 |
Lack of prevention of heart failure by serial electrical cardioversion in patients with persistent atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Electric Countershock | 1999 |
Implantable atrial defibrillator and detection of atrial flutter.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Defibrillators, Implantable; Electrocar | 2000 |
Atrial defibrillation at the millennium: new challenges for evolving technology.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Defibrillators, Implantable; Equipment | 2000 |
Widening of the excitable gap during pharmacological cardioversion of atrial fibrillation in the goat: effects of cibenzoline, hydroquinidine, flecainide, and d-sotalol.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Female | 2000 |
Safe and efficacious dosage of flecainide acetate for treating equine atrial fibrillation.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Electrocardi | 2000 |
ST segment elevation in the right precordial leads following administration of class Ic antiarrhythmic drugs.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Electrocardiography; Female | 2001 |
The actions of ibutilide and class Ic drugs on the slow sodium channel: new insights regarding individual pharmacologic effects elucidated through combination therapies.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Therapy, Combination; Electrocardiogr | 2000 |
Frequency-dependent electrophysiological effects of flecainide, nifekalant and d,l-sotalol on the human atrium.
Topics: Action Potentials; Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Func | 2001 |
Differential effects of dofetilide, amiodarone, and class lc drugs on left and right atrial refractoriness and left atrial vulnerability in pigs.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Atrial Function, L | 2001 |
Torsades de pointes ventricular tachycardia induced by mosapride and flecainide in the presence of hypokalemia.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzamides; Drug Therapy, Combination; Electrocar | 2001 |
Class IC antiarrhythmic drug induced atrial flutter: electrocardiographic and electrophysiological findings and their importance for long term outcome after right atrial isthmus ablation.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Electro | 2001 |
[Intermittent atrial fibrillation. An "idiopathic" emergency. Torsade de pointes].
Topics: Atrial Fibrillation; Diagnosis, Differential; Electrocardiography, Ambulatory; Emergencies; Flecaini | 2001 |
Symptomatic bradycardia secondary to interaction between topical timolol maleate, verapamil, and flecainide: a case report.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Antihypertensive Agent | 2002 |
Atrial fibrillation recurrence after internal cardioversion: prognostic importance of electrophysiological parameters.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Electro | 2002 |
Documentation of acute rise in ventricular capture thresholds associated with flecainide acetate.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Equipment Failure; Flecainide; Heart Ventricles; | 2002 |
[Electrophysiologic effects of flecainide on guinea pig atrium].
Topics: Animals; Atrial Fibrillation; Atrial Function; Electric Stimulation; Electrophysiology; Flecainide; | 1992 |
Flecainide in quinidine-resistant atrial fibrillation.
Topics: Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Drug Therapy, Combination; Electrocardiograph | 1992 |
Mechanism of flecainide's antiarrhythmic action in experimental atrial fibrillation.
Topics: Action Potentials; Animals; Atrial Fibrillation; Cardiac Pacing, Artificial; Dogs; Electric Stimulat | 1992 |
Flecainide for supraventricular tachyarrhythmias.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Flecainide; Humans; Tachycardia, Paroxysmal; Tachycardia, | 1992 |
Correlation of symptoms with occurrence of paroxysmal supraventricular tachycardia or atrial fibrillation: a transtelephonic monitoring study. The Flecainide Supraventricular Tachycardia Study Group.
Topics: Atrial Fibrillation; Electrocardiography; Female; Flecainide; Humans; Male; Middle Aged; Predictive | 1992 |
A study of the use of flecainide acetate in the long-term management of cardiac arrhythmias.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Administration Schedule; Dru | 1990 |
Antiarrhythmic treatment with flecainide (Tambocor). Clinical experience from 107 patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Atrial Flutte | 1990 |
The interaction of antiarrhythmic drugs and the energy for cardioversion of chronic atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cerebrovascular Disorders; Chr | 1991 |
Flecainide therapy in patients treated for supraventricular tachycardia with near normal left ventricular function.
Topics: Atrial Fibrillation; Atrial Flutter; Female; Flecainide; Follow-Up Studies; Humans; Male; Middle Age | 1992 |
Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter.
Topics: Actuarial Analysis; Aged; Amiodarone; Analysis of Variance; Atrial Fibrillation; Atrial Flutter; Chr | 1991 |
Cardioversion of atrial fibrillation of recent onset with flecainide.
Topics: Adult; Aged; Atrial Fibrillation; Female; Flecainide; Humans; Infusions, Intravenous; Male; Middle A | 1991 |
Flecainide acetate in atrial flutter and fibrillation. The arrhythmogenic effects.
Topics: Aged; Aged, 80 and over; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Flecainide; Huma | 1990 |
The hazards of using type 1C antiarrhythmic drugs for the treatment of paroxysmal atrial fibrillation.
Topics: Anilides; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Encainide; Flecainide; Hemodynamics; | 1990 |
Effects of flecainide on the atrial defibrillation threshold.
Topics: Atrial Fibrillation; Atrial Flutter; Electric Countershock; Female; Flecainide; Humans; Male; Middle | 1989 |
[Effects of intravenous flecainide in the treatment of paroxysmal or recent-onset atrial fibrillations].
Topics: Adult; Aged; Atrial Fibrillation; Drug Evaluation; Echocardiography; Female; Flecainide; Humans; Mal | 1989 |
Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation.
Topics: Adult; Atrial Fibrillation; Digoxin; Drug Therapy, Combination; Electrocardiography; Exercise Test; | 1989 |
[Supraventricular tachyarrhythmia of recent onset in the absence of documented cardiac pathology: different therapeutic approaches].
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Electric Countershock; | 1989 |
[A case of atrial paralysis during the use of intravenous flecainide acetate].
Topics: Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Electrocardiography; Female; Flecai | 1989 |
[Syncope in a 16-year-old young man during a football match].
Topics: Adolescent; Atrial Fibrillation; Flecainide; Humans; Male; Syncope; Wolff-Parkinson-White Syndrome | 1986 |
[Flecainide by the intravenous route: a new method for decreasing auricular fibrillation].
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Female; Flecainide; Humans; Injections, Intrave | 1987 |
Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillation.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Flecainide; Heart Atria; Heart Ventricles; Humans; Tachyc | 1987 |
Intravenous flecainide acetate for the clinical management of paroxysmal tachycardias.
Topics: Adolescent; Adult; Aged; Atrial Fibrillation; Atrial Flutter; Electrocardiography; Female; Flecainid | 1987 |
Flecainide acetate in the treatment of tachycardias associated with Mahaim fibres.
Topics: Adult; Atrial Fibrillation; Atrial Flutter; Atrioventricular Node; Electrocardiography; Flecainide; | 1987 |
[Reduction of auricular fibrillation and tachycardia using intravenous flecainide].
Topics: Adult; Aged; Atrial Fibrillation; Atrial Flutter; Electrocardiography; Flecainide; Heart Atria; Hemo | 1987 |
Long term evaluation of flecainide acetate in supraventricular tachyarrhythmias.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Electrocardiography; Fema | 1988 |
Successful use of flecainide in atrial fibrillation with rapid ventricular rate in the Wolff-Parkinson-White syndrome.
Topics: Adult; Atrial Fibrillation; Electrocardiography; Electrophysiology; Flecainide; Heart Rate; Heart Ve | 1988 |
Use of flecainide acetate in the treatment of supraventricular tachyarrhythmias.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Flecainide; Humans; Tachycardia, Paroxysm | 1988 |
Intravenous flecainide acetate for supraventricular tachycardias.
Topics: Adult; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing, Artificial; Electrocardiography; Electro | 1988 |
Treatment of atrial tachyarrhythmias and preexcitation syndrome with flecainide acetate.
Topics: Adult; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing, Artificial; Electrocardiography; Electro | 1988 |
Restoration of sinus rhythm with flecainide in patients with atrial fibrillation.
Topics: Atrial Fibrillation; Electrocardiography; Female; Flecainide; Humans; Male; Middle Aged; Time Factor | 1988 |
[Bundle branch reentry tachycardia: a possible mechanism of flecainide proarrhythmia effect].
Topics: Amiodarone; Atrial Fibrillation; Cardiomyopathy, Alcoholic; Drug Therapy, Combination; Electrocardio | 1988 |
[Predictive factors of the therapeutic result in the prevention of auricular fibrillation. Role of electrophysiological studies].
Topics: Aged; Atrial Fibrillation; Electrophysiology; Evaluation Studies as Topic; Female; Flecainide; Human | 1988 |
[Flecainide-induced hepatitis].
Topics: Aortic Valve Stenosis; Atrial Fibrillation; Chemical and Drug Induced Liver Injury; Flecainide; Hear | 1988 |
[Value of flecainide in supraventricular arrhythmias].
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial F | 1986 |
Flecainide acetate in resistant atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Flecainide; Humans; Male; Pi | 1985 |
Flecainide acetate in atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Flecainide; Humans; Piperidines | 1985 |
Cardioversion with flecainide in patients with atrial fibrillation of recent onset.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Flecainide; Heart Rate; Humans; Ma | 1985 |
Evaluation of flecainide acetate in rapid atrial fibrillation complicating Wolff-Parkinson-White syndrome.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Electroc | 1985 |